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ABSTRACT 
THE ROLE OF GENETIC AND ENVIRONMENTAL OXIDATIVE STRESS FACTORS IN PROSTATE 
CANCER 
Nicole A. Lavender 
November 19, 2010 
Prostate cancer (PCA) development may be influenced by genetic variations 
within oxidative stress response (OSR) related mechanisms, such as antioxidation (e.g., 
carcinogen metabolism/detoxification), DNA repair, and apoptotic regulation. Excessive 
oxidative stress can produce DNA base changes, damage tumor suppressors, enhance 
proto-oncogene expression, and induce malignant transformation of cells. Persistent 
oxidative stress may even trigger apoptosis. Environmental reactive oxygen species 
(ROS) exposure attributable to lifestyle factors may exacerbate this situation by 
increasing oxidative stress. Therefore, it is likely that genetic variation resulting in 
compromised ROS capacity combined with increased environmental ROS exposure may 
increase PCA risk and disease aggressiveness. Consequently, this research evaluated the 
individual and joint modifying effects of OSR 242 genetic and 27 environmental factors 
in relation to PCA development among men of European and African descents. This 
analysis utilized a combination of traditional and innovative advanced mathematical 
methodologies that provided an opportunity to visualize, verify, and evaluate the 
v 
predictive accuracy of higher-order interactions as indicators of disease risk and 
aggressiveness. 
Our analysis identified several OSR sequence variants to individually associated 
PCA risk among MED. In addition, antioxidative- and apoptotic-related SNPs were linked 
to increased disease risk in MAD. Higher order interaction analyses for across both 
populations detected gene-gene combinations among antioxidative- and apoptotic-
related sequence targets associated with increased risk. The potential functional 
consequences of these polymorph isms suggest that compromised detoxification and 
apoptotic induction may cause increased risk for PCA and more aggressive disease. Our 
results also indicate that environmental factors related to meat consumption and 
cooking methods may contribute to PCA mechanisms. Unfortunately, we were not able 
to characterize environmental factors alone or combined with gene variants that are 
involved in PCA. This may be attributed to MDR data filtering, small MAD sample size, 
or limitations in some study variables (e.g., meat-derived carcinogen exposure). 
However, future analysis within larger study populations, more accurate exposure 
variables, and improved computational power may allow us to identify and validate 
environmental factors relevant to PCA development. 
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INTRODUCTION 
Prostate cancer (PCA) ranks second highest in incidence and mortality among all 
cancers occurring in American men, but its etiology remains is poorly understood. 1 For 
instance, age and family history are the strongest risk factors for peA, but men of 
African descent (MAD) are 1.5-2.0 times more likely to develop the disease than any 
other racial or ethnic group.l MAD have a greater chance of being diagnosed with peA 
at a younger age, with more aggressive disease and poorer prognosis. 2. 4 Despite 
increases in five year survival rates for African-American men over the last few decades; 
their rates still lag far behind other races. 1 In addition to age, family history and race, 
genetic factors are believed play an important role in peA initiation and progression. 1, 3, 5 
Also, lifestyle habits (e.g., cigarette smoking, diet) are suggested to increase risk; 
indicating that environmental factors may also influence peA. 1, 3 Based on its 
complexity, prostate carcinogenesis and its disparity most likely involve a multifaceted 
interplay between genetic and environmental contributors. Unfortunately, 
characterization of these factors and how their interactions modify peA risk and disease 
progression are largely unknown.3, 5-6 Essential to overcoming gaps in understanding 
peA and eliminating its disparities is identification and validation of genomic profiles in 
important biological pathways.3,7-8 These profiles, along with environmental factors 
may serve as effective predictors of peA risk and disease progression.3, 7-8 
1 
Oxidative stress response (OSR) is one such biological pathway that is becoming 
increasingly important in prostate carcinogenesis.9-12 PCA development may be 
influenced by genetic variations within OSR related mechanisms, such as antioxidation 
(e.g., carcinogen metabolism/detoxification), DNA repair, and apoptotic regulation, as 
shown in Figure 1.2-3,9,13 Excessive oxidative stress can produce DNA base changes, 
damage tumor suppressors, enhance proto-oncogene expression, and induce malignant 
transformation of cells. 13-14 Persistent oxidative stress may even trigger apoptosis. 
Environmental reactive oxygen species (ROS) exposure attributable to lifestyle factors 
may exacerbate this situation by increasing oxidative stress. Therefore, it is likely that 
genetic variation resulting in compromised ROS capacity combined with increased 
environmental ROS exposure may increase PCA risk and disease aggressiveness. 
Consequently, this research evaluated the individual and joint modifying effects of 
genetic and environmental OSR factors in relation to PCA among a case control 
population of men of European and African descents. 
2 
Figure 1. Oxidative Stress Response Mechanisms 
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Figure 1: Oxidative Stress Response Mechanisms. Oxidative stress can result when the amount of reactive 
oxygen species produced exceeds that which can be removed . Prevention of oxidative stress involves 
multiple biological pathways, such as antioxidation (e.g., carcinogen metabolism/detoxification). DNA 
repair, and apoptotic regulation. Antioxidants function to remove or reduce reactive oxygen species and 
DNA repair corrects oxidative damage. However, excessive or persist oxidative damage may signal 
apoptosis to avoid induce malignant transformation of cells. 
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OXIDATIVE STRESS 
Oxidative stress is a condition in which the amount of reactive oxygen species 
(ROS) produced exceeds the amount removed and can result from multiple endogenous 
and exogenous ROS-generating sources.13-16 Therefore, maintenance of homeostatic 
ROS levels is critical to prevent these highly reactive electrophiles from interacting with 
biomolecules, interfering with cell signaling and promoting cellular transformation. 11,14-
17 This includes direct damage to nucleic acids and proteins, resulting in bulky adducts, 
oxidized DNA bases, and protein catalytic sites.9, 14-15, 17-18 Reactive species can also 
modify secondary or tertiary protein structures, subsequently effecting protein function 
or activation. 1S In addition, ROS are capable of increasing intracellular calcium 
concentration, causing changes in calcium signaling that may ultimately affect protein 
activation states. 15 These effects can be manifested as altered gene and protein 
expression, cell proliferation or apoptosis.1S Left unrepaired, accumulating ROS damage 
can lead to cellular transformation and ultimately progress into to cancer.12, 15, 18-19 
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CIGARETIE SMOKE AS A SOURCE OF REACTIVE OXYGEN SPECIES 
Oxidative stress can arise from exogenous sources such as environmental toxins 
and contaminants. 13-14, 20 For example, cigarette smoke contains more than 60 known 
carcinogens, including polycyclic aromatic hydrocarbons (PAHs) and aromatic amines. 21-
23 Senzo[a]pyrene (SaP) is a prototypical and heavily studied PAH produced by 
combustion processes, such as smoke from cigarettes or grilled meats.23-24 SaP is a 
suspected carcinogen capable of producing oxidative damage and bulky DNA adducts.17 
As shown in Figure 2, during its metabolism, SaP is bioactivated as more reactive 
metabolites are generated that can lead to oxidative DNA damage and possibly tumor 
formation. Exposure to PAHs, such as SaP, and other compounds in cigarette smoke 
result in higher ROS levels as a consequence of antioxidant metabolic reactions. 13, 25-26 
Over time increased ROS exposure can lead to cellular oxidative stress as well as 
oxidative DNA damage.13, 25-26 Inevitability, these conditions may contribute to 
increased cancer risk and progression. 13, 25-26 
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Figure 2. Metabolism of benzo[a]pyrene27 
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Figure 2: Metabolism of benzo[a]pyrene. The tobacco carcinogen benzo[a]pyrene can be converted to 
DNA-reactive compounds through its metabolism. This figure illustrates SaP metabolism by Cytochrome 
P4S0 (CYP) and Epoxide Hydrolase enzymes to generate either SaP 4,S-dihydrodiol or SaP 7,8-dihydrodiol. 
Although both mutagenic, stereoselectivity as well as CYPs or ROS support the generation of S[ajP 7,8-
dihydrodiol-9,lO-epoxide (SPDE). SPDE can ssubsequently react with DNA to produce stable guanosine 
adducts, ultimately leading to tumor formation . Alternatively, SaP 7,8-dihydrodiol can be reduced to 
catechol and further oxidized to reactive ortho-quinone. 
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Although cigarette smoke is a suspected contributor to carcinogenesis based on 
its chemical composition its role in PCA remains unclear. For example, a cohort study 
with over 22,000 men in the Physicians' Health Study (PHS) found no association 
between smoking and overall PCA risk.28 In comparison to never smokers, the risk ratio 
(RR) and corresponding 95% Confidence Interval was 1.14 (1.00-1.30) for former 
smokers.28 The number of cigarettes smoked per day also had no effect on risk: RR 
(95%CI) = 1.10 (0.78-1.55) for less than 20 cigarettes per day and RR (95%CI) = 1.10 ( 
0.84-1.44) for 20 or more cigarettes.28 This study also considered the number of years 
smoked, but found no significant effects between duration and risk [RR (95%CI) =1.69 
(0.75-3.82) for 29-38 years and [RR (95%CI) = 1.05 (0.41-2.70)] for ~ 39 years.28 With 
respect to PCA mortality, smoking history [RR (95%CI) = 1.30 (0.87-1.95)], daily 
frequency [RR (95%CI) = 1.25 (0.87-1.95) for < 20 and 1.22 (0.54-2.74) ~ 20 
cigarettes/day] nor number of years smoked were associated with fatal PCA [RR (95%CI) 
= 1.69 (0.75-3.82) for 29-38 and 1.05 (0.41-2.70) ~ 39 years].28 
In contrast to the PHS cohort, a population-based case control study of 752 
subjects found smoking at the time of diagnosis was associated with 2.7-fold increase in 
PCA mortality risk.29 Another report observed a decrease in risk associated with 
smoking but an increase in fatality among participants of the NIH-AARP Diet and Health 
Study.3o They found former and current smokers were less likely to be diagnosed with 
non-aggressive PCA [HR (95% CI) = 0.90 (0.87-0.93) and HR (95%CI) = 0.85 (0.80-0.90), 
respectively].30 However, an increased risk of PCA mortality was associated with 
current and not former smokers [HR (95%CI) = 1.69 (1.25-2.27)].30 
7 
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A recent meta-analysis cites that inconsistencies in published findings may be 
due to differences in study type (e.g., cohort, case-control) as well as clinical outcome 
(e.g., incidence versus mortality).31 To address this issue, this analysis pooled data from 
24 previous publications to evaluate role of smoking in peA risk, progression and 
mortality.31 They found former, but not current smokers were at increased risk of peA 
development.31 When the data was stratified by cigarettes smoked per day or years 
smoked, the increased use and duration translated to increased risk of disease and 
fatality.31 
In addition to differences in study design and endpoints, conflicting results may 
be due to lack of considering mUltiple genetic and environmental factors along with 
smoking exposure. Biological evidence suggests that cigarette smoking may contribute 
to prostate carcinogenesis due to increased exposure to suspected carcinogenic and 
ROS . d 13 25-26 30-31 H .. . h -generating compoun S." owever, genetic vanatlon or ot er 
environmental oxidative stress factors can influence the detoxification and damaging 
effects of cigarette smoking. Therefore, our study evaluated cigarette smoking as part 
of a comprehensive OSR panel to characterization of the role of these factors in peA 
development. 
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MEAT-DERIVED SOURCES OF REACTIVE OXYGEN SPECIES 
HCAs such as, 2-amino-l-methyl-6-phenylimidazo[4,s-b]pyridine (PhIP); 2-
amino-3,8-dimethylimidazo[4,s-b]quinoxaline (MeIQx); and 2-amino-3,4,8-
trimethylimidazo[4,s-f]quinoxaline (DiMeIQx), naturally form from creatinine or 
creatine, amino acids and sugar condensing when meats are cooked.32-33 However, 
consumption of meat cooked at high temperatures or for prolonged periods (e.g., grilled 
or 'well-done'), has been found to produce high HCA exposure levels.32, 34-36 Although 
these compounds are typically attributed to red meat, white (e.g., chicken, pork) and 
processed (e.g., cold cuts) meats are also sources of HCAs.32-33 Since HCAs are produced 
during cooking, exposure is heavily influenced by method and duration used. 33 Total 
HCA concentration can vary, but cooked meat generally contains::;; 100 ng/g, but can 
range between::;; 1-500 ng/g.33 Done or well-done chicken has been shown to have low 
or undetectable MelQx (::;; 1) and PhlP concentrations (6-64ng/g).37 Very well-done or 
grilled chicken has been shown to have high MelQx (3ng/g) and PhlP concentrations (70-
480ng/g).37 
Similar to SaP, HCA are bioactivated by metabolic enzymes to highly reactive 
compounds capable of forming DNA adducts (See Figures 3 & 4).11,24,27 Furthermore, 
processed meats containing nitrates/nitrites can produce nitrosamines that are also 
9 
potentially genotoxic.33, 38 Once metabolically activated, nitrosamines function as 
alkylating agents capable of reacting with DNA bases. 39 
Figure 3. Major metabolism of Phlp27 
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Figure 3: Major metabolism of PhIP. Cytochrome P450 enzymes bioactivate PhlP by catalyzing the N-
oxidation of its exocyclic amine group. The resulting N-hydroxy-PhIP is subsequently acetylated or sulfated 
by acetyltransferases (NATs) or sulfotransferases (SULTs) to yield highly unstable esters that react with DNA 
to form adducts. Detoxification can occur via glucuronidation by UGTlAl directly reacting with PhlP or N-
hydroxy-PhIP. GSTAl can also catalyze detoxification by reducing N-acetoxy-PhIP to PhIP. 
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Figure 4. MelQx Metabolism27 
DetoJli uon 
NH2 
:c:ti-
• 5 
".lQx 
CVPtA2 
8-M1thyl.oH-IQx 
ICYp A2 
, 
CYPIA2 
CVPtA111B1 - S-:-LT_;.- ( ::n7o.v~ ) 
r ONA 
, 
[ c~ ) 
Figure 4: MelQx metabolism. The metabolism of MelQx is catalyzed by cytochrome P4S0 lA2 (CYP1A2) . 
Subsequent acetylation or sulfation by acetyltransferases (NATs) or sulfotransferases (5ULTs) produce N2_ 
acetoxy-MelQx and N2-sulfonyloxy-MeIQx. These esters can ultimately generate highly reactive 
arylnitrenium ions capable of cross-linking DNA molecules. Detoxification of MelQx is achieved by either N-
conjugation or oxidation of the C8 methyl group by CYP1A2. 
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Meat-derived PAHs, HCAs, and nitrosamines are all suspected carcinogens based 
on experimental evidence showing their ability to generate oxidative and DNA 
damage.32-33 Unfortunately, studies examining the role of meat consumption and 
cooking methods in relation to PCA development have not yielded entirely consistent 
findings. For instance, a prospective study among more than 29,300 men from the 
Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial found no 
association between PCA risk and the consumption of red, white, or processed meats. 40 
However, based on the population's median daily intake of 109 of well-done meat, men 
consuming more than this amount per daily had a 42% increase in disease risk [RR 1.42 
(1.05-1.92; P = 0.02].40 This study also considered the effect of meat-derived 
carcinogens (i.e., PhlP, DiMelQx, MelQx, BaP) on PCA; but only high levels of PhlP 
(>269.2 ng/day) was associated with an increase in risk [RR 1.22 (1.01-1.48; P = 0.04].40 
A more recent study evaluated the effect of meat intake and these carcinogens 
on PCA risk, aggressiveness, and fatality among participants of the NIH-AARP Diet and 
Health Study.38 Within a study cohort of more than 175,000 men, consumption of both 
red and processed meats was associated with an increased of PCA risk and advanced 
disease [hazard ratio(HR) = 1.13 (1.02-1.25); Ptrend = 0.003 and HR = 1.45 (1.10-1.92); P 
trend = 0.006, respectively.38 
A 2009 review of published reports examining the role well-done meat and HCA 
on cancer risk concluded that most evidence suggests that high intake of well-done 
meat and exposure to meat-derived carcinogens increase PCA risk.24 This included a 
1999 population-based study of 317 cases and 480 controls that found well-done beef 
12 
and streak associated with an 1.7-fold increase in risk [OR (95%CI) = 1.7 {1.1-2.8)].24 
However, no associations were detected for other well-done meats or individual and 
total HCA exposure.24 This review also referenced a 2008 cohort study of 613 cases (140 
advanced) that observed an increase in PCA risk [RR (95%CI) = 1.26 (1.02-1.54)] and 
advanced [RR (95%CI) = 1.97 (1.26-3.08)] disease associated with well- / very-well done 
meat consumption. 24,34 
Inconsistent findings from previous studies may be attributed to additional 
factors that may modify meat-carcinogen exposure or limited statistical power to model 
these effects. Carcinogenic dietary exposures are difficult to measure, since levels can 
fluctuate according to the type of meat, as well as cooking duration and temperature. 
Furthermore, exposure levels are also affected by genetic variants and other dietary 
habits (e.g., vegetable intake, vitamin/supplement use) that contribute to ROS 
metabolizing/ detoxifying capacity. To address this shortcoming, this study evaluated 
meat intake, cooking method and duration, meat-derived carcinogens; alone and 
combined with mUltiple genetic and environmental OSR factors. 
13 
DIETARY ANTIOXIDANTS 
In contrast to meat consumption, a diet abundant in fruits and vegetables is 
presumed to reduce the risk of developing PCA. 32, 41-42 These foods contain dietary 
antioxidants, such as carotenoids, vitamins C & E, and selenium, capable of protecting 
cells from oxidative stress. 23, 32, 41 They have also been shown to possess certain anti-
carcinogenic properties that may retard cancer-cell development and inhibit tumor 
promotion.41 Compounds found in cruciferous vegetables (e.g., glucosinolates, 
isothiocyanates, flavonoids) have been shown to protect cells from DNA damage, induce 
apoptosis, and inhibit cell proliferation of PCA. 42 For example, some flavonoids have 
antioxidant properties capable of binding of free radicals, and consequently reducing 
oxidative DNA damage and possibly preventing cancer. 42 Vitamin E is a major lipid-
soluble antioxidant in cell membranes; capable of scavenging free radicals; inducing 
apoptosis; and inhibiting expression of prostate specific antigen and androgen receptor 
mRNA as well as protein kinase C activity.23, 41 Similarly, vitamin C is a potent ROS 
scavenger that can also induce apoptosis and reduce lipid peroxidation in cellular 
membranes. 23,41 Selenium has been shown to induce apoptosis, inhibit cellular 
proliferation and angiogenesis as wel1. 42 
Based on their biological functions, dietary antioxidants are believed to protect 
against PCA development, but epidemiological research investigating this claim is largely 
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inconclusive.42-44 For example, the Alpha-Tocopherol, Beta-Carotene Cancer Prevention 
(ATBC) Study examined the effects of family history and lifestyle factors (e.g., 
micronutrient intake) on disease risk.44 This placebo-controlled, double-blinded study 
was designed primarily as a prevention trial and consisted of more than 29,000 Finnish 
male smokers.44 Study participants received either a placebo or a daily supplement of 
50 mg a-tocopheryl acetate, 20 mg ~-carotene or both a-tocopheryl acetate and ~­
carotene.44 Among men with no family history of PCA, neither vitamin was significantly 
associated with disease risk [a-tocopheryl acetate: RR (95%CI) = 0.83 (0.74-0.94) and ~­
carotene: RR (95%CI) = 1.09 (0.97-1.23)].44 There were also no statistically significant 
findings for subjects with a family history of PCA, however, their findings suggest that 
elevated ~-carotene serum levels increase risk (interaction p = 0.08).44 Low ~-carotene 
serum levels nor a-tocopherylj ~-carotene supplement use affected PCA risk among 
men with a family history of the disease.44 
The Selenium and Vitamin E Cancer Prevention Trial (SELECT)' investigated 
whether selenium and vitamin E, taken alone or combined could prevent PCA with little 
or no toxicity in relatively healthy men. 45 Among more than 35,500 men from multiple 
sites in the United States, Canada, and Puerto Rico, this project found that daily oral use 
of 200llg selenium or 400 IU vitamin E, individually or together did not prevent PCA.45 
A study conducted within the Cancer Prevention Study Nutrition Cohort 
observed no protective effects against PCA from vitamin E use.46 However, when only 
current smokers were considered, a decrease in risk was detected for those with regular 
or long-term supplement use compared to non-users.46 
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In a 2009 publication, Zhang et al. examined the use of multivitamins and 
supplements in relation to PCA among a hospital-based case-control population.47 They 
found no statistically significant associations between single supplement and 
multivitamin use of vitamin E, selenium, zinc, and l3-carotene in relation to disease risk 
or aggressiveness [p ~ 0.089].47 In contrast to the Cancer Prevention Study findings, this 
report determined there was no impact of vitamin Eon PCA risk in smokers.47 The 
effects of 11 micronutrients [i.e., 7 carotenoids, retinol (vitamin A), vitamin E] on PCA 
was examined using plasma concentration collected from male subjects of the European 
Prospective Investigation into Cancer and Nutrition (EPIC) cohort.48 Although no 
significant associations were observed in relation to risk (Ptrend ~ 0.50), Iycopene alone 
and the combined carotenoids were both shown to protect against advanced disease 
(Ptrend ~ 0.05).48 
The lack of consistent findings may be due to failure to consider multiple genetic 
and environmental factors along with dietary antioxidants that may jointly modify PCA 
susceptibility and aggressiveness. Consequently, this study investigated this mUltiple 
dietary factors (e.g., meat, vegetable, vitamin/supplement intake) as part of our unique 
panel OSR-related panel to elucidate their role in PCA development. 
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GENETIC OXIDATIVE STRESS RESPONSE PATHWAYS 
As a consequence of the potentially damaging effects of ROS, cells have multiple 
protective OSR mechanisms to prevent excess ROS, oxidative stress and genetic 
damage.1S,18-19 Several biological processes are relevant to oxidative stress status in 
prostate cells, including detoxification (via antioxidant enzymes), DNA repair, and 
apoptosis.2-3, 9, 13 
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Antioxidation Targets & Prostate Cancer 
Antioxidant enzymes are a major cellular oxidative stress defense mechanism in 
the removal of ROS.ll, 14,49-50 These enzymes reduce ROS to produce a less reactive 
species and thereby prevent cellular damage.9, 14, 19, 49-51 For example, superoxide 
dismutases (SODs) scavenge superoxide radicals, converting them to hydrogen peroxide 
molecules.5o Reactive hydrogen peroxide is then subsequently removed by either 
catalase (CAT) or glutathione peroxidases (GPX}.15, 19, 50 Other antioxidative-related 
enzymes important in detoxification and metabolism include, cytochrome P4S0s (CYPs), 
epoxide hydrolase (EPHX1), uridine S'-diphospho (UDP}-glucuronosyltransferase (UGTs), 
sulfotransferases (SULTs), N-acetyltransferases (NATs) and glutathione S-transferases 
(GSTs) [See Table 1].17,34,52 CYPs are a diverse class of enzymes that catalyze the 
oxidation or reduction of endogenous and exogenous substrates. 17, 34 Ephxl converts 
epoxides from aromatic compounds to dihydrodiols that can be conjugated and 
excreted.52 There are two NAT genes (NA T1 and NAT2) that function in the metabolism 
of arylamines by catalyzing the transfer of an acetyl group from acetyl-CoA.17, 34 In 
contrast, other phase II metabolizing enzymes function by conjugating xenobiotics to 
less reactive, water soluble compounds that are more easily excreted.17,52 More 
specifically, ugt enzymes transfer a glucuronic acid; suits catalyze the sulfate 
conjugation; and gsts catalyze the conjugation of ROS to glutathione to produce less 
reactive, water soluble compounds that are more easily excreted. 19, 53 
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Table 1. Phase I & II Metabolizing Enzymes17, 52 
Phase I Epoxide hydrolase 1 (EPHX1) 
ione S-transferase 
N-acetyltransferase (NATs) 
xenobiotics, including PAHs 
intermediates. 
to dihydrodiols to detoxify or 
of reduced glutathione to electrophilic and 
Unfortunately, in some cases antioxidation reactions can convert compounds 
such as PAHs and HCAs derived from cigarette smoke or meat to more reactive 
intermediates.27, 40, 54-56 As shown in figure 4, cyps catalyze the N-hydroxylation of 
MelQx which can be further metabolized by NATs or SULTs to form N2-acetoxy-MeIQx or 
N2-sulfonyloxy-MeIQx.27, 57 These highly reactive compounds can form DNA adducts 
that may lead to tumor formation if left unrepaired. 27, 57 This is also true for 
endogenous ROS generated from cellular processes (e.g., respiration, electron-transport 
chain) such as superoxide radicals. 13, 17, 58 Although, SODs scavenge these radicals, this 
reaction produces hydrogen peroxide which is a more unstable ROS. 13, 17,58 Without 
intervention from CAT or GPX, hydrogen peroxide can interfere with cellular signaling.13, 
17, 58 
Due to their function in detoxification of potentially damaging ROS and 
carcinogens that may be critical to prostate carcinogenesis, antioxidant enzymes have 
been commonly studied in PCA risk.3, 21, 59-60 It has been previously shown that men with 
PCA possess lower antioxidant enzyme levels in prostate tissues compared to both 
healthy controls and men with benign prostatic hyperplasia (BPH).59 Several previous 
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studies have shown PCA tissues contain higher amounts of ROS and oxidative DNA 
damage.21,59.60 Also, in vitro studies have shown ROS to be associated with PCA 
. d . h t 9 61 progression an more aggressive p eno ypes. ' 
Although, genetic variation in polymorphic antioxidation-related genes has been 
implicated in the etiology of prostate cancer and other malignancies, the associations 
are not accepted across all observational studies. 53, 59, 62-66 For instance, a 2006 
publication examined the effect of GSTMl and T1 gene deletions as well as the GSTPl 
lIe105Vai SNP on PCA susceptibility.67 These variants are believed to increase disease risk 
due to decreased detoxification capacity.67 This population-based study consisted of 
590 cases (559 Caucasian, 31 African-American) and 538 controls (523 Caucasian, 15 
African-American}.67 Among the Caucasian subjects, they found deletion of GSTMl was 
moderately associated with increased risk [OR (95%CI) = 1.54 (1.19-2.01}].67 However, 
neither the GSTTl deletion nor GSTPl SNP modified risk in the Caucasians participants.67 
No associations were detected in the African-Americans, but this is most likely due to 
the limited sample size.67 Although a larger study of 378 African-Americans (274 cases 
and 104 controls) investigated the GSTPll05 variant and did not find any statistically 
significant effects in relation to PCA risk [OR (95%CI) = 1.30 (0.43-3.94); P = 0.65]68 
Nock et al. 2007 examined polymorphic PAH-metabolizing genes and cigarette 
smoking in PCA tumors collected from 210 Caucasian and 177 African-American 
subjects.36 More specifically, this study evaluated the individual and joint effects of 
CYP1Allle462Val; CYP181 Ala119Ser and Leu432Val; EPHXl Tyr113His and His139Arg; CYP3A4 
A-392G; GSTMl gene deletion; GSTPl lIe105Val; and cigarette smoking in relation to PAH-
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DNA adducts in PCA tumor and adjacent non-tumor cells.36 Cigarette smoking was 
stratified by never- or ever-smokers with ever smokers including former and current 
smokers. They did not observe any significant effects in the total population, but 
Caucasian participants possessing EPHXl 139Arg alleles had higher adduct levels in tumor 
and non-tumor cells compared to the EPHXl 139His alleles (p = 0.03).36 For Caucasian 
subjects with the heterozygous GSTPl105 genotype higher adducts were found in non-
tumor cell compared to those with two GSTP1 105 11e alleles (p = 0.02).36 The EPHXl 
139Arg alleles were also associated with higher adduct levels in the African-American 
subjects, but only in non-tumor cells compared to the EPHXl 139His alleles (p = 0.07).36 
In the African-Americans, possessing at least one variant CYP181 432Val allele was 
linked to higher adduct levels in tumor cells (p ~ 0.04).36 
A more recent study evaluated gene-environment interactions between CYP1Al 
and EPHXl gene variants and cigarette smoking in relation to PCA risk among a case-
control Indian population (130 cases, 140 controls).69 No significant effects were 
observed in non-smokers possessing the variant CYP1Al or EPHXl 139 Arg alleles (p ~ 
0.54).69 However, the variant EPHXl l13His allele, alone and combined with cigarette 
smoking was associated with an increase at least a 2.6-fold increase in risk (p ~ 0.008).69 
They found smokers carrying the CYP1Al polymorphism had a 1.2-to 1.6-fold increase in 
risk, while those with at least one variant EPHXl 139 Arg was associated with a 3.0-fold 
increase in risk.69 
Although studies such as these may be limited by sample size or scope; 
investigating polymorphic xenobiotic metabolizing genes combined with environmental 
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ROS exposures in relation to PCA development has failed to produce consistent 
findings. 34-35, 43, 70 For instance, Koutros et al. 2009 evaluated 127 polymorph isms across 
mUltiple metabolizing genes (CYP1A1, CYP1A2, CYP181, GSTA1, GSTM1, GSTM3, GSTP1, 
NATl, NAT2, SULTlA1, SULTlA2, and UGTlA locus) and meat-derived HCAs in relation 
to PCA susceptibility within a subset participants selected from the Prostate Lung 
Colorectal and Ovarian Cancer Screening Trial. 34 Meat-derived carcinogen exposures 
was estimated using questionnaire data regarding meat consumption and cooking 
method for a study population of 1126 cases (473 non-aggressive, 654 aggressive) and 
1127 controls.34 From this analysis, possession of at least one or more variant GSTM3 
356Ser was associated with increased risk among subjects in the highest percentile of 
DiMelQx compared to subjects in the lowest percentile [OR (95%CI) = 2.3 (1.2 - 4.7). 
HCA-SNP analyses revealed significant interactions between GSTM3 356Ser and MelQx 
and DiMelQx (p = 0.001). Although data generated from this study suggests joint risk 
effects may exist among GSTP1 105Val or the UGTlA locus and meat-derived 
carcinogens, the interactions were no longer significance after adjusting for False 
Discovery Rate (FDR).34 
More recently, Sharma et al. examined eight NA Tl and seven NAT2 SNPs, along 
with well-done red meat consumption in relation to PCA risk using a multi-ethnic cohort 
population (2106 cases, 2063 controls).70 Individual and multivariate statistical analyses 
were conducted using possession of the NA Tl *10 or 'slow' NAT2 phenotypes and 
frequent well-done red meat consumption designated as the high risk groups.70 No 
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single or combined risk effects were observed between variant NA T1 or NAT2 acetylors 
and well-done red meat intake.7o 
Discrepancies across antioxidative gene variant study findings may be partially 
attributed to failure to consider interactions among antioxidation sequence variants 
along with downstream targets such as those involved in DNA repair and cell death. 
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Base Excision Repair (BER) & Prostate Cancer 
In the event that antioxidant enzymes are not capable of removing ROS, 
DNA repair mechanisms help prevent replication of damaged nucleotides. 16, 18,49,71 ROS 
can damage DNA by oxidizing bases, resulting in mismatches or adducts and that can 
possibly lead to deletions, mutations and distortions in the helix.18 One of the most 
important pathways for removing oxidative DNA damage is base excision repair (BER).72 
BER incorporates several enzymes which recognize and remove an erroneous base. The 
process, shown in Figure 5, is initiated by a glycosylase, such as 8-oxoguanine 
glycosylase (OGG1) or Thymine-DNA glycosylase (TDG).73-75 The glycosylase catalyzes 
the cleavage of the helical backbone to liberate the damaged base, creating an abasic 
site.73-75 Then the phosphodiester bond on the 5' side of the intact 
apurinic/apyrimidinic site is incised by either a glycosylase with lyase activity 
(bifunctional) or an apurinic/apyrimidinic endonuclease (APEX1).73-75 Finally, repair is 
completed with the recruitment of DNA polymerase ~ and ligase (LlG1) by X-ray repair 
cross-complementing group 1 (XRCC1) along with poly (ADP-ribose) polymerase 
(PARP1).73-75 
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Figure S. Base Excision DNA Repair76 
Base Excision (BE) Genes 
(Special iZlOd E><cision Repair Gen_ ~ UNG, 
TOG, SMUG1, MB04, OGG1 , MYH, NTH1, MPG) 
Short-patch 
Figure S: Base Excision DNA Repair. BER is initiated by a glycosylase which catalyzes the cleavage of the 
helical backbone to liberate the damaged base. The phosphodiester bond on the 5' side of the abasic site is 
incised by either a glycosylase with lyase activity (bifunctional) or an apurinic/apyrimidinic endonuclease 
(APE) . X-ray repair cross-complementing group 1 (XRCC1) or poly (ADP-ribose) polymerase (PARP1) recruit 
polymerase ~ and ligase (LlGl) to complete the repair process . 
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Several investigators have examined if non-sysnonymous BER variants (e.g., 
OGG1, APEX1, XRCC1) alter DNA repair capacity of encoded proteins and ultimately 
influence cancer risk. 77-83 Previous studies on the functional consequence of the OGG1 
Ser326Cys polymorphism observed a decreased capacity to repair 8-
hydroxydeoxyguanosine (8-0HdG) adducts linked with the 326Cys allele.84-86 Yamane et 
al. 2003 demonstrated that the OGG1 326Cys allele had a significantly lower capacity to 
suppress spontaneous mutagenesis relative to the 326Ser protein using 
complementation activity assay in Escherichia COIi.84 In addition, two reports found 
higher levels of 8-0HdG in biospecimens (e.g., peripheral blood lymphocyte DNA or cord 
blood) collected from individuals with the Cys/Cys genotype relative to those who were 
Ser/Ser carriers.85-86 Another study revealed that the OGG1 Cys/Cys genotype was 
predictive of prostate cancer at the time of biopsy among 2,088 predominantly 
Caucasian men prescreened with prostate-specific antigen and digital rectal exam.87 
Although the APEX1 Asp148Glu amino acid change does not appear to influence 
endonuclease activity, it may reduce the ability for APEX1 to communicate with other 
BER proteins (e.g., XRCC1), resulting in a reduced BER efficiency and thus a potential link 
to carcinogenesis.88-9o When the APEX1 148Glu allele was considered in combination 
with the XRCC1 399Gln variant allele in Caucasians (258 cases and 215 controls), Chen et 
al. 2006 observed a 2-3 fold increase in the risk of developing PCA relative to those with 
the referent genotype.91 The XRCC1 Arg399Gln polymorphism, located within the PARP-
binding domain has been extensively examined and the presence of the Gin allele has 
been associated with reduced DNA repair capacity as reflected in the persistence of 
26 
bulky DNA adducts and genotoxic DNA damage.92-94 However, when examined 
individually, no investigators have found any association between this polymorphism 
and DNA adducts.92 Similar to Chen et al. 2006, other studies suggest the variant XRCCl 
allele may playa role in PCA risk when considered with other DNA repair targets. 79,95-96 
For instance, Rybicki et al. (2004) observed a 4.8-fold increase in the risk of developing 
PCA among individuals with both the XRCCl 399Gln/Gln and XPD 312Asn/Asn genotypes.79 
Unfortunately, there are limited published reports on whether complex 
interactions among BER genes and up-/ downstream targets in relation to PCA 
susceptibility, particularly among high-risk MAD. To clarify the role of BER genes alone 
and in concert with other OSR targets, we evaluated their individual and joint modifying 
effects in relation to PCA development. 
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Apoptosis & Prostate Cancer 
In cases of persistent, severe or unrepaired oxidative damage, cells will signal 
apoptosis as a protective measure to prevent the replication and advancement of 
cellular damage into tumorigenesis.97-100 Apoptosis is an important biological process 
for cell differentiation, proliferation, death and overall whole body homeostasis. 98, 100-101 
As shown in Table 2, this process is controlled by pro- and anti-apoptosis genes that 
function to induce or block apoptosis, respectively.98-100,102 Regulation of these genes is 
critical in prevention of tumor formation and carcinogenesis.97-99 Clonal expansion and 
tumor growth are believed to result from increased cell proliferation and decreased 
apoptotic cell death.98 Failure to undergo apoptosis may enable survival of transformed 
cells that are prone to undergo further genetic alteration and show genomic instability, 
leading to more invasive phenotypes. lOO 
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Table 2. Major genes involved in the regulation of Apoptosis52 
Gene Function 
Tumor Protein S3 Transcriptionally regulates target genes that induce cell cycle arrest, 
(TPS3) apoptosis, senescence, DNA repair, or changes in metabolism in 
response to cellular stresses 
Tumor Protein pS3 Regulates cell cycle progression and apoptosis, dependently & 
inducible nuelear independently from TPS3 
Pro- & Anti-
protein 1 (TPS3INP) 
Tumor Necrosis Factor Binds and functions through its receptors TNFRSF1A/TNFR1 and 
apoptotic (TNF) TNFRSF1B/TNFBR to regulate cell proliferation, differentiation, 
apoptosis 
BCL2-like 1 (BCL2L1) (AKA: BCL-XL); Outer mitochondrial membrane protein that 
regulates membrane potential, controlling ROS production and 
cytochrome c release. Exists in two isoforms: the longer isoform 
acts as an apoptotic inhibitor and the shorter is pro-apoptotic 
Fas & FAS ligand (FASL) I Death domain-containing receptor, binding of FASl to FAS allows 
the formation of a death-inducing signaling complex 
Caspases (CASP) Cysteine-aspartic acid protease (caspase) gene family involved in 
the execution of cell apoptosis 
Bel2-associated X (BAX) Forms a heterodimer with BCL2 and functions as an apoptotic 
activator involved mitochondrial release of cytochrome c 
BCL2-antagonist/killer Induces apoptosis by increasing cytochrome c release; interacts 
1 (BAK1) with the TP53 after exposure to cell stress 
BCL2-associated Forming heterodimers with BCl-Xl and BCL-2 to reverse their death 
agonist of cell death repressor activity. 
Pro-apoptotic (BAD) 
BCL2-like 10 (BCL2L10) Interact with BCL2 proteins (e.g., BCL2, BCL2L1/BCL-XL, and BAX) 
BCL2-like 11 (BCL2L11) I (AKA BIM); Interacts with other members of the BCL-2 protein 
family (e.g., BCL2, BCL2Ll/BCL-XL), and MCLI) to act as an 
apoptotic activator 
BCL2-like 14 (BCL2L14) apoptosis facilitator 
BH3 interacting Induced by caspase-S (CASPS); CASPS cleaves this encoded protein, 
domain death agonist and the COOH-terminal part translocates to mitochondria and 
(BID) triggers cytochrome c release 
BCL2-interacting killer Interacts with survival-promoting proteins to enhance programmed 
(BIK) cell death; possible target for anti-apoptotic proteins 
B-cell CLL/lymphoma 2 Blocks the release of pro-apoptotic cytochrome c from and block 
(BCL2) caspase activation. 
BCL2-related protein Reduces cytochrome c release from mitochondria and blocks 
A1 (BCL2A1) caspase activation 
Anti-apoptotic Baculoviral lAP repeat- (AKA CIAP1); Inhibits apoptosis by binding to tumor necrosis factor 
containing 2 (BIRC2) receptor-associated factors TRAFI and TRAF2 
BCL2/adenovirus E1B (AKA NIX); BCL2/adenovirus ElB 19 kd-interacting protein (BNIP) 
19kDa interacting gene that may function simultaneously with BNIP3 and playa role 
protein 3-like (BNIP3L) in tumor suppression 
One of the key genes in apoptotic induction is Tumor Protein 53 (TP53) which is 
regarded as "guardian of the genome" due to its multiple functions in regulating the cell 
cycle and supporting genomic stability.103-104 As a transcription factor (TF) for apoptotic 
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genes, TP53 can directly and indirectly trigger permanent or temporary arrest of the cell 
cycle as well as induce apoptosis when DNA repair cannot be achieved.104-105 TP53's 
cycle cell regulatory activity is dictated from intrinsic (cytotoxic stress) or extrinsic 
(outside the cell) signals that indicate the presence of oxidative damage.104-105 Intrinsic 
signals initiated by cytotoxic damage or stress can activate TP53 to arrest the cell cycle 
or induce apoptosis. 104-106 Extrinsic signals are mediated through the binding of ligands 
[e.g., tumor necrosis factor (tnf), fas ligand (fasl)], to their respective cellular membrane 
'death' receptors. 106 [See Figure 6] This interaction can signal apoptosis or survival to 
downstream targets, such as BCL2-related genes. lOO The BCL2 family consists of pro-
and anti-apoptotic proteins capable of inducing or blocking cell death, respectively.6, 107-
109 BCL2 regulates the transport of molecules and apoptotic transcription factors 
through mitochondria channels based on the oxidative state of the cell. 107 BAKl (BCL2 
Antagonist Killer-i) and BIM (BCL2-lnteracting Protein) help accelerate channel opening. 
These proteins, as well as BAX (BCL2 Associated X-protein), these are initially inactive 
and must translocate to mitochondria to induce apoptosis.108-109 They can either 
forming pores in mitochondria directly or by binding to and antagonizing anti-apoptotic 
targets, such as BCL2 or BCL-XL (BCL2 Related Protein Long Isoform).108-109 
BCL2 genes can activate additional apoptotic induction pathways, including the 
cysteine-dependent aspartate-specific proteases or caspases (casps).97, 107 For example, 
cytochrome-C from the mitochondria binds to Apoptotic Protease Activating Factor-i 
(APAFi) with dATP and Procaspase 9 to activate Caspase 9.106 The activation of Caspase 
9 leads to activation of the caspase cascade.106 Casp proteins can activate downstream 
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apoptotic events by either extrinsic (receptor-mediated) or intrinsic (mitochondrial) 
cellular pathways.100 
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Figure 6: Apoptosis. Apoptosis is a complex process involving multiple proteins that can either block or 
induce cell death. Pro-apoptotic proteins can be activated by extrinsic or intrinsic signaling that indicate to 
the cell is no longer needed or damaged beyond repair. In the extrinsic pathway, signaling begins outside a 
cell, when conditions in the extracellular environment determine that a cell must die. This signaling 
activates cell surface receptors that in turn transmit the apoptotic signal to downstream targets, such as 
BID (Bcl2 Interacting Protein) . The COOH-terminal part of BID translocates to the mitochondria and triggers 
the release of cytochrome-Co The released cytochrome-C binds to Apoptotic Protease Activating Factor-l 
(APAFl) with dATP and Procaspase 9 to activate Caspase 9. The activation of Caspase 9 leads to activation 
of the caspase cascade. The intrinsic apoptosis pathway is initiated by cytotoxic stress or damage. TP53 
(aka P53) is a sensor of cellular stress and is a critical activator of the intrinsic pathway. As a transcription 
factor, TP53 can initiate apoptosis by either activating pro-apoptotic (BAX) or suppressing anti-apoptotic 
(BAKl aka BAK) BCL2-related targets. 
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Apoptotic targets play an important role in PCA progression as well as disease 
susceptibility. For instance, TP53, which is the most commonly mutated tumor 
suppressor in cancer, has a low mutation rate in primary PCA but is frequently mutated 
in metastatic PCA.s Nam et al. 2005 reported that the TNF promoter SNP at -308 
associated with increased TNF transcription activity was linked to PCA risk in population 
of 996 cases and 1092 controls (p = 0.04).87 Studies have also found that expression of 
the TNF receptor family member FAS is reduced in PCA tissues, suggesting SNPs 
decreasing FAS or FASL functionality may contribute to disease progression. I11-112 Also, 
overexpression of bcl-2 protein in prostate tumor epithelial cells has been correlated 
with tumor progression to androgen independent disease (e.g., more aggressive 
phenotypes).6 In fact, increased expression of either TP53 or BCL2 has each been linked 
to poorer PCA prognosis.s-6 Another report found a decrease in the risk of developing 
PCA among African-American men harboring the low expressing BCL2 -938 AA 
genotype.97 Higher bcl-2 immunostaining has been associated with more advanced 
disease (Le., higher Gleason grade), suggesting that an increase in this anti-apoptotic 
protein may occur during PCA progression. l13 McConkey et al. also revealed an increase 
in bcl-2 expression levels and loss of pro-apoptotic bax expression in prostatic 
carcinoma cells. 114 
Based on these studies, it is apparent that genetic alterations in apoptosis-
related genes have an important role in the pathogenesis of PCA, presumably due to an 
accumulation of genetically altered and transformed cells. Previous studies indicate 
that in isolation, apoptotic SNPs may minimally influence PCA progression.s-6, 87, 97, 113-115 
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However, combinations of variants may have a joint modifying effect. To our 
knowledge, there are limited published reports on the relationship between apoptotic 
polymorph isms, alone or in combination with variations in other biological pathways, 
and their association with peA development. 
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HYPOTHESIS STATEMENT 
This research project hypothesizes that inheritance of alleles in oxidative stress 
response (OSR) genes associated with compromised OSR capacity, combined with 
exposure to environmental oxidative stress factors will increase prostate cancer 
susceptibility and aggressiveness. 
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SPECIFIC AIMS 
The following three specific aims were executed to evaluate the hypothesis of 
this study: 
Specific Aim 1: Determine the single- and joint-modifying effects of variations 
within oxidative stress response (OSR}-related genes in relation to PCA risk. Oxidative 
stress is a condition in which the amount of reactive oxygen species (ROS) produced 
exceeds the amount that can be removed. 13-16 Several biological processes have 
relevant effects on the oxidative stress status in prostate cells, including detoxification 
(via antioxidant enzymes), DNA repair, and apoptosis.2-3, 9,13 Polymorphisms in OSR 
genes may influence the capacity to suppress ROS, repair oxidative DNA damage, and 
regulate cell death signaling pathways. Hence, it is likely that genetic variation in OSR 
genes resulting in compromised ROS capacity may increase PCA risk. 
Specific Aim 2: Evaluate the individual- and combined effects of apoptotic 
polymorphisms on PCA progression (e.g., disease aggressiveness, tumor grade). Genetic 
variations that disrupt cell death and cell cycle regulation pathways may result in more 
aggressive phenotypes in prostatic tumors.2, 6 Regulation of the cell death is critical to 
maintain cellular homeostasis, proliferation, and differentiation by facilitating repair or 
induction of cell death.98 This process involves multiple pathways and a balance 
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between pro- and anti-apoptotic genes that function to activate or block apoptosis.16, 98 
Decrease or loss of apoptotic induction can permit escape of transformed cells from 
programmed cell death, increase the accumulation of damaged cells, and lead to tumor 
formation and progression.98 Therefore, genetic variations linked with decreased 
apoptosis and/or cell cycle arrest capacity may result in more aggressive disease. lOo, 116 
Specific Aim 3: Identify Oxidative Stress Response-related genetic-environment 
interactions capable of serving as effective predictors of prostate cancer development. 
Endogenous and exogenous ROS sources can contribute to oxidative stress.13.16 This 
includes normal cellular respiration and metabolic processes as well as polycyclic 
aromatic hydrocarbons and heterocyclic amines. 13-14 Excessive oxidative stress can 
produce DNA base changes, damage tumor suppressors, enhance proto-oncogene 
expression, and induce malignant transformation of cells. 13-16 Persistent oxidative stress 
may even trigger apoptosis.13-14, 16 OSR mechanisms function to protect cells against 
oxidative stress damage, however genetic alterations may diminish the ability to 
maintain ROS.3-4 Increased exposure to environmental ROS can exacerbate this effect. 
Consequently, OSR gene variants associated with decreased ROS capacity, combined 
with elevated ROS levels due to environmental factors may increase the risk of PCA 
disease and aggressiveness. 
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RESEARCH DESIGN AND METHODS 
POPULATION DESCRIPTION 
Cancer Genetic Markers of Susceptibility (CGEMS) subjects 
Setting and Participant. This population consists of nationally available genetic 
data from 2,277 men of European-descent (488 non-aggressive cases, 688 aggressive 
cases and 1101 controls) collected through the NCI Prostate, Lung, Colon, and Ovarian 
(PLCO) Cancer Screening TriaI. 117-118 Randomization for the PLCO Trial began in 1993 
and ended in2001 among men ages 55-74 years to evaluate the effect of screening on 
disease specific mortality, relative to standard care. 
Men were included in the current analysis if they had a baseline PSA 
measurement before October 1, 2003, completed a baseline questionnaire, 
returned at least one Annual Study Update (ASU), and had available SNP profile 
data through the CGEMS data portal. For PCA screening, blood samples were 
collected and men received a Prostate Specific Antigen (PSA) test and Digital Rectal 
Exam (DRE). Subsequent to the initial screen, participants received a PSA and DRE 
annually for three and five years, consecutively. Men who had PSA levels >4ng/ml 
or abnormal DRE were referred to their health care provider for follow-up care. 
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Identification of PCA Cases and Controls. The PLCa Trial identified 1172 incident 
PCA cases (484 non-aggressive and 688 aggressive) through various sources 
including: screening exams; reports from patients, physicians, or relatives; linkage 
with the National Death Index; or linkage with the state cancer registries. Incident 
PCA (non-aggressive) cases were pathologically confirmed (Gleason score <7 or 
tumor stage I/II). Cases were diagnosed with aggressive disease based on a Gleason 
score ~7 or tumor stage III/IV (regional or metastatic disease). Incident cases were 
defined as men receiving a diagnosis after the first year of follow-up. Controls (n = 
1157) were matched to cases based on age, time since initial screening, and year of 
blood draw using incidence density sampling. Incidence Density sampling accounts 
the dynamic nature of a cohort study.ll9 Under this selection strategy, controls 
were selected independently for each case from those who were at risk at the time 
of the diagnosis of the case. Identification as a control for a given case set is 
independent of the following: future diagnosis as a case, selection as a control for 
other case sets, and the number of entry and exit times. Therefore, individuals may 
be included as both a case and a control. The genotype data for individuals who 
have been selected multiple times are taken into consideration for each selection. 
Other covariates that vary with time, such as age are defined differently each time, 
depending on the characteristics of the case set for which he was selected as a 
control. 119 
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All participants signed informed consent documents approved by both the NCI 
and local institutional review boards. Access to clinical and background data collected 
through examinations and questionnaires was approved for use by the PLCO. 
Demographic, Anthropometric and Lifestyle factors. Questionnaire data included 
information regarding age, family history of prostate cancer, as well as a comprehensive 
dietary and supplemental usage. For patient characteristics and lifestyle factors, risk 
categories were designated using guidelines recommended by the 2005 United States 
Department of Agriculture (USDA) Report of Dietary Guidelines and the NIH Office of 
Dietary Supplements.12O-121 For a male with median height and weight, a BMlless than 
24.9 was considered normal or underweight.12o The USDA also advises that adult men 
get at least 30 minutes of physical activity each day.120 A BMI between 25 and 29.9 is 
overweight and men with a BMI greater than 30 are classified as obese.120 Men over 
the age of 19, with a normal BMI should consume between 2000-3000 calories per day 
with at least 4 servings of fruits and 5 servings of vegetables, but no more than 5 
servings of meat.120 Total fat intake should be limited to 20-35% of daily calories and 
less than 10% percent of calories ought to come from saturated fatty acids.120 Alcoholic 
consumption should be limited to no more than drinks per day.12O 
According to the NIH office of Dietary Supplements, each day adult men need 
approximately 90 mg of vitamin C, 900 Ilg or 3,000 IU (International Units) of vitamin A, 
and 15 mg or 22.4 IU of vitamin E.l2l It is also recommended than adult men intake at 
least 11 mg of zinc and 55 Ilg of selenium daily.l2l 
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For variables related to meat consumption and cooking methods, as well as 
exposure to meat-derived carcinogens were divided into quartiles using data for the 
control subjects. The 1st quartile was used as the low risk category. These categories 
included daily total meat intake as well the amount of white (i.e. chicken and fish), 
processed, or red meats. Red meat consumption was also stratified by type or cooking 
duration into non-processed, rare/medium-well, and well-/very-well done. The meat-
derived carcinogens used in this analysis were MelQx, DiMelQx, PhlP, and BaP. 
Men of African Descent subjects 
Between 2001 and 2005, 774 unrelated male residents were recruited from the 
Washington, D.C. and Columbia, SC areas through the Howard University Hospital (HUH) 
Division of Urology or PCA screening programs. The study population of men of African 
descent (i.e., self-reported African-Americans, East African-Americans, West African-
Americans, and Afro-Caribbean Americans) consisted of 219 incident PCA cases and 694 
unrelated controls. PCA patients between the ages of 41 and 91 were diagnosed within 
one year of enrollment. Following a visit to the HUH Division of Urology for an annual 
PCA screening exam or urinary symptoms, incident PCA cases were identified by a 
urologist using a transrectal ultrasound-guided biopsy. Biopsy cores were reviewed by 
members of the Department of Pathology at the Howard University College of Medicine. 
PCA cases were classified according to a well-established Gleason scoring system. 122 
Inclusion criteria of controls included men older than 45 with a low prostate specific 
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antigen (PSA) level ~ 4.0 ng/ml and normal digital rectal exams (DREs) or biopsies. 
Clinical characteristics including age at diagnosis/enrollment, family history of PCA, PSA 
level (ng/ml), and Gleason score for PCA patients, were obtained from medical records. 
Histopathological grade was recorded as the Gleason score. Information on smoking 
history was also collected at the time of recruitment using a short questionnaire. Male 
residents from D.C. were classified as either never (n = 107) or ever smokers (n = 109), 
where 'ever' includes former and current smokers. All study participants had DNA 
extracted from whole blood and provided written informed consent for participation in 
genetic analysis studies under a protocol approved by Howard University, the HUH 
Division of Urology, and the University of Louisville Institutional Review Board. 
Ancestry Markers. One hundred previously validated ancestry markers 
autosomal markers were included to account for potential population stratification 
among our admixed population of self-reported African-Americans, West African, East 
African, Afro-Caribbean, as previously described.123 Study participants were grouped 
from lowest to highest genetic West African Ancestry (WAA), with scores ranging from 
0-100%. These 100 markers were assembled using DNA from self-identified African-
Americans (Coriell Institute for Medical Research, n = 96), Yoruban West Africans 
(HapMap, n = 60), West Africans (Bantu and Nilo Saharan speakers, n = 72), Europeans 
(New York City, n = 24), and CEPH Europeans (HapMap Panel, n = 60), as previously 
reported. 123 Individuals (n = 873) with a high degree of WAA greater than or equal to 
25% were considered in the final analysis. 
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OSR GENE SELECTION 
In an attempt to focus our investigation of OSR related genes in relation to PCA 
risk and disease progression, a panel of candidate SNPs was generated from genes 
involved in antioxidation, DNA repair and apoptotic mechanisms. A list of 118 OSR 
genes generated based on published PCA epidemiology studies as well as pathway 
databases and tools, including KEGG, Kyoto Encyclopedia of Genes and Genomes 
(www.genome.jp/kegg), Ingenuity (www.ingenuity.com), BioCarta 
(www.biocarta.com),and SNPs3D (www.SNPs3D.org), as summarized in Figure 7.110,124-
128 More specifically, KEGG and BioCarta sites provide diagrams illustrating gene 
interactions within human biological pathways.110, 124-126 Ingenuity is a pathway analysis 
software that allows researchers to model and investigate biological systems (e.g., 
genes, mechanisms, and diseases).127 SNPs3D is a website which assigns molecular 
functional effects of non-synonymous SNPs (nsSNPs) based on structure and sequence 
analysis.128 SNPs3D also allows users to generate candidate gene lists and interactive 
maps for various conditions based on published literature as well as other 
functional/pathway databases [e.g., KEGG and the Gene Ontology (GO)].128 Together, 
these tools show important molecular interactions and genes not readily found by 
literature search or other traditional methods. In order to predict the functional effects 
of a SNP, this site considers factors such as, protein structure, gene regulation, splicing 
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and miRNA binding, and whether the alternative alleles are likely to have differential 
effects on function. 129 
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SNP SELECTION 
Phase I Selection of SNPs for men of European Descent. Prior to uploading our 
initial list (i.e., 118 OSR genes) into the CGEMS data portal, we secured the HUGO gene 
name equivalents for the targets of interest using National Center for Biotechnology 
Information (NCBI, http://www.ncbi.nlm.nih.gov) Entrez Gene. SNP profile data was 
available for more than 1516 SNPs [Figure 7].119 However, the final analysis focused on 
242 SNPs detected in 83 OSR genes collected from 2276 European-Americans CGEMS 
participants, as summarized in Tables 3-8. Emphasis was placed on sequence variants 
that were: (1) detected within all exons, 2.5kb upstream of the gene, 2.5kb downstream 
of intron 1, 2.5kb downstream of the gene; (2) had a minor allele frequency >1%. SNPs 
were discarded if the observed genotype frequency among controls significantly 
deviated from the Hardy-Weinberg Equilibrium (HWE p < 0.005). Over 240 sequence 
variants detected in 83 OSR genes fit the aforementioned selection criteria, following 
assessment using NCBI Entrez SNP, as detailed in figure 7. 52,129 
Phase /I Selection of SNPs for men of African Descent. 25 OSR SN Ps were 
selected for analysis using one or more of following criteria: (1) epidemiological 
evidence from the CGEMS prostate cancer database or published reports indicating 
their involvement in cancer based on p values < 0.05; (2) commonly studied loci; (3) 
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marked disparities in genotype frequency comparing men of African descent to their 
Caucasian counterparts; (4) evidence demonstrating a link with alterations in mRNA 
expression/stability or protein expression/structure or function using in silico tools (e.g., 
SNPinfo, SNPs3D) or published reports; and (5) minor allele frequency >1%. The SNPs 
that were analyzed among men of African descent are indicated in tables 3-8 by 
magenta font. 
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PREDICTED FUNTION OF SELECTED SNPS 
Tools such as SNPinfo and SNPs3D aid investigators in annotating and/or 
predicting the functional consequence of selected SNP targets. 129 For instance, in the 
case of SNPs located in gene coding regions, the server identifies nonsense SNPs that 
lead to premature termination of translation or nsSNPs that lead to amino acid changes 
affecting protein function. 129 Sequence variants at transcription factor binding sites 
(TFBS) may affect the level or timing of gene expression. 129 Also, non-coding SNPs that 
are located in intronic or near gene regions may impact either splice- or microRNA-
(miRNA) binding sites.129 SNPs that are located within two base pairs of an intron-exon 
junction or at exonic splicing- enhancer (ESE)/ silencer (ESS) binding sites may disrupt 
messenger RNA (mRNA) splicing and severely affect protein function. 129 miRNA are 21-
23-base single-stranded RNA molecules that are usually complementary to a site in the 
3' UTR region of an mRNA.129 miRNA bound to the end of mRNA can inhibit protein 
translation. 129 
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Figure 7. Gene and SNP Selection Flow Diagram 
1. Indentify gene targets 
-Published literature & Pathway 
Analysis 
4. Evaluate SNPs 
-Oetermine effects of SNPs & 
environmental factors on risk & disease 
progression (LR,MOR, hlG) 
2. (GEMS data query 
-PCA Incidence density 
sampling 
3. SNP Filtering 
-MAF >1% 
-Coding SNPs; noncoding SNPs 
within +/- 2.S kb gene flanking 
region; intron 1 
-HWE P < O.OOS 
Figure 7: SNP Selection Flow Diagram. By exploring published literature and pathway analysis tools for 
genes involved in prostate cancer and oxidative stress response, an initia l list of more than 100 genes was 
generated . Upon analyzing these genes in CGEMS association finding dataset, we found 1,516 SNPs had 
genotype data available in the CGEMS database. National Center for Biotechnology Information (NCBI) was 
reviewed to ensure that the selected targets were related to our pathways of interest, had a minor allele 
frequency >1%, resided in regions likely to modify mRNA expression/stability/splicing or protein 
expression/structure/function. The finalized panel consisting of 242 SNPs detected in 83 OSR genes was 
then analyzed by logistic regression analysis (LR), multifactor dimensionality reduction (MDR). and 
hierarchical interaction graphs (hIG) 
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Table 3. NCB I data for Antioxidative Polymorphisms52 
5'near gene (-1616) 
rs2470893 3'near gene (-1540) 
rs4646903 72828970 3'near gene (+1188) 
rs2069514 75038220 5'region (-3859) 
rs2069522 72826286 5'near gene (-1757) 
rs762551 CYP1A2 15 75041917 Intron 1 
rs1800440 CYP181 2 Exon 2 
rs11673270 CYP286 19 
rs2860840 10 
10 lys399Arg 
10 
10 5'near gene (-120) 
10 135240981 Intron 1 
rs2515642 CYP2El 10 135240894 Intron 1 T>C 
rs6413420 CYP2El 10 135229710 5'near gene (+38) G>T 
rs1051740 EPHXl 1 222326368 Exon4 T>C Tyr113His 
C>T Asn357Asn 
His139Arg 
rs563464 
rs638820 5'near gene (+765) 
rs7483 
rs1695 lIe105Vai 
rs6591256 5'near gene (+1197) 
rs7003890 
rs7017402 
rs8190870 NAT! 8 18125552 3'near gene (-452) 
rs1112005 NAT2 8 18300156 Intron 1 
rs1208 NAT2 18302596 Exon 2 lys268Arg 
rs1390358 NAT2 8 18297035 Intron 1 T>C 
rs4646247 3'near gene (-224) G>A 
Abbreviations: Chr, chromosome; Cau, Caucasians; AA, African-Americans 
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Table 3. NCB I data for Antioxidative Polymorphisms, continued52 
rs2758331 
rs6717546 2 234464119 
Intron 1 
3'near gene (-174) 
Abbreviations: Chr, chromosome; Cau, Caucasians; AA, African-Americans 
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Table 4. NCBI data for Base Excision Repair Polymorphisms52 
Ser326Cys 
rs3087374 Exan 16 
rs3730814 POll 18 50072899 Intran 1 G>T 
rs545979 POll 18 50073748 Intran 1 C>T 
rs8305 POll 18 50074803 Exan 1 A>G 
rs4135036 TOG 12 102883184 5'near gene (+587) T>C 
rs3219243 UNG 12 108026775 Intran 1 T>C 
rs3890995 UNG 12 108017912 5'near gene (+1953) T>C 
rs25487 Exan 10 G>A Arg399Gln 
rs2682585 5'near gene (-1518) 
Intran 1 
Abbreviations : Chr, chromosome; Cau, Caucasians; AA, African-Americans 
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Table S. NCB I data for Apoptosis-related Polymorphisms52 
dbSNP ID Gene Chr Chr position Location Nucleotide Amino Acid 
change Change 
rs 1885097 ACINI 14 22619159 E 6 xon A>G S 467P er ro 
rs37S1501 ACINI 14 22619125 Exon 2 G>A Ser478Phe 
rs10157763 AKT3 1 240321082 Intron 1 C>T 
rs10803155 AKT3 1 240220823 Intron 1 G>A 
rs10927067 AKT3 1 240249285 Intron 1 G>A 
rs12031994 AKT3 1 240243350 Intron 1 T>C 
rs2034915 AKT3 1 240204544 Intron 1 C>T 
rs2125230 AKT3 I 1 240211889 Intron 1 G>A 
rs2125231 AKT3 1 240088340 Intron 1 G>A 
rs234S994 AKT3 1 240258316 Intron 1 C>T 
rs4132509 AKT3 1 240269125 Intron 1 C>A 
rs4614244 AKT3 1 240326915 Intron 1 I T>C 
rs897960 AKT3 1 240259609 Intron 1 A>G 
rs10745834 APAFI 12 97562818 Intron 1 A>G 
rs10860361 APAFI 12 97631965 3'near gene (-298) A>G 
rs1439123 APAFI 12 97578784 Intron 1 T>C 
rs1439124 APAFI 12 97622538 Intron 1 A>C 
rs2288714 APAFI 12 97610756 Intron 1 T>C 
rs4319556 APAFI 12 97579054 Intron 1 G>A 
rs7299S36 APAFI 12 97603878 Intron 1 G>A 
rs7315397 APAFI 12 97552834 Intron 1 G>A 
rs919699 APAFI 12 97586794 Intron 1 C>T 
rs210134 BAKI 6 33648187 3'near gene (+212) G>A 
rs5745568 BAKI 6 33656372 5'near gene (-265) C>A 
rs11667351 SAX 19 54147966 5'near gene (-2477) T>G 
rs4645878 SAX 19 49457938 5'near gene (-248) C>T 
rs4645900 SAX 19 54156175 Intron 1 C>T 
rs905238 SAX 19 54157196 3'near gene (-85) I A>G 
rs1016860 SCL2 18 58946054 3'UTR (mRNA 1997) G>A 
rs1564483 SCLl 18 58945634 3'UTR (mRNA 2417) G>A 
rs3927911 SCL2 18 59084606 Intron 1 C>T 
rs1138357 SCL2AI 15 78050461 Exon 1 G>A Cys19Tyr 
rs1138358 SCL2AI 15 78050400 Exon 1 T>G Asn39Lys 
rs3826007 SCL2AI 15 78050272 Exon 1 • G>A Gly82Asp 
rs13405741 SCL2LlI 2 111629287 Intron 1 T>C 
rs3789068 8CLlLlI 2 617170 Intron 5 I T>C 
AbbreViations: Chr, chromosome; Cau, Caucasians; AA, African-Americans 
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Table S. NCBI data for Apoptosis-related Polymorph isms, continuedS2 
rs724710 111623922 Exon 1 lIe9511e 
rs4488761 BCL2L13 22 16584167 Exon 1 Ser2575er 
rs10772530 BCL2Ll4 12 12157308 Intron 1 
rs10845479 BCL2Ll4 12 12135568 Intron 1 
Intron 1 
Intron 1 
Intron 1 
Intron 1 
Intron 1 
rs2448063 BCL2Ll4 12 12113301 5'near gene (-1844) 
rs6488494 12 12121219 Intron 4 
rs4763780 BCL2Ll4 12 12144858 Intron 1 
rs4763781 BCL2Ll4 12 12145743 Intron 1 
rs4763782 BCL2Ll4 12 12146023 Intron 1 
rs879732 Tyr162Tyr 
rs885637 
rs885720 
3'UTR (mRNA 1294) 
Intron 1 
rs181405 Intron 1 
rs181408 Intron 1 
rs181417 Intron 1 
rs366542 
Intron 1 
Intron 1 
rs4988360 5'near gene (-1725) 
rs4988366 5'near gene (-1101) 
rs738276 Intron 1 
3'UTR (mRNA 2047) 
3'UTR (mRNA 2792) 
19 53443620 C>T 
Abbreviations: Chr, chromosome; Cau, Caucasians; AA, African-Americans 
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Table S. NCB I data for Apoptosis-related Polymorphisms, continued52 
rs11670259 
rs11672725 
rs6509364 
Intran 2 
3'UTR (mRNA 1267) 
Intran 1 T>G 
rs507879 11 104383137 Exan 2 A>G Thrl06Ala 
rs537093 CASPS 11 104371256 Intran 5 G>A 
rs3181187 CASP6 4 110980514 Intran 1 G>A 
rs3212153 CASP6 4 110967085 3'near gene (+337) 
rs768063 CASP6 4 110978060 Intran 1 
rs12415607 CASP7 10 115428194 S'near gene (-740) 
rsl0931934 CASPS 2 201945295 Intran 
Intran 1 
rs12817549 Intran 2 
rs3858606 92760016 Intran 2 
rs11588734 5'near gene (-419) 
Exan 2 Arg196Lys 
Pra318Pra 
5'near gene (+756) 
rs12870 3'UTR (mRNA 1633) 
rs7972948 Intran 1 
rs9669553 12 115778069 Intran 1 C>T 
rsl048906 12 97531754 Exan 1 G>A Gly265Ser 
rs12371097 12 97531767 Intran 1 A>G 
rs12821083 12 
rs11578093 1 3'near 
rs1539243 1 203036182 Exan4 
rs1930438 IKBKE 1 203031501 5'near gene (+710) G>A 
rs944775 IKBKE 1 203056988 Intran 1 A>G 
rs11688 JUN 1 58960014 Exan 1 G>A Gln250Gln 
Abbreviations: Chr, chromosome; Cau, Caucasians; AA, African-Americans 
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Table s. NCB I data for Apoptosis-related Polymorph isms, continued52 
3'UTR (mRNA 1260) 
4 103893462 
rs4648135 NFKBl 4 103893871 A>G 
rs1056890 NFKB2 10 104152760 3'near gene (-523) C>T 
rs696 NFKBIA 14 34940844 3'UTR (mRNA 1190) G>A 
rs8904 NFKBIA 3'UTR (mRNA 1066) C>T 
rs2230365 NFKBILl Exon 2 C>T Ser126Ser 
rs1607237 PIK3CA 180432999 Intron 1 T>C 
rs500687 139942901 Intron 1 
5'near gene (+473) 
rs9890506 PRKCA 17 62214645 Intron 1 
rs1530668 PRKCE 2 46318270 Intron 1 
rs17034455 PRKCE 2 46225132 Exon 4 C>T 
rs2594489 PRKCE 2 46319722 Intron 1 C>T 
rs281472 T>C 
rs281476 T>C 
T>C 
rs281508 
rs3820729 PRKCE 2 Intron 1 
rs608139 45789207 5'near gene (+1360) 
rs935672 45957610 Intron 
rs935673 46034008 Intron 
rs951012 46309282 Intron 1 
rs2236379 Exon 3 C>T Pro330Leu 
(mRNA2458) 
rs519951 
rs571715 PRKCQ 10 Intron 1 
rs574521 PRKCQ 10 6596860 Intron 1 
rs585881 PRKCQ 10 6598275 5'near gene (-1172) 
rs11128607 RAFl 3 12648275 Intron 1 
rs11709504 RAFl 3 12649199 Intron 1 T>C 
Abbreviations: Chr, chromosome; Ca u, Caucasians; AA, Africa n-Americans 
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Table 5. NCBI data for Apoptosis-related Polymorphisms, continuedS2 
rs13060691 
rs6442322 
rs6792773 
rs7643321 
rs7956 
rs281505 
rs7739011 
rs11247963 
rs1865077 
rs1000294 
rs13278062 
rs6557634 
rs7842021 
rs1001793 
rs1047266 
rs11135693 
rs7957 
rs1860545 
rs4149570 
rs4149576 
rs4149577 
rs365238 
2 
6 
1 
19 
TNFRSFIOA 8 
TNFRSFIOB 8 
TNFRSFIOB 8 
TNFRSFIOB 8 
TNFRSFIOD 8 
TNFRSFlA 12 
TNFRSFIA 12 
TNFRSFIA 12 
12 
3057529 
26539543 
22956646 
22981099 
23049312 
6317038 
6321851 
6319376 
6317783 
Intron 1 
Intron 1 
5'near gene (+468) 
3'near gene (+417) 
Intron 1 
5'near gene (+722) 
Exon 3 
Intron 1 
5'near gene (-890) 
Intron 1 
Exon 2 
Intron 1 
near gene (-957) 
3'UTR (mRNA 3269) 
Intron 1 
5'near gene (+222) 
Intron 1 
Intron 1 
Intron 1 
Exon 4 
Abbreviations: Chr, chromosome; Cau, Caucasians; AA, African-Americans 
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G>A 
T>C 
C>T 
C>A 
C>T 
C>T 
T>C 
G>T 
T>G 
Asnll1Asn 
Arg44lLys 
His141Arg 
5er310leu 
Met196Arg 
Table 5. NCBI data for Apoptosis-related Polymorphisms, continued52 
Abbreviations: Chr, chromosome; Cau, Caucasians; AA, African-Americans 
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Table 6. NCBI Prevalence Data for Variant Antioxidative Targets52 
Abbreviations: Cau, Caucasians; AA, African-Americans, WT, wild-type; VT, variant 
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Table 6. NCB I Prevalence Data for Antioxidative Targets, continued52 
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Table 7. Prevalence Data for Variant Base Excision Repair Targets52 
dbSNP ID Gene (au WT/WT (au WT/VT (au VT/VT AAWT/WT AA WT/VT AA VT/VT 
rs1130409 APEXl 26.7 45.0-33.3 28.3-40.0 25.0-53.2 40.3-54.2 6.5-20.3 
rs1052133 OGGl 51.1-63.3 30.0-38.9 6.7-6.9 79.2 20.8 0.0 
rs125701 OGGl 74.6-77.3 22.7-23.7 1.7 87.0-88.0 12.0-13.0 0.0 
rs2445837 POLDl 88.3 11.7 0.0 19.4 43.5 37.1 
rs3087374 POLG 81.7-87.5 8.3-18.3 4.2 100.0 0.0 0.0 
rs3730814 POLl 58.3-65.0 33.3 1.7-8.3 91.3 8.7 0.0 
rs545979 POLl 51.7-58.3 33.3-41.7 6.7-8.3 78.3 21.7 0.0 
rs8305 POLl 45.8-51.7 41.7-45.0 3.3-12.5 78.3-80.6 17.7-21.7 1.6 
rs4135036 TOG 90.0 8.3 1.7 95.2 4.8 0.0 
rs3219243 UNG 66.1 30.5 3.4 nfa n/a nfa 
rs3890995 UNG 65.2-67.8 30.5-34.8 1.7 68.2 31.8 0.0 
rs25487 XRCCl 25.8-47.9 12.5-43.7 8.5-19.4 83.3 12.5 4.2 
rs2682585 XRCCl 63.3 I 31.7 5.0 nfa nfa nfa 
rs2854496 XRCCl 73.3 23.3 3.3 nfa nfa nfa 
rs3213255 XRCCl 25.0-38.3 48.3-70.8 4.2-13.3 38.7-39.1 43.5-51.6 9.7-17.4 
AbbreViations: (au, Caucasians; AA, African-Americans, WT, wild-type; VT, variant 
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Table 8. Prevalence Data for Variant Apoptotic Targets52 
Abbreviations: Cau, Caucasians; M, African-Americans, WT, wild-type; VT, variant 
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Table 8. Prevalence Data for Variant Apoptotic Targets, continued52 
Abbreviations: Cau, Caucasians; AA, African-Americans, WT, wild-type; VT, variant 
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Table 8. Prevalence Data for Variant Apoptotic Targets, continued52 
Abbreviations: Cau, Caucasians; AA, African-Americans, WT, wild-type; VT, variant 
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Table 8. Prevalence Data for Variant Apoptotic Targets, continued52 
dbSNP 10 Gene (au WT/Wl (au WT/VT (au VT/VT AAWT/WT AAWT/VT AA VT/VT 
rs696 NFKBIA 31.7-40.0 SO.o-55.0 5.0-18.3 17.4 43.5 39.1 
rs8904 NFKBIA 31.7-48.4 38.7-50.0 12.5-18.6 6.7-20.8 40.9-58.3 20.8-46.7 
rs2230365 NFKBIU 58.1-75.0 25.0-38.7 3.2 90.0-95.8 • 4.2-10.0 0.0 
rs11656099 PRKCA 55.0-56.7 36.7-38.3 6.7 nfa n/a nfa 
rs8074995 PRKCA 80.0 20.0 0.0 nfa nfa I nfa 
rs9890506 PRKCA 86.4-86.7 11.7-11.9 1.7 nfa n/a I nfa 
rs1530668 PRKCE 93.3 6.7 0.0 nfa n/a I nfa 
rs17034455 PRKCE 78.3-100.0 , 10.3-17.4 3.4-4.3 95.7 4.3 r 0.0 
rs2594489 PRKCE 41.4-41.7 37.5-SO.0 8.3-20.8 4.3 26.1 I 69.6 
rs281472 PRKCE 83.1-83.3 15.0-15.3 1.7 nfa n/a nfa 
rs281476 PRKCE 53.3-66.7 28.8-33.3 16.7-16.9 56.5 34.8 8.7 
rs281505 PRKCE 32.8-33.3 SO.O 16.4-17.2 nfa nfa I nfa 
rs281508 PRKCE 40.7-75.0 16.7-43.3 8.3-12.5 17.4-50.0 50.0-78.3 4.3 
rs3820729 PRKCE 80.0 16.7 3.3 I nfa nfa I nfa 
rs608139 PRKCE 63.3 31.7 5.0 nfa nfa ~ nfa 
rs935672 PRKCE 33.3-49.2 32.2-54.2 12.5-18.3 4.3 47.8 47.8 
rs935673 PRKCE 31.7-37.5 50.0-60.0 8.3-12.5 12.5 50.0 37.5 
rs951012 PRKCE 35.0-50.0 36.7-45.8 8.3-21.7 21.7-35.0 50.0-60.9 8.3-15.0 
rs2236379 PRKCQ 61.7 35.0 3.3 47.2 43.4 9.4 
rs2236380 PRKCQ 45.0-54.2 41.7-SO.0 4.2-5.1 8.7 26.1 65.2 
rs519951 PRKCQ 58.3-68.3 30.0-37.5 1.7-4.2 39.1 43.5 17.4 
rs571715 PRKCQ 58.3-85.7 14.3-37.5 1.7-4.2 43.5-77.8 11.1-39.1 10.0-17.4 
rs574521 PRKCQ 58.3-66.7 31.7-37.5 , 1.7-4.2 43.5 39.1 17.4 
rs585881 PRKCQ 58.3-66.7 
• 
31.7-37.5 1.7-4.2 I 39.1 43.5 t 17.4 
rs11128607 RAF1. 65.0 31.7 3.3 nfa n/a I nfa 
rs11709504 RAF1. 66.7-69.5 27.1-29.2 3.4-4.2 39.1 43.5 I 17.4 
rs11710163 RAF1. 83.3 
. 
16.7 0.0 nfa n/a I nfa 
rs13060691 RAF1. 88.7 11.3 0.0 nfa n/a I nfa 
rs6442322 RAF1. 33.3 50.0-51.7 15.0-16.7 56.5 39.1 I 4.3 
rs6792773 RAF1. 65.0 31.7 3.3 nfa nfa nfa 
rs7643321 RAF1. 68.3-79.6 16.7-28.3 3.3-3.7 n/a n/a , nfa 
rs7956 RAF1. 61.0-62.5 33.3-33.9 4.2-5.1 52.4 33.3 14.3 
rs904453 RAF1. 31.7-42.9 45.5-57.1 15.0-18.2 28.6-35.5 43.5-45.5 14.3-21.0 
rs9817675 RAF1. 56.7-69.6 26.1-40.0 3.3-4.3 50.0 38.9 11.1 
rs7101916 RELA 71.7 25.0 3.3 nfa nfa I nfa 
rs7739011 RIPK1. 86.7 13.3 0.0 nfa n/a I nfa 
rs11247963 RPS6KA1. 66.7-67.9 23.2-23.3 8.9-10.0 nfa n/a I nfa 
Abbreviations: (au, Caucasians; AA, African-Americans, WT, wild-type; VT, variant 
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Table 8. Prevalence Data for Variant Apoptotic Targets, continued52 
Abbreviations: Cau, Caucasians; AA, African-Americans, WT, wild -type; VT, variant 
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GENETIC ANALYSIS OF VARIANT OSR MARKERS 
To evaluate interactions among candidate OSR related genetic alterations in 
relation to PCA development we used genetic profile data collected from participants 
within our study populations. The CGEMS project has genotyped nearly 550,000 
common genetic variants (SNPs) among 2,277 men of European descent (488 non-
aggressive cases, 688 aggressive cases and 1101 controls).119 Genetic profiling was 
performed using the Iliumina Human HapMap500 chips (iliumina, Inc, San Diego, CAl. 
Access to clinical and background data collected through examinations and 
questionnaires was approved for use by PLCO. UofL IRB approval is not required for the 
use of nationally available de-identified data. 
Candidate SNPs were detected among MAD subjects using TaqMan®- PCR allelic 
discrimination assays (Applied Biosystems, Foster City, CAl and 48-Plex GenomeLab™ 
SNPstream® Genotyping System (Beckman Coulter, Brea, CAl. Based on 24 non-DNA 
template controls per batch analysis (n = 384), the percent cross-contamination during 
sample handling was minimal «4.0%). Duplicate genotyping was performed for 72 
randomly selected samples for quality control purposes, resulting in concordance rates 
>98%. 
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SINGLE & MULTIPLE OSR FACTORS IN RELATION TO PROSTATE CANCER OUTCOMES 
Logistic Regression Analysis. Logistic regression analysis was used to evaluate 219 and 
25 OSR associated SNPs among men of European and African descent, respectively, in 
relation to prostate cancer outcomes. To assess whether individuals possessing at least 
one variant (i.e., minor) oxidative stress allele have an elevated risk of developing PCA, 
we tested for significant differences in the distribution of homozygous wildtype, 
heterozygous, and homozygous minor genotypes between cases and controls using the 
chi-square test of heterogeneity. Case-control and case-case analyses were used to 
evaluate variant OSR related alleles in relation to PCA risk and aggressive disease 
(Gleason score < 7 and tumor stage ~3 versus Gleason score >7 and tumor stage :S;2). 
The associations between PCA and candidate polymorphic genes, expressed as odds 
ratios (ORs) and corresponding 95% confidence intervals (Cis), were estimated using 
unconditional multivariate LR models adjusted for potential confounders. LR analysis 
for genetic variants and PCA development were conducted using the wild-type or 
common genotype as referent category. Risk estimates for MED were adjusted for age 
and family history of prostate cancer. Whereas, risk estimates for MAD were adjusted 
for age and WAA. All chi-square tests and LR analyses were conducted using SAS 9.2 
(SAS Institute Inc., Cary, NC). Statistical significance was assessed using a p value < 0.05. 
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Analysis of SNP pairwise interactions using LR. Two-way (i.e., gene-gene and gene-
environment) interactions were evaluated by the significance of the coefficient of the 
product term 63factor_l *factor_2 in the following model: Logit = 60 + 61/actor_l + 62 
factor_2 + 63 factor_l * factor_2. Interaction models were adjusted for potential 
confounders. 
Reduction. To evaluate the single- and joint- modifying effects of hundreds of 
candidate SNPs within a large dataset, such as CGEMS is computationally challenging. 13o-
131 In order to overcome this problem, Multifactor Dimensionality Reduction (MDR) 2.0 
(SourceForge, Inc, Sourceforge.net) was used to prioritize OSR sequence variants. The 
MDR software is open-source and freely available online. 132 MDR is a method for 
detecting and characterizing high-order interactions in case-control studies, one 
remaining effective with relatively small sample sizes.so With MDR, multi-locus 
genotypes are pooled into high-risk and low-risk groups, reducing high-dimensional data 
to a single variable dimension and permitting an investigation of gene-gene and gene-
environment interactions. Concisely, this one-dimensional multi-locus genotype 
variable was evaluated for its ability to classify and predict disease susceptibility through 
cross-validation and permutation testing. Among all of the gene-gene and gene-
environment combinations, a single model was selected that maximized the case-to-
control ratio of the high-risk groups while minimizing classification and prediction 
errors. 
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The current version of MDR used in this project allows for the incorporation and 
adjustment of mUltiple covariates. 133 To remove the covariate effect, we integrated two 
sampling methods (i.e., over- and under-sampling). This approach is computationally 
efficient, thus allowing for adjustment of multiple covariates without significantly 
increasing computational burden. Inclusion of covariates allows estimates of specificity, 
sensitivity, and overall predictive accuracy with and without the genetic factors, to 
assess the gains in predictive ability afforded by the genetic factors. 
To evaluate how many times the same MDR model is identified in each possible 
9/10ths of the data and repeats this 10-fold cross-validation 10 times until the entire 
dataset is evaluated.134 Therefore, eve values can range from 1/10 up to 10/10, with a 
eve = 10/10 indicating that a model was selected as the best predictor 10 out 10 
times. 134 The prediction error is calculated as the average of prediction errors across 
each ofthe 10 cross-validation subsets.134-135 The model with the greatest eve (e.g. ~ 
7/10) and lowest prediction error [e.g., Average Testing Accuracy (ATA) values between 
0.540-0.600] is selected as the best predictor of disease outcome.134-135 MDR models 
are validated by comparing the average eve to the distribution of the average 
consistencies under the null hypothesis of no association, to be derived empirically from 
1,000 permutations. The null hypothesis is rejected when the upper-tail Monte Carlo p 
value is ::;; 0.05. LR was used to calculate risk estimates of the joint modifying effects of 
two or more factors identified by MDR. 
Most data mining methods, including MDR, are by nature nonparametric, model 
free, and data-driven. Determining the statistical significance of these models requires 
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rigorous permutation testing to evaluate statistical significance while accounting for 
multiple testing issues. With permutation testing, the data relationships are 
randomized in a way consistent with the null hypothesis of no association. With many 
such datasets, the distribution of the statistical measure of association under the null 
hypothesis can be generated and used to calculate an empirical p value for the statistic 
calculated in the original dataset. This approach accounts for multiple testing issues as 
long as the entire model-fitting procedure is repeated for each randomized dataset to 
provide an opportunity to identify false-positives. 
MDR with Covariate Adjustment. A newly updated version of the MDR software allows 
for the incorporation and adjustment of covariates in evaluating gene-gene interactions. 
To remove the covariate effect, we will incorporate two sampling methods (Le, over-
and under-sampling). The approach is computationally efficient, thus allowing for 
adjustment of multiple covariates without significantly increasing computational 
burden. 
with Spatially Uniform ReliefF (SURF) & Tuned ReliefF (TuRF) Filtering. Filtering options, 
such as RefliefF, built into MDR that rank and select factors most likely to be associated 
with the outcome of interest. 13()'l3l Since the filter removes SNPs possessing the lowest 
predictive value, the "background noise" is typically reduced.130-131 Hence, using a 
filtered dataset improves the likelihood of detecting relevant interactions associated 
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with a particular outcome.130-131 For this study, a combinatorial version of Relief called 
Spatially Uniform ReliefF (SURF) & Tuned ReliefF (TuRF) was used to filter the large 
candidate SNP list in order to select the most promising targets. 130-131 With respect to 
genetic association studies, ReliefF assigns a weight to each SNP using multiple 
individuals that are genetically similar. 130-131 TuRF repeats the ReliefF algorithm and 
with each repetition of SNPs with the lowest predictive values are removed; while SURF 
adjusts the weights of all the SNPs using all neighbors within a fixed distance (i.e., 
similarity threshold).130 The combined effect of combining both approaches as SURF & 
TuRF essentially iterates SURF, but substantially improves detection of epistatic 
interactions compared to using either method individually.130 
To minimize any interactions that could potentially be removed by filtering, the 
OSR candidate panel was analyzed separately by each pathway in additional to analyzing 
the entire panel with the SURF & TuRF. Hence, there were a total offour MDR analyses 
conducted for the genetic factors, one combined analysis that was filtered, as well as 
separate analyses for all the antioxidative-, BER- and apoptosis-related SNPs. 
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SPECIALIZED VISUALIZATION TOOLS (INTERACTION ENTROPY ALGORITHMS & 
HIERARCHICAL GRAPHS 
Interaction entropy algorithm, based on information theory, is a method to 
verify, visualize, and interpret combination effects identified by LR and MDR.80, 136-138 
Orange software was used to perform interaction entropy analysis among candidate 
OSR factors and PCA development. This strategy will help to interpret multi-locus 
interactions identified by parametric and non-parametric modeling. Interaction entropy 
uses information gain (lG) to gauge whether interactions between two or more factors 
provide more information about PCA outcomes relative to each factor considered 
independently.80,136-138 
Individual and all possible pairwise loci are assigned an IG percentage score in 
relation to disease risk or aggressiveness (scores < 5% are typical).80, 136-138 Explain why 
IG scores <5% are reasonable. Pairwise SNP combinations are deemed important if the 
pairwise IG is greater than the IG for each individual locus (IGFACTOR_1+ FACTOR_2> IGFACTOR_1 
and IG FACTOR 1+ FACTOR 2>IGFACTOR 2).80,137-139 Interactions can be further visualized using 
- - -
an interaction graph. Strongly interacting factors are coded either red or orange, 
indicating high and medium levels of synergistic effects on outcomes, respectively [See 
Figure 8].80, 136-139 Weakly interacting factors are coded either blue or green to denote 
high or modest levels of redundancy between markers, respectively. Gold colored 
branches are neither redundant nor synergistic. 137-139 Similarly, this tool can also be 
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used to visualize whether single or multi-markers have a stronger outcome prediction 
capacity relative to gold standard demographic and clinic-pathological parameters.137.139 
Figure 8. Interaction Entropy Graph 
0.09% 
Figure 8: Interaction Entropy Graph. Interaction entropy uses information gain (IG) to gauge whether 
interactions between two or more factors provide more information about PCA outcomes relative to each 
factor considered independently. The strongest interacting factors are coded in red indicating a high level 
of synergy. As shown in this figure, the strongest interaction detected is between Factors 4 and 5 
evidenced by an IG score of 0.19%. Factors 4 and 5 provide more information about the outcome of 
interest re lative to either factor when considered alone based on individuallG scores of 0.13% and 0.17%, 
respectively. A moderately synergistic interaction exists between Factor 1 and 2, as shown in orange. 
Weakly interacting factors are coded either blue (i.e., Factor 2-4, Factor 3-4, and Factor 3-5) or green (i.e., 
Factor 1-5 and Factor 2-5) to denote high or modest levels of redundancy between markers, respectively. 
Gold colored branches are neither redundant nor synergistic. 
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RESULTS 
Population Description among CGEMS Participants. CGEMS study participants 
consisted of middle aged non-Hispanic Caucasian men (MED), ranging in ages between 
55 and 81. A large portion of the study participants consumed adequate amounts of 
fruits (>4 servings/day) and vegetables (>5 servings/day), vitamins, and supplements. 
Despite these healthy eating practices, a majority of the men were overweight/obese 
(61.1%), as delineated in Tables 9 & 13. Men diagnosed with prostate cancer were more 
likely to have a family history of prostate cancer (11.4% versus 6.3%), PSA levels> 
4ng/ml (49.8% versus 6.5%), and irregular DRE exams (64% versus 48.9%) relative to 
controls, as depicted in table 8. However there were no marked differences in smoking 
status, body mass index (8MI), lifestyle characteristics (i.e, meat intake, fruit/vegetable 
intake, vitamin supplement usage, physical activity, usage, alcohol consumption), daily 
total caloric intake, comparing cases to controls or aggressive and non-aggressive cases, 
as depicted in Tables 9 & 11-15. 
Population Description among men of African Descent. Descriptive information 
for the men of African Descent (MAD) study participants is summarized in Table 10. 
Cases were significantly older and had higher PSA levels relative to controls. There was 
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a significant difference in median West African genetic ancestry estimates comparing 
cases and controls (p = 0.004). 
Table 8. Patient and Tumor Characteristics by disease status among European-
American male participants of the CGEMS Study 
Family History of Prostate Cancer, n (%) 
Yes 
No 
PSA (ng/ml), n (%) 
<4 
~4 
ORE results, n (%) 
Normal 
Abnormal, suspicious 
Abnormal, non-suspicious 
Gleason Score, n (%) 
4 
5 
6 
7 
8 
9 
10 
Body Mass Index (8M I), n (%) 
Underweight or normal 
Overweight 
Obese 
Missing 
Tobacco Use, n (%) 
Never 
Former 
Current 
Ever (Former & Current) 
133 (1104) 
1031 
398 (36.0) 
472 (42.8) 
234 (21.2) 
60 
49 (4.2) 
151 (13 .0) 
357 (30.7) 
467 (40.2) 
69 (5.9) 
44 (3.8) 
3 
305 (26.2) 
612 (52 .6) 
246 (21.2) 
1 (OA) 
477 (41.0) 
593 (51.0) 
93 (8.0) 
686 (59.0) 
537 (51.1) 
438 (41.8) 
75 (7.1) 
63 
271 (24.4) 
574 (51.7) 
266 (23.9) 
2 (0.9) 
421 (37.9) 
570 (51.3) 
120 (10.8) 
690 (62.1) 
<0.0001 
<0.0001 
<0.0001 
0.244 
0.648 
0.111 
0.045 
0.880 
0.022 
0.128 
Abbreviations: PSA, prostate specific antigen; DRE, digital rectal examination; "Differences in frequencies were tested 
by a Chi-square test of heterogeneity; Differences in continuous variables between cases and controls were tested 
using the Wilcoxon sum Rank test; bUnderweight or normal : BMI <24.9; Overweight: BMI 25-29.9; Obese: BMI >30 
based on values established by the 2005 USDA Dietary Guidelines/2o 
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Table 10. Patient and Tumor Characteristics for Men of African Descent 
Characteristics Cases Controls p value a 
Number of Participants, n 219 I 694 ---
Age at diagnosis (yrs), median (range) 65 (41-91) 53 (26-89) 0.0001 
PSA (ng/ml), n (%) 
<4 45 (20.5) 636 (91.6) < 0.0001 
~4 174 (79.5) 58(8.4) 
Gleason Score, n (%) 
4 18 (13.1) 
5 16 (11.7) 
6 35 (25.6) 
7 41 (29.9) 
8 7 (5.1) 
9 16 (11.7) 
10 4 (2.9) 
Tobacco Use, n (%) 
Current 26 (12.0) 11(2.0) 0.825 
Former 53 (24.5) 20(3.6) 
Never 71 (32.9) 33 (6.0) 
Missing 66 (30.6) 491 (88.4) 
Global WAA, mean (SO) 0.734 (0.253-0.937) 0.716 (0.255-0.946) 0.004 
Abbreviations: PSA, prostate specific antigen; WAA, West African Ancestry; · Differences in frequencies were tested 
by a Chi-square test of heterogeneity, differences in age and Global West African Ancestry between cases and 
controls were tested using the Wilcoxon sum Rank test. 
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Table 11. Lifestyle Characteristics by disease status among European-American male 
participants of the CGEMS Study 
Dietary Factor Cases Controls p value 
Meat Consumption (gJday), median (IQR) 
Total meat 173.9 (118.4-254.2) 174.5 (129.3-252.9) 0.166 
White Meat (chicken & fish) 42.6 (25.1-71.9) 44.6 (26.2-71.8) 0.478 
Processed meat 11.4 (6.1-21.0) 11.4 (6.1-21.0) 0.646 
Red Meat group 80.9 (47.6-125.0) 82.7 (53.9-124.2) 0.278 
Red meat not processed 62.1 (38.6-95.7) 62.1 (38.6-95.7) 0.396 
Red meat rare/med done 15.0 (3.8-33.6) 16.0 (3.9-32.4) 0.567 
Red meat well/very well done 9.3 (4.1-19.8) 9.8 (4.9-19.8) 0.141 
Fruit (servings/day), D n (%) 
~4 975 (83 .8) 952 (85.7) 0.219 
<4 188 (16.2) 159 (14.3) 
Missing 1 (0.4) 2 (0.9) I 
Vegetables (servings/day), D n (%) l • ~5 907 (78.0) 831 (74.8) 0.073 <5 256 (22.0) 280 (25.2) 
Missing 1 (0.4) 2 (0.9) I 
Kcal from diet (gJday),D n (%) 
2000-3000 559 (48.1) 522 (47.0) 0.821 
< 2000 395 (33.9) 391 (35.2) 0.538 
>3000 209 (18.0) 198 (17.8) 0.926 
Missing 1 (0.4) 2 (0.9) 
Fat from diet (gJday), median (IQR) 
Fat 
I 
73.1 (95.5-56.4) 72.7 (99.2-55.7) 0.884 
Saturated 25.0 (32 .4-18.6) 24.6 (34.0-18.5) 0.790 
Missing 1 (0.4) 2 (0.9) 
Physically Active (at least 30 min/day),' n (%) 
I 
Currently 556 (47.8) 494 (44.5) 0.177 
Since age 40 559 (50.3) 620 (53.3) 0.224 
Missing 1 (0.4) 2 (0.9) 
Alcohol Consumption (drinks/day), D n (%) 
s2 960 (82.6) 923 (83.1) 0.736 
>2 203 (17.4) 188 (16.9) 
Missing 1 (0.4) 2 (0.9) 
" 
Abbreviations: IQR, Interquartile range; "Differences in frequencies were tested by a Chi-square test of heterogeneity; 
Differences in continuous variables between cases and controls were tested using the Wilcoxon sum Rank test 
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Table 12. Vitamin and supplement by disease status among European-American male 
participants of the CGEMS Study 
<900 
Vitamin C (mg/day), n (%) 
~75 
< 75 
Vitamin E (IU/day), n (%) 
~ 15 
< 15 
<11 
Selenium hll/day), n (%) 
~55 
< 55 
1054 (90.6) 
110 (9.4) 
o 
1014 (87.1) 
150 (12 .9) 
0 
838 (72.0) 
326 (28.0) 
0 
1128 (97.0) 
35 (3.0) 
1 
100S (90.6) 
105 (9.4) 
o 
952 (S7.1) 
161 (14.5) 
0 
775 (69.6) 
33S (30.4) 
0 
lOSS (97.7) 
26(2.3) 
2 
0.990 
0.245 
0.273 
0.215 
0.324 
"Differences in frequencies were tested by a Chi-square test of heterogeneity; Differences in continuous variables 
between cases and controls were tested using the Wilcoxon sum Rank test; bRisk categories are based on values 
established in the 2005 USDA dietary guidelines & NIH office of dietary supplements 
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Table 13. Patient and Tumor Characteristics among CGEMS participants diagnosed 
with Prostate Cancer 
Family History of Prostate Cancer, n (%) 
Yes 
No 
PSA (ng/ml), n (%) 
<4 
~4 
Gleason Score, n{%) 
4 
5 
6 
7 
8 
9 
10 
ORE results, n (%) 
Normal 
Abnormal, suspicious 
Abnormal, non-suspicious 
Body Mass Index (BMI), n (%) 
Underweight or normal 
Overweight or normal 
Obese 
M 
Tobacco Use, n (%) 
Never 
Former 
347 (52 .1) 
319 
4 (0.6) 
18 (2.6) 
86 (12.6) 
459 (67 .3) 
68 (10.0) 
44 (6.5) 
3 
241 (36.9) 
282 (43.2) 
130 (19 .9) 
180 (26.2) 
350 (51.0) 
157 (22.8) 
296 (43.1) 
335 (48.8) 
56 (8.1) 
391 56.9 
230 (48.0) 
249 
45 (9.8) 
133 (29.0) 
271 (59.2) 
8 (1.8) 
1 (0.2) 
o (O.O) 
0 
159 (34.4) 
197 (42.6) 
106 (23.0) 
127 (26.0) 
272 (55.8) 
89 (18.2) 
186 (38.1) 
265 (54.3) 
37 (7.6) 
302 
< 0.0001 
0.435 
0.126 
0.105 
0.055 
0.169 
0.061 
0.722 
0.088 
Abbreviations : P5A, prostate specific antigen; DRE, digital rectal examination; "Differences in frequencies were tested 
by a Chi -square test of heterogeneity; Differences in continuous variables between cases and controls were tested 
using the Wilcoxon sum Rank test; bUnderweight or normal : BMI <24.9; Overweight: BMI 25-29.9; Obese: BMI >30 
based on values established by the 2005 USDA Dietary Guidelines/ 2o 
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Table 14. Lifestyle characteristics for CGEMS participants diagnosed with Prostate 
Cancer 
Meat Consumption (g/day), median (IQR), 
Total meat 174.5 (124.3-24.7) 174.5 (118.1-245.6) 0.918 
White Meat (chicken & fish) 44.6 (25.6-66.6) 44.6 (27.6-71.4) 0.129 
Processed meat 11.4 (5.9-21.4) 11.4 (5.2-23.5) 0.928 
Red Meat group 82.7 (50.8-122.8) 82.7 (50.2-119.8) 0.992 
Red meat not processed 62 .1 (36.2-93. 6) 62.1 (36.7-91.9) 0.831 
Red meat rare/med done 16.0 (3.9-32.7) 16.0 (3.8-31.6) 0.838 
Red meat well done 9.8 7-19 9.8 0.496 
Fruit (servings/day), n (%) 
<4 584 (85.0) 403 (82.6) 0.264 
~4 103 (15.0) 85 (17.4) 
1 0 
Vegetables (servings/day), n (%) 
<5 0.121 
~5 
Kcal from diet (Bfday), n (%) 
2000-3000 336 (48.9) 0.352 
<2000 237 (34.5) 0.591 
>3000 114 (16.6) 0.149 
1 
Fat from diet (g/day), median (IQR) 
Fat 0.196 
Saturated 0.114 
least 30 min/day), n (%) 
333 (48.5) 229 (46.9) 0.601 
371 (54.0) 254 (52.1) 0.508 
Alcohol Consumption (drinks/day), n(%) 
s2 579 (84.3) 390 (79.9) 0.053 
>2 108 (15 .7) 98 (20.1) 
0 
Abbreviations : IQR, Interquartile range; "Differences in frequencies were tested by a Chi-square test of heterogeneity; 
Differences in continuous variables between cases and controls were tested using the Wilcoxon sum Rank test; bRisk 
categories are based on values established in the 2005 USDA Dietary Guidelines & NIH Office of Dietary 
Supplements120.121 
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Table 15. Vitamin and supplement use for among CGEMS participants diagnosed with 
Prostate Cancer 
Vitamin/Mineral Cases Controls p value a 
Itamln ay, n V A (Ili/d) (%) 
<!:900 620 (90.1) 444 (91.0) 0.636 
<900 68 (9.9) 44(9.0) 
Missing 0(0.0) 0(0.0) 
Vitamin C (mg/day), D n (%) 
<!:75 40 (5.8) 22 (4.5) 0.324 
<75 648 (94.2) 466 (95.5) 
Missing 0(0.0) 0(0.0) 
Vitamin E (IU/day), D n (%) 
<!: 15 93 (13.5) 59 (12.1) 0.472 
< 15 595 (13.6) 429 (87.9) 
Missing 0(0.0) 0(0.0) 
Zinc (mg/day), D n (%) 
<!:11 491 (71.5) 351 (71.9) 0.876 
<11 196 (28.5) 137 (28.1) 
Missing 0(0.0) 0(0.0) 
Selenium (lli/day),Dn (%) 
~55 24 (3.5) 11 (2.3) 0.218 
< 55 663 (96.5) 477 (97.7) 
Missing 0(0.0) 0(0.0) 
"Differences in frequencies were tested by a Chi-square test of heterogeneity; Differences in continuous variables 
between cases and controls were tested using the Wilcoxon sum Rank test; bRisk categories are based on values 
established in the 2005 USDA Dietary Guidelines & NIH Office of Dietary Supplements120-l21 
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SPECIFIC AIM 1 FINDINGS - MED SUBJECTS 
To determine the single- and joint-modifying effects of variations within 
oxidative stress response (OSR)-related genes in relation to PCA risk, we evaluated 219 
genetic variations across 80 OSR genes in relation to disease risk among 2277 MED 
(1176 cases, 1101 controls). LR analysis revealed two antioxidative-related SNPs were 
associated with an increase in PCA risk [See Table 16]. Possession of at least one minor 
CYP2C8Js7909236 T allele was associated with an increase in risk [OR (95%CI) = 1.24 
(1.05-1.47); P = 0.011]. The EPHX1Js1051741 IT genotype was linked with 2.5-fold 
increase in risk compared to wild-type CC genotype. In contrast, possession of two 
minor NATl_rs4921581 AA alleles was associated with a decrease in PCA risk [OR 
(95%CI) = 0.75 (0.56-0.99); p = 0.042; 
We also observed a 1.2-fold increase in risk linked to possession of at least one 
minor T allele in the BER polymorphisms OGG1Js125701 [OR (95%CI) = 1.22 (1.02-
1.45); p = 0.030; See Table 17]. However, we found a decrease in risk associated with 
men whom had one or more variant POL'-rs8305 T alleles [OR (95%CI) = 0.84 (0.71-
0.99); p = 0.036]. 
Among our apoptotic targets, we found four SNPs were linked with a 18-27% 
decrease in PCA risk (BIKJs4988366, BNIP3L_rs10503786, IKBKE_rs1539243, or 
TNFRSF1AJs4149576) [See Table 18]. 
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Table 16. Association between Antioxidative-related polymorphisms and Prostate Cancer Risk among MED 
AC 404(34.9) 375 (33.9) 1.03 (0.86-1.23) 1.02 (0.86-1.22) 0.808 
CC 62 (5.4) 71 (6.4) 0.84 (0.59-1.19) 0.79 (0.55-1.13) 0.188 I 0.674 I 0.342 
AC+CC 466(40.3) 446 (40.3) 1.00 (0.85-1.18) 0.98 (0.83-1.17) 0.853 
rs7909236 I CYPZCB I GG 626(54.2) 659 (59.6) 1.00 (reference) 1.00 (reference) 
TG 468(40.5) 386 (35.0) 1.21 (1.07-1.52) 1.27 (1.07-1.52) 0.007 
IT 61 (5.3) 60 (5.4) 1.07 (0.74-1.55) 1.06 (0.73-1.54) 0.779 I 0.036 I 0.107 
TG+IT 529(45.8) 446 (40.4) 1.25 (1.06-1.48) 1.24 (1.05-1.47) 0.011 
rs1051741 I EPHXJ I CC 947(81.4) 898 (80.7) 1.00 (reference) 1.00 (reference) 
TC 199(17.1) 208 (18.7) 0.91 (0.73-1.13) 0.91 (0.73-1.13) 0.391 
I IT 18(1.5) 7 (0.6) 2.44 (1.01-5.86) 2.50 (1.04-6.02) 0.042 I 0.892 l 0.300 00 I TC+IT w 217(18.6) 215 (19.3) 0.96 (0.78-1.18) 0.96 (0.78-1.19) 0.711 
rs638820 I GSTMZ I CC 298(25.6) 294 (26.4) 1.00 (reference) 1.00 (reference) 
TC 555(47.8) 553 (49.7) 0.99 (0.81-1.21) 1.00 (0.82-1.22) 0.998 
IT 309(26.6) 266 (23.9) 1.15 (0.91-1.44) 1.16 (0.92-1.46) 0.204 I 0.249 I 0.196 
TC+IT 864(74.4) 819 (13.6) 1.04 (0.86-1.26) 1.05 (0.87-1.27) 0.596 
rs1695 I GSTPJ I AA 513(44.1) 495 (44.5) 1.00 (reference) 1.00 (reference) 
AG 505(43.4) 491 (44.1) 0.99 (0.83-1.18) 0.98 (0.83-1.17) 0.854 
GG 145 (12.5) 127 (11.4) 1.10 (0.84-1.44) 1.10 (0.84-1.44) 0.493 j 0.616 I 0.326 
AG+GG 650(55.9) 618 (55.5) 1.02 (0.86-1.20) 1.01 (0.85-1.19) 0.932 
rs6591256 I GSTPJ I AA 390(33.6) 384 (34.5) 1.00 (reference) 1.00 (reference) 
AG 567(48.8) 544 (48.9) 1.03 (0.85-1.23) 1.02 (0.85-1.23) 0.839 
GG 205 (17.6) 185 (16.6) 1.09 (0.86-1.39) 1.09 (0.85-1.39) 0.510 I 0.502 I 0.380 
AG+GG 772(66.4) 729 (65.5) 1.04 (0.88-1.24) 1.04 (0.87-1.23) 0.690 
*Adjusted OR are adjusted for age & family history 
Table 16. Association between Antioxidative-related polymorph isms and Prostate Cancer Risk among MEO, continued 
TC 578(49.7) 563 (50.6) 0.95 (0.79-1.14) 0.94 (0.78-1.13) 0.522 
TT 199(17.1) 193 (17.3) 0.95 (0.75-1.22) 0.94 (0.74-1.21) 0.637 I 0.624 I 0.296 
TC+TT 777 (66.8) 756 (67.9) 0.95 (0.80-1.13) 0.94 (0.79-1.12) 0.502 
rs4921581 I NAn I GG 554(48.0) 512 (46.3) 1.00 (reference) 1.00 (reference) 
AG 493 (42.7) 463 (41.9) 0.98 (0.83-1.17) 0.98 (0.82-1.16) 0.779 
AA 108(9.3) 131 (11.8) 0.76 (0.58-1.01) 0.75 (0.56-0.99) 0.042 I 0.137 I 0.207 
AG+AA 601 (52.0) 594 (53.7) 0.94 (0.79-1.10) 0.92 (0.78-1.09) 0.353 
rs7003890 I NAn I TT 239(20.5) 205 (18.4) 1.00 (reference) 1.00 (reference) 
TC 598(51.4) 582 (52.3) 0.88 (0.71-1.10) 0.88 (0.70-1.09) 0.237 
I CC 327(28.1) 326 (29.3) 0.86 (0.68-1.10) 0.86 (0.67-1.09) 0.210 I 0.251 I 0.202 00 I TC+CC ~ 925(79.5) 908 (81.6) 0.87 (0.71-1.08) 0.87 (0.71-1.07) 0.187 
rs1208 I NAT2 I AA 382 (32.8) 340 (30.5) 1.00 (reference) 1.00 (reference) 
AG 547 (47.0) 556 (50.0) 0.88 (0.73-1.06) 0.88 (0.73-1.07) 0.199 
GG 235 (20.2) 217 (19.5) 0.96 (0.76-1.22) 0.97 (0.76-1.23) 0.781 I 0.595 I 0.216 
AG+GG 782 (67.2) 773 (69.5) 0.90 (0.76-1.08) 0.91 (0.76-1.08) 0.282 
rs1390358 I NAT2 I TT 395 (34.2) 352 (31.8) 1.00 (reference) 1.00 (reference) 
TC 557 (48.2) 557 (50.4) 0.89 (0.74-1.07) 0.90 (0.75-1.08) 0.259 
CC 204(17.6) 197 (17.8) 0.92 (0.n-l.18) 0.93 (0.73-1.19) 0.558 I 0.392 I 0.271 
TC+CC 761 (65.8) 754 (68.2) 0.90 (0.76-1.07) 0.91 (0.76-1.08) 0.274 
rs7832071 I NAT2 I TT 386(33.2) 344 (30.9) 1.00 (reference) 1.00 (reference) 
TC 550(47.2) 559 (50.2) 0.88 (0.73-1.06) 0.88 (0.73-1.07) 0.199 
cc 228(19.6) 210 (18.9) 0.97 (0.76-1.23) 0.97 (0.76 (1.23) 0.797 1 0.604 I 0.211 
TC+CC 778(66.8) 769 (69.1) 0.90 (0.76-1.08) 0.91 (0.76-1.08) 0.283 
·Adjusted OR are adjusted for age & family history 
Table 17. Association between Base Excision Repair polymorph isms and Prostate Cancer Risk among MED 
TG 354(30.4) 304 (27.3) 1.18 (0.98-1.42) 1.20 (1.00-1.44) 0.055 
TT 40 (3A) 28 (2.5) 1.45 (0.89-2.37) 1.44 (0.88-2.36) 0.150 I 0.028 I 0.140 
TG+TT 394(33.9) 332 (29.8) 1.20 (1.01-1.44) 1.22 (1.02-1.45) 0.030 
rs2445837 I POLOl I AA 1020(87.6) 955 (85.8) 1.00 (reference) 1.00 (reference) 
AG 137 (11.8) 152 (13.7) 0.14 (0.66-1.08) 0.84 (0.66-1.08) 0.176 
GG 7 (0.6) 6 (0.5) 1.09 (0.37-3.26) 1.11 (0.37-3.32) 0.857 I 0.245 I 0.214 
AG+GG 144(12.4) 158 (14.2) 0.85 (0.67-1.09) 0.85 (0.67-1.09) 0.200 
rs545979 I POU I cc 566(48.7) 529 (47.6) 1.00 (reference) 1.00 (reference) 
TC 485 (41.7) 480 (43.1) 0.94 (0.79-1.12) 0.94 (0.79-1.12) 0.505 
I TT 112 (9.6) 104 (9.3) 1.01 (0.75-1.35) 0.98 (0.73-1.31) 0.891 I 0.756 I 0.291 00 I TC+TT U'l 597(51.3) 584 (52.4) 0.96 (0.81-1.13) 0.95 (0.81-1.12) 0.536 
rs8305 I POU I AA 601(51.6) 526 (47.3) 1.00 (reference) 1.00 (reference) 
AG 462 (39.7) 496 (44.6) 0.12 (0.69-0.97) 0.81 (0.68-0.97) 0.018 
GG 101 (8.7) 90 (8.1) 0.98 (0.72-1.34) 0.98 (0.72-1.33) 0.898 I 0.163 I 0.109 
AG+GG 563 (48.4) 586 (52.7) 0.14 (0.71-0.99) 0.84 (0.71-0.99) 0.036 
rs4135036 I TDG I TT 1010(86.8) 962 (86.4) 1.00 (reference) 1.00 (reference) 
TC 148(12.7) 148 (13.3) 0.95 (0.75-1.22) 0.96 (0.75-1.23) 0.760 
cc 6(0.5) 3 (0.3) 1.91 (0.48-7.64) 1.76 (0.43-7.13) 0.430 I 0.952 I 0.391 
TC+CC 154(13.2) 151 (13.6) 0.97 (0.76-1.24) 0.98 (0.77-1.25) 0.863 
rs2682585 I XRCCl I GG 747 (64.9) 680 (61.7) 1.00 (reference) 1.00 (reference) 
AG 355 (30.9) 375 (34.0) 0.86 (0.72-1.03) 0.85 (0.71-1.02) 0.078 
AA 48(4.2) 48(4.3) 0.91 (0.60-1.38) 0.88 (0.58-1.33) 0.541 I 0.149 r 0.138 
AG+AA 403 (35.1) 423 (38.3) 0.87 (0.73-1.03) 0.85 (0.72-1.02) 0.073 
*Adjusted OR are adjusted for age & family history 
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O'l 
Table 17. Association between Base Excision Repair polymorph isms and Prostate Cancer Risk among MED, continued 
1.00 (reference) 
546 (49.1) 0.97 (0.81-1.17) 
219 (19.7) 0.86 (0.68-1.09) 
795 (68.8) 0.94 (0.79-1.12) 
*Adjusted OR are adjusted for age & family history 
1.00 (reference) 
0.97 (0.81-1.17) 
0.85 (0.67-1.08) 
0.94 (0.79-1.12) 
0.763 
0.187 
0.470 
0.240 0.245 
Table 18. Association between Apoptotic polymorph isms and Prostate Cancer Risk among MED 
rs12031994 I AKT3 I TT 853 (73.3) 802 (72.1) 1.00 (reference) 1.00 (reference) 
TC 284(24.4) 277 (24.9) 0.96 (0.80-1.17) 0.98 (0.81-1.19) 0.828 
CC 27 (2.3) 34 (3.0) 0.75 (0.45-1.25) 0.75 (0.45-1.25) 0.267 I 0.363 I 0.391 
TC+CC 311 (26.7) 311 (27.9) 0.94 (0.78-1.13) 0.95 (0.79-1.15) 0.613 
rs10860361 I APAFl I AA 332 (28.6) 345 (31.0) 1.00 (reference) I 1.00 (reference) 
AG 597(51.3) 519 (46.6) 1.20 (0.99-1.45) 1.20 (0.99-1.45) 0.063 
GG 234(20.1) 249 (22.4) 0.98 (0.77-1.23) 0.97 (0.77-1.23) 0.828 I 0.947 I 0.133 
AG+GG 831 (71.4) 768 (69.0) 1.12 (0.94-1.35) 1.13 (0.94-1.35) 0.195 
rs905238 I SAX I AA 315 (27.1) 302 (27.1) 1.00 (reference) 1.00 (reference) 
AG 554(47.6) 550 (49.4) 0.97 (0.79-1.18) 0.96 (0.79-1.17) 0.666 
I GG 295(25.3) 261 (23.5) 1.08 (0.86-1.36) 1.07 (0.85-1.35) 0.564 I 0.513 I 0.335 00 I AG+GG -..,J 849(72.9) 811 (72.9) 1.00 (0.83-1.21) 0.99 (0.83-1.20) 0.946 
rs616130 I BCLZUl I cc 313(26.9) 336 (30.2) 1.00 (reference) 1.00 (reference) 
AC 603(51.8) 527 (47.3) 1.23 (1.01-1.49) 1.21 (0.99-1.47) 0.058 
AA 248(21.3) 250 (22.5) 1.07 (0.84-1.35) 1.07 (0.84-1.35) 0.598 I 0.470 I 0.153 
AC+AA 851(73.1) 777 (69.8) 1.18 (0.98-1.41) 1.16 (0.97-1.40) 0.109 
rs10845479 I BCLZU4 I AA 635(54.6) 630 (56.6) 1.00 (reference) 1.00 (reference) 
AG 445(38.2) 420 (37.8) 1.05 (0.88-1.25) 1.06 (0.89-1.26) 0.518 
GG 84(7.2) 62 (s.6) 1.34 (0.95-1.90) 1.39 (0.98-1.97) 0.064 I 0.148 I 0.155 
AG+GG 529(45.4) 482 (43.4) 1.09 (0.92-1.29) 1.10 (0.93-1.30) 0.257 
rs366542 I BID I cc 275(23.6) 264 (23.7) 1.00 (reference) 1.00 (reference) 
TC 597(51.3) 535 (48.1) 1.07 (0.87-1.32) 1.08 (0.88-1.33) 0.450 
TT 292 (25.1) 314 (28.2) 0.89 (0.71-1.13) 0.90 (0.72-1.14) 0.391 I 0.308 I 0.169 
TC+TT 889 (76.4) 849 (76.3) 1.01 (0.83-1.22) 1.02 (0.84-1.23) 0.870 
*Adjusted OR are adjusted for age & family history 
Table 18. Association between Apoptotic polymorph isms and Prostate Cancer Risk, continued 
AG 208(17.9) 244 (21.9) 0.77 (0.63-0.95) 0.78 (0.64-0.96) 0.020 
GG 12(1.0) 14 (1.3) 0.78 (0.36-1.69) 0.79 (0.36-1.71) 0.545 I 0.015 I 0.154 
AG+GG 220(18.9) 258 (23.2) 0.77 (0.63-0.95) 0.78 (0.64-0.96) 0.017 
rs10503786 I BNIP3L I CC 556(48.9) 477 (43.9) 1.00 (reference) 1.00 (reference) 
TC 480(42.1) 489 (44.9) 0.14 (0.71-1.00) 0.85 (0.71-1.01) 0.061 
TT 103 (9.0) 122 (11.2) 0.72 (0.54-0.97) 0.73 (0.55-0.98) 0.036 I 0.011 I 0.055 
TC+TT 583(51.1) 611 (56.1) 0.82 (0.69-0.97) 0.82 (0.70-0.97) 0.022 
rs12870 I DIABLO I GG 386 (33.2) 360 (32.4) 1.00 (reference) 1.00 (reference) 
AG 568 (48.8) 540 (48.5) 0.98 (0.82-1.18) 098 (0.82-1.18) 0.850 
00 l I A~A 210 (18.0) 213 (19.1) 0.92 (0.72-1.17) 0.91 (0.71-1.15) 0.426 I 0.516 I 0.322 00 778(66.8) 753 (67.7) 0.96 (0.81-1.15) 0.96 (0.81-1.15) 0.656 
rs1539243 I IKBKE I CC 837 (71.9) 740 (66.6) 1.00 (reference) 1.00 (reference) 
TC 291 (25.0) 325 (29.2) 0.79 (0.66-0.95) 0.78 (0.65-0.95) 0.011 
TT 36(3.1) 47 (4.2) 0.68 (0.43-1.06) 0.68 (0.43-1.06) 0.085 I 0.005 r 0.072 
TC+TT 327 (28.1) 372 (33.4) 0.78 (0.65-0.93) 0.77 (0.64-0.92) 0.004 
rs11688 I JUN I GG 1043 (89.6) 999 (89.8) 1.00 (reference) 1.00 (reference) 
AG 120(10.3) 110 (9.9) 1.05 (0.80-1.37) 1.06 (0.80-1.39) 0.692 
AA 1 (0.1) 3 (0.3) 0.32 (0.03-3.08) 0.33 (0.03-3.19) 0.340 ! 0.970 I 0.406 
AG+AA 121(10.4) 113 (10.2) 1.03 (0.78-1.34) 1.04 (0.79-1.36) 0.789 
rs4727666 I PIK3CG I AA 741(64.2) 685 (62.1) 1.00 (reference) 1.00 (reference) 
AG 364(31.5) 366 (33.2) 0.92 (0.77-1.10) 0.91 (0.76-1.09) 0.317 
GG 49(4.3) 52 (4.7) 0.87 (0.58-1.30) 0.88 (0.59-1.32) 0.537 I 0.288 I 0.277 
AG+GG 413 (35.8) 418 (37.9) 0.91 (0.77-1.08) 0.91 (0.77-1.08) 0.274 
*Adjusted OR are adjusted for age & family history 
Table 18. Association between Apoptotic polymorph isms and Prostate Cancer Risk, continued 
1.00 (reference) 
TG "'~ I 438 (39.4) 0.93 (0.78-1.10) 0.92 (0.77-1.10) 0.347 TT 79(6.80 91 (8.2) 0.79 (0.57-1.09) 0.77 (0.56-1.07) 0.117 I 0.136 I 0.216 
TG+TT 524(45.0) 529 (47.6) 0.90 (0.77-1.06) 0.89 (0.76-1.06) 0.187 
rs571715 I PRKCQ I TT 755 (65.0) 720 (64.8) 1.00 (reference) 1.00 (reference) 
TC 353(30.4) 354 (31.8) 0.95 (0.80-1.14) 0.95 (0.80-1.14) 0.594 
CC 53(4.6) 38 (3.4) 1.33 (0.87-2.04) 1.36 (0.89-2.10) 0.159 I 0.715 l 0.267 
TC+CC 406 (35.0) 392 (35.2) 0.99 (0.83-1.17) 0.99 (0.83-1.18) 0.925 
rs585881 I PRKCQ I TT 765 (65.7) 723 (65.0) 1.00 (reference) 1.00 (reference) 
TC 349 (30.0) 352 (31.6) 0.94 (0.78-1.12) 0.94 (0.78-1.12) 0.485 
00 I I CC SO (4.3) 38 (3.4) 1.24 (0.81-1.92) 1.28 (0.83-1.98) 0.265 I 0.960 I 0.255 \.D TC+CC 399 (34.3) 390 (35.0) 0.97 (0.81-1.15) 0.97 (0.82-1.16) 0.738 
rs6442322 I RAFl j AA 342 (29.6) 361 (32.7) 1.00 (reference) 1.00 (reference) 
AG 568(49.1) 529 (48.0) 1.13 (0.94-1.37) 1.14 (0.94-1.37) 0.192 
GG 247 (21.3) 213 (19.3) 1.22 (0.97-1.55) 1.21 (0.96-1.54) 0.110 I 0.082 I 0.216 
AG+GG 815 (70.4) 742 (67.3) 1.16 (0.97-1.39) 1.16 (0.97-1.38) 0.110 
rsl1135693 I TNFRSF10B I CC I 574(49.4) 510 (45.8) 1.00 (reference) 1.00 (reference) 
AC 484(41.6) 486 (43.7) 0.89 (0.74-1.05) 0.89 (0.75-1.06) 0.199 
AA I 105 (9.0) 117 (10.5) 0.80 (0.60-1.07) 0.80 (0.60-1.07) 0.126 I 0.069 I 0.170 
AC+AA 589 (SO.6) 603 (54.2) 0.87 (0.74-1.02) 0.87 (0.74-1.03) 0.109 
rs4149576 I TNFRSFlA j AA 234(20.3) 183 (16.6) 1.00 (reference) 1.00 (reference) 
AG 545 (47.2) 545 (49.4) 0.78 (0.62-0.98) 0.79 (0.63-0.99) 0.038 
GG 375(32.5) 376 (34.0) 0.78 (0.61-0.99) 0.79 (0.62-1.01) 0.056 I 0.076 I 0.167 
AG+GG 920(79.7) 921 (83.4) 0.78 (0.63-0.97) 0.79 (0.63-0.98) 0.029 
*Adjusted OR are adjusted for age & family history 
Based on the size ofthe entire OSR SNP panel (Le., 219), MDR modeling would 
require analysis of more than 14 million one-, two-, and three-way combinations. Since 
it is not computationally feasible to analyze all 219 SNPs in MDR, we used the SURF & 
TuRF filter for the top 75 percentile OSR factors. This feature allows MDR to rank and 
select SNPs most likely to be associated with PCA risk and reduces the number of pair-
wise and three-way combinations to amount that is possible to analyze (Le., 
approximately 160,400). 
Unfortunately, MDR modeling for the top 25th percentile of the OSR SNP panel 
did not reveal any statistically significant models associated with PCA risk (permutation 
testing p value ~ 0.114) [See Table 19]. However, hlG revealed synergistic interactions: 
TNFRSF1A_,s4149576-GSTM2_,s638820 (IG = 0.26%), IKBIP_,s1048906-
GSTM2_,s638820 (IG = 0.20%), IKBIP_,s1048906-TNFSF10_,s9859259 (IG = 0.17%), and 
TNFRSF1A_,s4149576-PRKCE_,s935673 (IG = 0.16%) [See Figu,e 9]. Although, LR did not 
show any statistically significant effects when these SNPs were examined individually, 
two-way analysis their combined effects confirmed the TNFRSF1A-PRKCE interaction 
[See Table 20]. We found possession of ~3 minor TNFRSF1A-PRKCE alleles was 
associated with decreased risk [OR (95%CI) = 0.58 (0.42-0.81); P = 0.001]. 
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Table 19. Top 25th Percentile MDR models for OSR polymorphisms and prostate 
cancer risk among MED (adjusted for age and family history) 
Best Model Number of Cross Validation Average Testing Permutation 
Combinations Consistency (CVe) Accuracy (ATA) Testing p value 
One Factor 54 I BNIP3L '510503786 7/10 0.501 0.433 
Two Factor 
PRKCEJ5935673 2916 3/10 0.485 0.800 
TNFRSF1A '54149576 
Three Factor 
GSTMZJ56388Z0 157464 7/10 0.522 0.114 IKBIP J51048906 
TNFRSF1A '54149576 
Figure 1. Interaction entropy graph for OSR polymorphisms and prostate cancer risk 
among MED subjects 
___ 0.11% ___ _ 
IKBP J S1048t106 ••••••• [!;0.~20~% ••••••• GSTM2_rs63 .. 20 
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This graphical model describes the percent entropy that is expla ined by each OSR SNP or a combination of two loci 
w ith in ou r MED study population. The jOint effects of GSTM2J s638820-TNFRSFlAJ s4149576 yield an information 
ga in of 0.14%, comparing to either GSTM2 or TNFRSF1A loci alone (IG = 0.09% and 0.15%, respectively) . 
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Table 20. Association between OSR gene-gene interactions & peA risk among MED 
Genes Minor # Minor OR (95% (I) Adj OR (95% CI)* P value * interaction 
Alleles Alleles p value 
TNFRSFlAJs 4149576 AA 0 1.00 (reference) 1.00 (reference) 
GSTM2Js638820 TT 1 0.82 (0.54-1.24) 0.81 (0.53-1.22) 0.308 
2 0.74 (0.50-1.10) 0.74 (0.50-1.10) 0.141 0.383 
~3 0.87 (0.58-1.29) 0.87 (0.59-1.30) 0.505 
IKBIPJs1048906 AA 0 1.00 (reference) 1.00 (reference) 
GSTM2Js638820 TT 1 1.27 (0.96-1.67) 1.28 (0.97-1.69) 0.081 
2 1.13 (0.86-1.49) 1.14 (0.87-1.51) 0.344 0.399 
~3 1.18 (0.87-1.60) 1.20 (0.88-1.63) 0.250 
IKBIP Js1048906 AA 0 1.00 (reference) 1.00 (reference) 
TNFSF10_,s9859259 AA 1 1.06 (0.82-1.37) 1.07 (0.83-1.39) 0.589 
2 0.83 (0.64-1.07) 0.83 (0.64-1.08) 0.164 0.121 
~3 0.91 (0.67-1.23) 0.92 (0.68-1.24) 0.576 
TNFRSF1AJs 4149576 AA 0 1.00 (reference) 1.00 (reference) 
PRKCEJs935673 GG 1 0.75 (0.55-1.04) 0.77 (0.56-1.06) 0.112 
2 0.84 (0.62-1.15) 0.86 (0.63-1.17) 0.332 0.363 
I ~3 0.57 (0.41-0.79) 0.58 (0.42-0.81) 0.001 
*AdJusted OR are adjusted for age & family history 
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In order to verify that no interactions were missed by filtering the OSR SNP 
datafile, we performed additional analyses for all the SNPs separated by their respective 
biological pathway. Due to the large number of apoptosis-related markers, this panel 
was subjected to SURF & TuRF filtering. By selecting the top 50% ofthe apoptotic SNPs, 
the number of possible combinations was reduced from 5,177,717 to 636,056. 
However, no filtering was needed to analyze the antioxidative and BER SNP panels in 
MDR. 
From these analyses, we did not observe any significant MDR models for the top 
50th percentile apoptotic SNPs (permutation p value ~ 0.062) [Table 21]. The entropy 
diagram showed synergistic effects involving TNFRSF1A_rs4149576-PRKCE_rs281508 
and PRKCCrs281508-BCL2L11_rs616130 [See Figure 10]. However, LR two-way risk 
analysis did not validate either interaction (p ~ 0.093) [Table 24]. 
Table 21. Top 50th Percentile MDR models for apoptotic polymorph isms and prostate 
cancer risk among MED (adjusted for age and family history) 
Best Model Number of Cross Validation Average Testing Permutation 
Combinations Consistency (CVe) Accuracy (ATA) Testing p value 
One Factor 86 I TNFSF10 '54894559 5/10 0.505 0378 
Two Factor 
TNFRSF1A_'54149576 7396 4/10 0.497 0.508 
TNFSF10 '54894559 
Three Factor 
8CL2L11-,5616130 636056 7/10 0.529 0.062 PRKCE-,5281508 
TNFRSF1A '54149576 
93 
Figure 2. Interaction entropy graph for top 50th percentile apoptotic polymorph isms 
and peA risk among MED subjects 
TNFRSF1AJs4149576 
0.26% 
94 
TNFSF1 0 Js4894559 
0.27% 
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0.03% 
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.(1.05% 
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0.15% 
MDR did not detect any statistically significant models among the unfiltered BER 
SNP panel (permutation p value ~ 0.182) [Table 22]. hlG revealed synergistic 
interactions between XRCC1_rs3213255-POLl_rs8305 and UNG_rs3219243-
OGG1_rs125701 [See Figure 11]; however these combinations were not associated with . 
risk when analyzed by LR [See Table 24]. 
Table 22. Unfiltered MDR models for BER polymorph isms and prostate cancer risk 
among MED (adjusted for age and family history) 
Best Model Number of Cross Validation Average Testing Permutation 
Combinations Consistency (CVe) Accuracy (ATA) Testing p value 
One Factor 12 I 5/10 0.499 I POll rs8305 0.531 
Two Factor 
POLlJs8305 144 6/10 0.500 0.468 
XRCCl rs3213255 
Three Factor 
OGG1Js125701 1728 7/10 0.516 0.182 
POLCrs8305 
XRCCl rs2682585 
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Figure 3. BER polymorph isms and prostate cancer risk among MED 
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MDR analysis for the unfiltered antioxidative-related SNP panel confirmed the LR 
single effect finding for the anti oxidative CYP2C8 _rs7909236 (CVC = 10/10) [See Table 
23]. Although this model was identified as the best single predictor of risk, the 
permutation p value was not significant (p = 0.085). However, CYP2C8 combined with 
NA Tl_rs4951581 was selected as the best two-factor predictor of risk (CVC = 10/10; P = 
0.011). This interaction was confirmed by LR analysis, which indicated that possession 
of one minor CYP2C8-NATl allele was associated with a 1.3-fold increase in risk [OR 
(95%CI) = 1.28 (1.04-1.57); P = 0.019; Table 24]. 
Table 23. Unfiltered MDR models for antioxidative-related OSR polymorph isms and 
prostate cancer risk among MED (adjusted for age and family history) 
Best Model Number of Cross Validation Average Testing Permutation 
Combinations Consistency (CVC) Accuracy (ATA) Testing p value 
One Factor 34 10/10 0.527 0.085 CYP2C8 ,s7909236 
Two Factor 
CYP2C8Js7909236 1156 10/10 0.545 0.011 
NAT1 ,s4921581 
Three Factor 
CYP2C8Js7909236 39304 3/10 0.502 0.409 GSTP1Js1695 
NATl ,s4921581 
hlG showed only a moderately synergistic effect from the CYP2C8-NA Tl 
combination (IG = 0.11%) [See Figure 12]. However, the entropy graph revealed strong 
interactions between CYP2C8_rs7909236-GSTP1_rs1695 (IG = 0.31%), NATl_rs4921581-
GSTM2_rs638820 (IG = 0.28%), and GSTP1_rs6591256-GSTM2_rs638820 (IG = 0.27%). 
LR two-way analysis ofthese interactions validated CYP2C8-GSTP1 and NATl-GSTM2 
[Table 24]. Men possessing ~2 variant CYP2C8-GSTP1 alleles was associated with a 1.4-
97 
fold increase in risk [OR (95%CI) = 1.38 (1.10-1.74; p = 0.006] . Also, carriers of at least 
two minor NATl-GSTMl alleles were linked to increased PCA risk [OR (95%CI) = 1.39 
(1.06-1.82); P = 0.016]. 
Figure 4. Interaction entropy graph for antioxidative-related OSR polymorphisms and 
peA risk among MED subjects 
This graphical model describes the percent entropy that is explained by each OSR SNP or a combination of two loci 
within our MED study population. The joint effects of the GSTM2Js1638820-NATlJs4921581 interaction yields an 
information gain of 0.28%, in comparison to either GSTM2 or NA Tlloci alone (IG = 0.10% and 0.07%, respectively). 
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Table 24. Association between gene-gene interactions & peA risk among MED 
Genes Minor # Minor OR (95% CI) Adj OR (95% CI) · P value· interaction 
Alleles Alleles p value 
TNFRSFIA_,s4149576 AA 0 1.00 (reference) 1.00 (reference) 
PRKCEJs281508 TT 1 1.02 (0.75-1.38) 1.02 (0.75-1.38) 0.815 
2 0.76 (0.56-1.03) 0.76 (0.56-1.03) 0.093 0.972 
~3 0.82 (0.S9-1.14) 0.82 (0.59-1.14) 0.239 
PRKCEJs281508 TT 0 1.00 (reference) 1.00 (reference) 
BCL2LllJs616130 AA 1 1.25 (0.97-1.60) 1.22 (0.95-1.56) 0.123 
2 1.17 (0.91-1.51) 1.15 (0.90-1.49) 0.268 0.135 
~3 1.00 (0.74-1.36) 0.98 (0.72-1.32) 0.879 
XRCCIJs3213255 CC 0 1.00 (reference) 1.00 (reference) 
POLlJs8305 GG 1 0.75 (0.54-1.05) 0.76 (0.55-1.06) 0.103 
2 0.81 (0.59-1.12) 0.83 (0.60-1.14) 0.249 0.112 
~3 0.83 (0.59-1.15) 0.84 (0.60-1.17) 0.290 
UNGJs3219243 CC 0 1.00 (reference) 1.00 (reference) 
OGGIJs125701 GG 1 1.16 (0.97-1.39) 1.17 (0.98-1.40) 0.089 
2 1.02 (0.79-1.32) 1.04 (0.80-1.35) 0.776 0.329 
~3 1.71 (0.89-3.29) 1.74 (0.91-3.35) 0.097 
CYP2C8Js7909236 TT 0 1.00 (reference) 1.00 (reference) 
GSTPIJs1695 GG 1 1.12 (0.91-1.38) 1.10 (0.89-1.35) 0.384 
2 1.40 (1.11-1.76) 1.38 (1.10-1.74) 0.006 0.100 
~3 0.98 (0.70-1.38) 0.97 (0.69-1.37) 0.851 
NA TlJs4921581 AA 0 1.00 (reference) 1.00 (reference) 
GSTM2Js638820 TT 1 1.29 (0.98-1.69) 1.28 (0.98-1.68) 0.074 
2 1.39 (1.06-1.81) 1.39 (1.06-1.82) 0.016 0.001 
~3 1.03 (0.77-1.39) 1.03 (0.76-1.38) 0.860 
CYP2C8_,s7909236 TT 0 1.00 (reference) 1.00 (reference) 
NA TlJs4921581 AA 1 1.29 (1.05-1.58) 1.28 (1.04-1.57) 0.019 
2 1.07 (0.86-1.35) 1.06 (0.85-1.34) 0.598 I 0.389 ~3 1.06 (0.74-1.51) 1.02 (0.71-1.46) 0.912 
GSTPIJs6591256 GG 0 1.00 (reference) 1.00 (reference) 
GSTM2Js638820 TT 1 0.94 (0.69-1.28) 0.93 (0.68-1.26) 0.623 
2 0.79 (0.59-1.07) 0.78 (0.58-1.06) 0.111 0.034 
~3 1.19 (0.87-1.64) 1.19 (0.87-1.64) 0.274 
*Adjusted OR are adjusted for age & family history 
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SPECIFIC AIM 1 FINDINGS - MAD SUBJECTS 
For MAD, we examined the single effects of 25 OSR SNPs in relation to PCA risk 
among 224 PCA cases and 699 controls. From this analysis, we possession of one or 
more minor BAX (54645878 T allele was linked to a 1.8-fold increase in PCA risk [OR 
{95%CI} = 1.80 {1.11-2.92}; P = 0.017); See Table 27]. We also detected a significant 
association between men having one least variant BCL2L11_(s3789068 C allele and 
disease risk [OR {95%CI} = 1.93 {1.15-3.24}; P = 0.013}. We did not find any single risk 
effects among antioxidative or BER SNPs among MAD subjects [See Tables 25 & 26]. 
100 
Table 25. Association between Antioxidative-related polymorphisms and Prostate Cancer Risk among MAD 
55 (29.4) 
84 (44.9) 1.01 (0.69-1.49) 1.03 (0.66-1.61) 0.888 
GG I 125 (20.4) 48 (25.7) 1.36 (0.87-2.13) 1.55 (0.93-2.58) 0.095 I 0.204 I 0.212 
AG+GG 419 (68.2) 132 (70.6) 1.12 (0.78-1.60) 1.19 (0.79-1.79) 0.414 
GSTMl I *1/*1 37 (26.1) 55 (30.7) 
*1/*0 58(40.8) 76 (42.5) 0.88 (0.51-1.51) 0.92 (0.51-1.63) 0.765 
*0/*0 47(33.1) 48 (26.8) 0.69 (0.39-1.23) 0.71 (0.38-1.33) 0.287 I 0.202 I 0.313 
~ *0 105 (73.9) 124 (69.3) 0.79 (0.49-1.30) 0.83 (0.49-1.40) 0.477 
GSm I *1/*1 30(21.3) 53 (29.4) 1.00 (reference) 1.00 (reference) 
*1/*0 71 (50.3) 81 (45.0) 0.65 (0.37-1.12) 0.62 (0.34-1.14) 0.125 
~ I I *0/*0 40(28.4) 46 (25.6) 0.65 (0.35-1.21) 0.59 (0.30-1.17) 0.130 I 0.179 I 0.144 a ~ *0 111 (78.7) 127 (70.6) 0.65 (0.39-1.08) 0.61 (0.35-1.08) 0.090 ~ 
rs2069514 I CYPlA2 j GG 356 (55.0) 106 (57.6) 1.00 (reference) 1.00 (reference) 
GA 224(34.6) 62 (33.7) 0.93 (0.65-1.33) 0.87 (0.57-1.31) 0.498 
AA 67 (10.4) 16 (8.7) 0.80 (0.45-1.44) 0.54 (0.27-1.09) 0.083 I 0.448 I 0.186 
GA+AA 291 (45.0) 78 (42.4) 0.90 (0.65-1.25) 0.78 (0.53-1.15) 0.213 
rs4646903 , CYPlAl I AA 253 (39.2) 73 (37.8) 1.00 (reference) 1.00 (reference) 
AC 289 (44.7) 92 (47.7) 1.10 (0.78-1.57) 1.22 (0.81-1.83) 0.350 
CC 104 (16.1) 278 (14.5) 0.93 (0.57-1.53) 1.22 (0.69-2.15) 0.496 I 0.965 I 0.143 
AC+CC 393 (60.8) 120 (62.2) 1.06 (0.76-1.47) 1.22 (0.83-1.79) 0.321 
*Adjusted Odds Ratios are adjusted for age, family history, & WAA 
Table 26. Association between Base Excision Repair polymorphisms and Prostate Cancer Risk among MAD 
82 (43.6) 1.00 (reference) 1.00 (reference) 
TG 294(45.5) 87 (46.3) 0.94 (0.67-1.32) 1.02 (0.68-1.52) 0.928 
GG 92 (14.2) 19 (10.1) 0.66 (0.38-1.14) 0.92 (0.49-1.72) 0.797 I 0.185 I 0.346 
TG+GG 386(59.8) 106 (56.4) 0.87 (0.63-1.21) 1.00 (0.68-1.46) 0.993 
rs1052133 I 0061 I CC 465 (69.6) 135 (68.5) 1.00 (reference) 1.00 (reference) 
CG 182 (27.3) 58 (29.5) 1.10 (0.77-1.56) 1.05 (0.70-1.57) 0.832 
CG+GG 203(30.4) 62 (31.5) 1.05 (0.75-1.48) 1.00 (0.67-1.48) 0.991 I 0.772 I 0.290 
rs25487 I XRCC1 I GG 476(73.0) 138 (73.4) 1.00 (reference) 1.00 (reference) 
GA 159 (24.4) 46 (24.5) 1.00 (0.68-1.46) 0.98 (0.63-1.51) 0.921 
GA+AA 176(27.0) 50 (26.6) 0.98 (0.68-1.41) 0.95 (0.62-1.45) 0.814 I 0.836 I 0.245 
f-' *Adjusted Odds Ratios are adjusted for age, family history, & WAA 
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Table 27. Association between Apoptotic polymorph isms and Prostate Cancer Risk among MAD 
CT 42 (29.4) 70 (39.6) 1.73 (1.06-2.81) 1.80 (1.06-3.06) 0.029 
IT 15(10.5) 24 (13.6) 1.66 (0.81-3.38) 1.80 (0.85-3.84) 0.128 I 0.038 I 0.090 
CT+IT 57(39.9) 94 (53.1) 1.71 (1.09-2.67) 1.80 (1.11-2.92) 0.017 
rs3789068 I SCLlLlJ I IT 68(47.5) 67 (38.3) 1.00 (reference) 1.00 (reference) 
TC 53 (37.1) 92 (52.6) 1.76 (1.09-2.84) 1.93 (1.15-3.24) 0.013 
CC 22 (15.4) 16 (9.1) 0.74 (0.36-1.53) 0.82 (0.37-1.84) 0.632 I 0.690 I 0.125 
TC+CC 75 (52.5) 108 (61.7) 1.46 (0.93-2.29) 1.62 (1.00-2.64) 0.051 
rs4488761 I SCULl3 I AA 52 (36.1) 60 (33.3) 1.00 (reference) 1.00 (reference) 
AG 63 (43.8) 83 (46.1) 1.14 (0.70-1.87) 0.87 (0.51-1.48) 0.597 
...... I GG 29 (20.1) 37 (20.6) 1.11 (0.60-2.04) 0.95 (0.49-1.84) 0.875 I 0.695 I 0.259 0 AG+GG 92 (63.9) 120 (66.7) 1.13 (0.71-1.79) 0.89 (0.54-1.47) 0.648 w 
rs6488494 I SCULl4 IT 45 (31.5) 51 (27.7) 1.00 (reference) 1.00 (reference) 
TC 70 (49.0) 89 (48.4) 1.12 (0.68-1.87) 1.15 (0.67-1.99) 0.614 
CC 28 (19.5) 44 (23.9) 1.39 (0.75-2.58) 1.38 (0.71-2.69) 0.343 I 0.310 I 0.259 
TC+CC 98 (68.5) 133 (72.3) 1.20 (0.74-1.93) 1.22 (0.73-2.03) 0.4SO 
rs1883263 I SIK I AA 1 115 (79.9) 148 (81.8) 
AC+CC 29 (21.1) 33 (18.2) I 0.88 (0.51-1.54) I 0.69 (0.37-1.27) I 0.227 I 0.664 I 0.390 
rs738276 I SIK I GG 48(39.3) 73 (46.5) 
GA 61 (SO.O) 68 (43.3) 0.73 (0.44-1.21) 0.74 (0.43-1.28) 0.278 
AA 13 (10.7) 16 (10.2) 0.81 (0.36-1.83) 0.85 (0.36-2.03) 0.714 I 0.336 I 0.333 
GA+AA 74 (60.7) 84 (53.5) 0.75 (0.46-1.21) 0.76 (0.45-1.28) 0.299 
rs6509364 I CARDS I CC 88(61.5) 114 (64.4) 1.00 (reference) 1.00 (reference) 
CT 39(27.3) 54 (30.5) 1.07 (0.65-1.76) 1.06 (0.62-1.81) 0.838 
IT 16 (11.2) 9 (5.1) 0.43 (0.18-1.03) 0.51 (0.20-1.29) 0.158 I 0.210 I 0.221 
CT+IT 55 (38.5) 63 (35.6) 0.88 (0.56-1.40) 0.91 (0.56-1.49) 0.708 
*Adjusted Odds Ratios are adjusted for age, family history, & WAA 
Table 27. Association between Apoptotic polymorphisms and Prostate Cancer Risk among MAD, continued 
91 (63.6) 
GA 44(30.8) 65 (35.5) 1.28 (0.80-2.06) 1.32 (0.79-2.20) 0.290 
AA 8 (5.6) 8 (4.5) 0.87 (0.31-2.40) 0.76 (0.26-2.27) 0.627 I 0.591 I 0.343 
GA+AA 52 (36.4) 73 (41.0) 1.22 (0.77-1.91) 1.23 (0.75-2.00) 0.413 
rsl049216 I CASP3 I TT 88 (69.3) I 113 (66.9) TC+CC 39 (30.7) 56 (33.1) I 1.12 (0.68-1.83) 1.34 (0.79-2.28) l 0.282 I 0.658 . 0.355 
rs507879 I CASP5 I AA 25 (17.7) 31 (17.0) 1.00 (reference) 1.00 (reference) 
AG 67 (47.5) 91 (49.7) 1.10 (0.59-2.02) 1.38 (0.72-2.68) 0.336 
GG 49(34.8) 61 (33.3) 1.00 (0.53-1.92) 1.28 (0.64-2.57) 0.491 I 0.936 I 0.272 
AG+GG 116 (82.3) 152 (83.1) 1.06 (0.59-1.89) 1.34 (0.72-2.50) 0.359 
~ rs537093 I CASP5 I GG 78 (54.2) 91 (50.0) 1.00 (reference) 1.00 (reference) 0 ~ GA 58(40.3) 74 (40.7) 1.09 (0.69-1.73) 1.16 (0.71-1.90) 0.555 
AA 8 (5.6) 17 (9.3) 1.82 (0.75-4.45) 1.69 (0.65-4.40) 0.279 I 0.260 ! 0.212 
GA+AA 66 (45.8) 91 (50.0) 1.18 (0.76-1.83) 1.23 (0.77-1.97) 0.393 
rs6747918 I CASPB I AA 30 (30.0) 43 (38.0) 1.00 (reference) 1.00 (reference) 
AG 12 (12.0) 9 (8.0) 0.52 (0.20-1.40) 0.56 (0.19-1.61) 0.280 
GG 58(58.0) 61 (54.0) 0.73 (0.41-1.32) 0.98 (0.52-1.88) 0.962 I 0.342 I 0.356 
AG+GG 70 (70.0) 70 (62.0) 0.70 (0.39-1.24) 0.90 (0.48-1.69) 0.743 
rsl052576 I CASP9 I GG 69(48.6) 81 (44.5) 1.00 (reference) 1.00 (reference) 
GA 56 (39.4) 82 (45.1) 1.25 (0.78-1.99) 1.43 (0.86-2.38) 0.165 
AA 17 (12.0) 19 (10.4) 0.95 (0.46-1.97) 1.04 (0.48-2.26) 0.929 I 0.734 I 0.268 
GA+AA 73 (51.4) 101 (55.5) 1.18 (0.76-1.83' 1.34 (0.83-2.15) 0.232 
rs12817549 I CRADD I TT 79 (55.6) 96 (53.6) 
TC 50(35.2) 65 (36.3) 1.07 (0.67-1.72) 1.23 (0.74-2.05) 0.430 
CC 13 (9.2) 18 (10.1) 1.14 (0.53-2.47) 1.17 (0.51-2.69) 0.705 I 0.698 I 0.308 
TC+CC 63 (44.4) 83 (46.4) 1.08 (0.70-1.69) 1.22 (0.76-1.96) 0.420 
*Adjusted Odds Ratios are adjusted for age, family history, & WAA 
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Table 27. Association between Apoptotic polymorphisms and Prostate Cancer Risk among MAD, continued 
rs3858606 I CRADD I GG 43 (30.3) 39 {22.2} 1.00 (reference) 1.00 {reference} 
GA 72 (50.7) 99 {56.3} 1.52 (0.89-2.57) 1.23 {0.70-2.17} 0.476 
AA 27 (19.0) 38 {21.5} 1.55 (0.81-2.99) 1.55 {0.76-3.16} 0.224 I 0.163 I 0.357 
GA+AA 99(69.7) 137 {77.8} 1.53 (0.92-2.53) 1.31 {0.76-2.25} 0.325 
*Adjusted Odds Ratios are adjusted for age, family history, & WAA 
Consistent with LR, MDR found the BAX_fS4645878 polymorphism was the best 
single factor predictor of disease risk (CVC = 6/10; p = 0.350); however this model was 
not statistically significant [See Table 28]. Permutation testing indicated the three factor 
model containing BCL2L13_fs4488761-CASP5_fs507879-BCL2L14_fs6488494 was 
significant (p = 0.048) and although this model had a high testing accuracy (ATA = 0.585) 
the CVC value was only 3/10. 
Table 28. Unfiltered MDR models for OSR polymorph isms and prostate cancer risk 
among MAD (adjusted for age and family history) 
Best Model Number of Cross Validation Average Testing Permutation 
Combinations Consistency (CVC) Accuracy (ATA) Testing p value 
One Factor 25 6/10 0.517 0.350 BAX rs464S878 
Two Factor 
CRADDJs12817S49 625 8/10 0.571 0.073 
GSTTl deletion 
Three Factor 
BCL2L13Js4488761 15625 3/10 0.585 0.048 CASPSJsS07879 
BCL2L14 rs6488494 
The entropy graph also showed the largest independent IG was attributed to the 
BAX_fS4645878 variant (IG = 1.56%) in addition to revealing several strongly synergistic 
interactions occurred between polymorphic CASPs and BCL2-related genes [See Figufe 
13]. We also observed strong interactions between the GST gene deletions and 
apoptotic markers; however the BCL2L14_fs6488464-CASP_fs507879 was the only 
interaction that could be confirmed by LR two-way analysis (p interaction = 0.013) [See 
Table 29]. 
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Figure 1. Interaction entropy model for OSR polymorph isms and prostate cancer risk 
among MAD 
BCUl1 3_.........,.1 
This graphical model describes the percent entropy that is explained by each OSR SNP or a combination of two loci 
within our MAD study population. Note that the gene combination effect yields an information gain of 2.49% 
comparing the GSTT1_deletion-CRADDJs12817549 axis to either GSTTl or CRADD loci alone (IG = 1.34% and 0.17%, 
respectively). 
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Table 29. Association between gene-gene interactions & peA risk among MAD 
Genes Minor # Minor OR (95% (I) Adj OR (95% CI) - P value - interaction 
Alleles Alleles p value 
GSTT1_deletion *0/*0 0-2 1.00 (reference) 1.00 (reference) 
CRADD Js12817S49 (C 2-3 0.90 (0.54-1.48) 0.87 (0.50-1.48) 0.598 0.392 
4 0.62 (0.20-1.90) 0.61 (0.18-2.07) 0.430 
BCL2L14Js6488494 CC 0-2 1.00 (reference) 1.00 (reference) 
CASPSJsS07879 GG 2-3 0.70 (0.44-1.09) 0.70 (0.43-1.14) 0.152 0.013 
4 2.32 (0.89-6.05) 2.51 (0.91-6.92) 0.075 
BCL2L13Js4488761 GG I 0-2 1.00 (reference) 1.00 (reference) 
CASP9Js10S2S76 AA I 2-3 0.68 (0.41-1.12) 0.73 (0.43-1.25) 0.249 0.106 4 2.09 (0.41-10.58) 1.58 (0.29-8.51) 0.593 
GSTM1_deletion ·0/*0 0-2 1.00 (reference) 1.00 (reference) 
BCL2L13Js4488761 GG 2-3 0.62 (0.39-0.98) 0.65 (0.39-1.07) 0.088 0.229 
4 0.92 (0.38-2.25) 0.94 (0.36-2.45) 0.902 
BCL2L14Js6488494 CC 0-2 1.00 (reference) 1.00 (reference) 
CASP9Js10S2S76 AA 2-3 0.93 (0.58-1.51) 0.91 (0.54-1.53) 0.710 0.337 
I 4 1.87 (0.36-9.85) 1.88 (0.34-10.45) 0.469 
*AdJusted OR are adjusted for age & WAA 
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SPECIFIC AIM 2 FINDINGS - MED SUBJECTS 
We evaluated the individual- and combined impact of 173 apoptotic-related 
polymorphisms in relation to PCA aggressiveness for 1,176 MED subjects (688 
aggressive and 488 non-aggressive cases). LR analysis found that possession of at least 
one minor AKT3_rs12031994 C allele was associated with increased disease 
aggressiveness [OR (95%CI) = 1.50 (0.15-1.96); P = 0.003; See Table 30]. 
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Table 30. Association between Apoptotic polymorph isms and disease aggressiveness among MED 
0.001 
- -I I I 0.052 cc 13(1.9) I 14 (2.9) 0.73 (0.34-1.57) 0.73 (0.34-1.57) 0.421 0.025 
TC+CC 205(29.8) 108 (22.1) 1.49 (1.14-1.95) 1.50 (0.15-1.96) 0.003 
rs10860361 I APAFl I AA 200(29.1) 136 (27.9) 1.00 (reference) 1.00 (reference) 
AG 349 (SO.8) 252 (51.6) 0.94 (0.72-1.24) 0.94 (0.72-1.23) 0.6SO 
GG 138(20.1) 100 (20.5) 0.94 (0.67-1.32) 0.93 (0.67-1.31) 0.688 I 0.688 I 0.356 
AG+GG 487 (70.9) 352 (72.1) 0.94 (0.73-1.22) 0.94 (0.72-1.21) 0.623 
rs905238 I SAX I AA 189(27.5) 130 (26.6) 1.00 (reference) 1.00 (reference) 
AG 330(48.0) 228 (46.8) 1.00 (0.75-1.32) 0.99 (0.75-1.31) 0.928 
~ ~ I GG 169(24.5) 130 (26.6) 0.89 (0.65-1.23) 0.88 (0.64-1.21) 0.425 I 0.498 I 0.280 ~ 499(72.5) 358 (73.4) 0.96 (0.74-1.25) 0.95 (0.73-1.23) 0 AG+GG 0.686 
rs616130 I sazUl I CC 193(28.1) 123 (25.2) 1.00 (reference) 1.00 (reference) 
AC 353(51.3) 252 (51.6) 0.89 (0.68-1.18) 0.88 (0.66-1.16) 0.353 
AA 142 (20.6) 113 (23.2) 0.80 (0.57-1.12) 0.80 (0.57-1.11) 0.182 I 0.192 I 0.168 
AC+AA 495 (71.9) 365 (74.8) 0.86 (0.66-1.13) 0.85 (0.65-1.11) 0.232 
rs10845479 I sazU4 I AA 379(55.1) 265 (54.3) 1.00 (reference) 1.00 (reference) 
AG 256(37.2) 192 (39.3) 0.93 (0.73-1.19) 0.93 (0.73-1.19) 0.565 
GG 53(7.7) 31 (6.4) 1.20 (0.75-1.91) 1.23 (0.77-1.97) 0.388 I 0.879 I 0.223 
AG+GG 309(44.9) 223 (45.7) 0.97 (0.77-1.22) 0.97 (0.77-1.23) 0.811 
rs366542 r BID I CC 158(23.0) 120 (24.5) 1.00 (reference) 1.00 (reference) 
TC 351(51.0) 253 (51.8) 1.05 (0.79-1.40) 1.06 (0.79-1.41) 0.705 
TT 179(26.0) 115 (23.6) 1.18 (0.85-1.65) 1.20 (0.86-1.67) 0.296 I 0.323 I 0.216 
TC+TT 530(77.0) 368 (75.4) 1.09 (0.83-1.44) 1.10 (0.84-1.45) 0.493 
*Adjusted OR are adjusted for age & WAA 
Table 30. Association between Apoptotic polymorph isms and disease aggressiveness among MED, continued 
AG 130(18.9) 81 (16.6) 1.18 (0.87-1.60) 1.19 (0.87-1.62) 0.270 
GG 8(1.2) 4(0.8) 1.47 (0.44-4.90) 1.50 (0.45-5.04) 0.509 I 0.236 I 0.207 
AG+GG 138(20.1) 85 (17.4) 1.19 (0.88-1.61) 1.20 (0.89-1.62) 0.227 
rs10503786 I BNIP3L , CC 328 (48.8) 235 (49.2) 1.00 (reference) 1.00 (reference) 
TC 294(43.8) 189 (39.5) 1.11 (0.87-1.43) 1.11 (0.86-1.42) 0.424 
TT SO (7.4) 54 (11.3) 0.66 (0.44-1.01) 0.66 (0.44-1.01) 0.055 I 0.367 I 0.208 
TC+TT 344(51.2) 243 (50.8) 1.01 (0.80-1.28) 1.01 (0.80-1.28) 0.946 
rs12870 I DIABLO I GG 24Z (35.2) 146 (29.9) 1.00 (reference) 1.00 (reference) 
AG 328 (47.7) 250 (51.2) 0.79 (0.61-1.03) 0.80 (0.61-1.04) 0.091 
J-> I I A:AA 118(17.1) 92 (18.9) 0.77 (0.55-1.09) 0.78 (0.55-1.10) 0.151 I 0.092 I 0.171 J-> 446(64.8) 342 (70.1) 0.79 (0.61-1.01) 0.79 (0.62-1.02) J-> 0.067 
rs1539243 I IDICE j CC S02 (73.0) 341 (69.9) 1.00 (reference) 1.00 (reference) 
TC 172 (25.0) 125 (25.6) 0.94 (0.72-1.22) 0.95 (0.73-1.24) 0.712 
TT 14(2.0) 22 (4.5) 0.43 (0.22-0.86) 0.44 (0.22-0.88) 0.200 I 0.075 I 0.248 
TC+TT 186(27.0) 147 (30.1) 0.86 (0.67-1.11) 0.88 (0.68-1.13) 0.310 
rs11688 I JUN I GG 608(88.4) 446 (91.2) 1.00 (reference) 1.00 (reference) 
AG 79(11.5) 42(8.6) 1.38 (0.93-2.05) 1.38 (0.93-2.04) 0.112 I 0.084 I 0.243 
AG+AA 80(11.6) 42(8.6) 1.40 (0.94-2.07) 1.40 (0.94-2.07) 0.097 
rs4727666 I P/OCG I AA 447(65.5) 301 (62.3) 1.00 (reference) 1.00 (reference) 
AG 207(30.3) 162 (33.6) 0.86 (0.67-1.11) 0.86 (0.66-1.10) 0.225 
GG 29(4.2) 20 (4.1) 0.98 (0.54-1.76) 0.98 (0.54-1.76) 0.934 I 0.372 I 0.200 
AG+GG 236(35.5) 182 (37.7) 0.17 (0.69-1.11) 0.87 (0.68-1.11) 0.255 
*Adjusted OR are adjusted for age & WAA 
Table 30. Association between Apoptotic polymorph isms and disease aggressiveness among MED, continued 
rs281508 I PRKCE I GG 368 (53.5) 279 (57.2) 1.00 (reference) 1.00 (reference) 
TG 279(40.5) 170 (34.8) 1.24 (0.97-1.59) 1.24 (0.97-1.59) 0.089 
n 41 (6.0) 39(8.0) 0.80 (0.50-1.27) 0.80 (0.50-1.27) 0.334 I 0.654 I 0.102 
TG+n 320(46.5) 209 (42.8) 1.16 (0.92-1.47) 1.16 (0.91-1.46) 0.226 
rs571715 I PRKCQ I n 432 (62.9) 329 (67.7) 1.00 (reference) 1.00 (reference) 
TC 221 (32.2) 138 (28.4) 1.22 (0.94-1.58) 1.23 (0.95-1.59) 0.119 
CC 34(4.9) 19 (3.9) 1.36 (0.76-2.43) 1.37 (0.76-2.44) 0.293 I 0.086 I 0.178 
TC+CC 255 (37.1) 157 (32.3) 1.24 (0.97-1.58) 1.24 (0.97-1.59) 0.082 
rs585881 I PRKCQ I n 439(63.8) 332 (68.0) 1.00 (reference) 1.00 (reference) 
TC 217(31.5) 138 (28.3) 1.19 (0.92-1.54) 1.20 (0.93-1.55) 0.173 
...... I I CC 32(4.7) 18 (3.7) 1.34 (0.74-2.44) 1.35 (0.74-2.45) 0.328 I 0.123 I 0.206 ...... 249(36.2) 156 (32.0) 1.21 (0.94-1.54) 1.21 (0.95-1.55) IV TC+CC 0.124 
rs6442322 I RAFl I AA 203(29.6) 141 (29.2) 1.00 (reference) 1.00 (reference) 
AG 350(51.1) 223 (46.2) 1.09 (0.83-1.43) 1.08 (0.82-1.42) 0.580 
GG 132(19.3) 119 (24.6) 0.77 (0.56-1.07) 0.76 (0.55-1.06) 0.105 I 0.168 I 0.142 
AG+GG 482(70.4) 342 (70.8) 0.98 (0.76-1.26) 0.97 (0.75-1.25) 0.811 
rsll135693 I TNFRSFlOB I CC 330(48.0) 251 (51.5) 1.00 (reference) 1.00 (reference) 
AC 293(42.6) 196 (40.3) 1.14 (0.89-1.45) 1.14 (0.89-1.46) 0.296 
AA 65(9.4) 40(8.2) 1.24 (0.81-1.89) 1.25 (0.82-1.92) 0.307 I 0.210 I 0.182 
AC+AA 358(52.0) 236 (48.5) 1.15 (0.92-1.46) 1.16 (0.92-1.46) 0.217 
rs4149576 I TNFRSFlA I AA 138(20.2) 97 (20.1) 1.00 (reference) 1.00 (reference) 
AG 320(46.9) 232 (48.0) 0.97 (0.71-1.32) 0.99 (0.72-1.34) 0.923 
GG 224(32.5) 154 (31.9) 1.02 (0.73-1.42) 1.04 (0.75-1.45) 0.814 I 0.849 I 0.343 
AG+GG 554(79.4) 386 (79.9) 0.99 (0.74-1.33) 1.01 (0.75-1.35) 0.962 
*Adjusted OR are adjusted for age & WAA 
Since the apoptotic SNP panel contained 173 targets, we had to use the SURF & TuRF 
filter in order to conduct the analysis. To analysis the entire panel would require MDR 
to evaluate more than 5 million one-, two-, and three-way combinations. Since it is not 
computationally possible to exhaustively analyze all 173 SNPs, we used the SURF & TuRF 
filter for the top 50 percentile. This feature allows MDR to rank and select apoptotic 
polymorph isms most likely to be associated with disease aggressiveness and reduces 
the number of pair-wise and three-way combinations to amount that is possible to 
analyze (i.e., approximately 643,500) . 
For the filtered apoptotic SNP datafile MDR identified AKT3Js12031994 as the 
best single factor model, but permutation testing indicated this finding was not 
statistically significant [See Table 31]. However, MDR modeling and permutation testing 
found this SNP combined with PRKC~rs571715 was the best predictor of peA 
aggressiveness (eVe = 8/10; p = 0.024). 
Table 31. Top 50th Percentile MDR models for apoptotic SNPs and prostate cancer 
aggressiveness among MED (adjusted for age and family history) 
Best Model Number of Cross Validation Average Testing Permutation 
Combinations Consistency (CVe) Accuracy (ATA) Testing p value 
One Factor I 86 I 6/10 f 0.533 , 0.095 AKT3 r512031994 
Two Factor 
AKT3J512031994 7396 8/10 0.542 0.024 
PRKCo....r5571715 
Three Factor I I BA)Cr5905238 636056 5/10 0.538 0.072 BCL2L14J51 0845479 
RAF1 r56442322 
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When the apoptotic SNPs were visualized using hlG, we also observed two 
synergistic interactions: BCL2L14_rs10845479-BAXJs905238 (IG = 0.92%) and 
BCL2L14Js10845479-BCL2L11Js724710 (IG = 0.77%) [See Figure 14]. Although LR two-
analysis did not find the AKT3-PRKCQ significant (p ~ 0.102), the BCL2L14-BAX and 
BCL2L14-BCL2L11 combinations were each associated with increased PCA 
aggressiveness [OR (95%CI) = 1.72 (1.20-2.45); P = 0.003 and OR (95%CI) = 1.44 (1.07-
1.95); P = 0.017, respectively]; See Table 32]. 
Figure 1. Interaction entropy model for apoptotic SNPs in relation to prostate cancer 
aggressiveness among MED 
The combined effects of BCL214Jsl0845479-BAXJs905238 and BCL214Jsl0845479 -BCL2L11Js724710 yield an 
information gain of 0.92% and 0.77%, respectively; compared to considering any on these loci individually BCL2L14 
(IG = 0.07%), BAX (IG = 0.10%), or BCL2L11 (IG = 0.05%). 
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Table 32. Association between apoptotic gene-gene interactions & peA 
aggressiveness among MED 
1.00 (reference) 
cc 1 1.84 (1.43-2.38) 0.102 
2 1.37 (0.93-2.03) 0.915 
~3 1.04 (0.51-2.13) 1.04 (0.51-2.13) 0.484 
BCL2L14_,s10845479 GG 0 1.00 (reference) 1.00 (reference) 
BAXJs905238 TT 1 1.74 (1.22-2.48) 1.72 (1.20-2.45) 0.003 
2 1.11 (0.78-1.57) 1.10 (0.77-1.56) 0.599 
~3 1.26 (0.83-1.91) 1.23 (0.81-1.88) 0.326 
BCL2L14Jsl0845479 GG 0 1.00 (reference) 1.00 (reference) 
BCL2L11Js724710 TT 1 1.45 (1.07-1.95) 1.44 (1.07-1.95) 0.017 
2 0.97 (0.70-1.34) 0.97 (0.70-1.34) 0.838 
~3 0.95 (0.57-1.59) 0.95 (0.57-1.60) 0.867 
*Adjusted OR are adjusted for age & family history 
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0.013 
0.055 
0.042 
SPECIFIC AIM 2 FINDINGS - MAD SUBJECTS 
Among MAD subjects, we examined 15 apoptotic polymorphisms within our OSR 
panel as predictors of PCA progression as measured by Tumor Stage (Le., Gleason 
score). The study population consisted of 137 case subjects, (68 aggressive and 69 non-
aggressive). LR analysis of independent SNP effects did not reveal any significant 
associations in disease aggressiveness (p ~ 0.062) [See Table 33]. 
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Table 33. Association between Apoptotic polymorph isms and Tumor Grade among MAD 
rs4645878 I SAX I CC 18(33.3) 28 (50.0) 1.00 (reference) 1.00 (reference) 
CT 29 (53.7) 21 (37.5) 0.47 (0.21-1.05' 0.43 (0.19-1.00) 0.049 
IT 7 (13.0) 7 (12.5) 0.64 (0.19-2.14) 0.64 (0.19-2.20) 0.482 I 0.188 I 0.272 
CT+IT 36(66.7) 28 (50.0) 0.50 (0.23-1.08) 0.47 (0.21-1.04) 0.062 
rs3789068 I BCl.2L11 I IT 21 (38.9) 16 (30.2) 1.00 (reference) 1.00 (reference) 
TC 29(53.7) 30 (56.6) 1.36 (0.59-3.10) 1.61 (0.66-3.89) 0.291 
CC 4(7.4) 7 (13.2) 2.30 (0.57-9.22) 2.64 (0.64-10.95) 0.182 I 0.232 I 0.263 
TC+CC 33(61.1) 37 (69.8) 1.47 (0.66-3.28) 1.75 (0.74-4.11) 0.200 
rs4488761 I SQZL13 ~ AA 19 (33.9, 18 (32.7) 1.00 (reference' 1.00 (reference) 
AG 21 (37.5, 27 (49.1) 1.36 (0.57-3.21, 1.39 (0.58-3.34) 0.461 
.... I I GG 16(28.6) 10 (18.2) 0.66 (0.24-1.83, 0.66 (0.24-1.87) 0.437 I 0.517 I 0.159 .... 37 (66.1, 37 (67.3) 1.06 (0.48-2.33, 1.07 (0.48-2.40) 0.862 --.J AG+GG 
rs6488494 I BazL14 I IT 16(28.1, 16 (28.6) 1.00 (reference' 1.00 (reference) 
TC 26(45.6' 27 (48.2) 1.04 (0.43-2.50, 0.96 (0.39-2.40) 0.931 
CC 15 (26.3, 13 (23.2) 0.87 (0.31-2.39) 0.79 (0.28-2.25) 0.660 I 0.793 I 0.262 
TC+CC 41 (71.9, 40 (71.4) 0.98 (0.43-2.21) 0.90 (0.38-2.11) O.BOS 
rs1883263 I BlK I AA 41 (74.6) I 48 (87.3) 1.00 (reference) I 1.00 (reference) AC+CC 14(25.5) 7 (12.7) 0.43 (0.16-1.16) 0.45 (0.16-1.23) I 0.120 0.095 0.326 
rs738276 I BlK I GG 22 (48.9) 23 (41.8) 1.00 (reference, 1.00 (reference) 
GA+AA 23(51.1) 32 (58.2) 1.33 (0.60-2.94) 1.30 (0.59-2.91) I 0.517 0.222 0.224 
rs6509364 I CAROB I CC 35 (63.6) 35 (68.6) 1.00 (reference) 1.00 (reference) 
CT+IT 20(36.4) 13 (25.5) 0.80 (0.36-1.79, 0.83 (0.37-1.88) I 0.656 0.932 0.272 
rs6509366 I CAROB I GG 35 (62.5, 30 (57.7) 1.00 (reference, 1.00 (reference) 
GA 18(32.1, 18 (34.6) 1.17 (0.52-2.64' 1.17 (0.52-2.67) 0.705 
AA 3 (5.4) 4 (7.7) 1.5& (0.32-7.51, 1.46 (0.30-7.10) 0.643 I 0.547 L 0.336 
GA+AA 21 (37.5, 22 (42.3) 1.22 (0.57-2.64' 1.21 (0.56-2.64) 0.625 
*Low Tumor Grade: Gleason score : >7; High Tumor Grade: Gleason score : 57; **Adjusted Odds Ratios (DRs) are adjusted for age, family history, & WAA 
Table 33. Association between Apoptotie polymorph isms and Tumor Grade among MAD, continued 
rs1049216 I CASP3 n 37 (69.8) 35 (67.3) 1.00 (reference) 1.00 (reference) 
Te 13 (24.5) 15 (28.9) 1.22 (0.51-2.93) 1.21 (0.50-2.95) 0.670 
CC 3 (5.7) 2 (3.9) 0.71 (0.11-4.47) 0.68 (0.11-4.38) 0.688 I 0.951 I 0.371 
TC+CC 16(30.2) 17 (32.7) 1.12 (0.49-2.56) 1.11 (0.48-2.57) 0.803 
rs507879 CASPS AA 11(19.6) 6 (10.7) 1.00 (reference) 1.00 (reference) 
AG 27 (48.2) 29 (51.8) 1.97 (0.64-6.06) 2.50 (0.70-8.94) 0.159 
GG 18 (32.1) 21 (37.5) 2.14 (0.66-6.94) 2.14 (0.56-8.11) 0.265 I 0.268 I 0.235 
AG+GG 45 (80.4) 50 (89.3) 2.04 (0.7D-5.96) 2.34 (0.69-7.931 0.171 
rs537093 CASPS GG 30(53.6) 28 (50.9) 1.00 (reference) 
GA+AA 26(46.4) 27 (49.1) 1.11 (0.53-2.34) I 1.12 (0.53-2.39) I 0.764 I 0.779 I 0.431 
I-' rs6747918 CASPS AA 15 (39.5) 14 (41.2) 1.00 (reference) 1.00 (reference) 
I-' 
3 (7.9) 3 (8.8) 00 AG 1.07 (0.19-6.22) 0.97 (0.16-5.77) 0.971 
GG 20(52.6) 17 (50.0) 0.91 (0.34-2.41) 0.85 (0.32-2.31) 0.755 I 0.847 I 0.433 
AG+GG 23 (60.5) 20 (58.8) 0.93 (0.36-2.39) 0.87 (0.33-2.28) 0.774 
rs1052576 I CASPS GG 19(34.6) 27 (48.2) 1.00 (reference) 1.00 (reference) 
GA 29(52.7) 24 (42.9) 0.58 (0.26-1.29) 0.59 (0.27-1.32) 0.203 
AA 7(12.7) 5 (8.9) 0.50 (0.14-1.82) 0.51 (0.14-1.86) 0.306 I 0.163 I 0.163 
GA+AA 36(65.5) 29 (51.8) 0.57 (0.26-1.22) 0.58 (0.27-1.24) 0.160 
rs12817549 I CRADD n 32 (57.1) 26 (48.2) 1.00 (reference) 1.00 (reference) 
TC 19 (33.9) 19 (35.2) 1.23 (0.54-2.79) 1.27 (0.56-2.93) 0.568 
ee 5(8.9) 9 (16.7) 2.22 (0.66-7.43) 2.29 (0.68-7.76) 0.182 I 0.215 I 0.295 
TC+CC 24(42.9) 28 (51.9) 1.44 (0.68-3.05) 1.49 (0.70-3.19) 0.305 
rs3858606 I CRADD GG 13 (24.5) 11 (20.0) 1.00 (reference) 1.00 (reference) 
GA 32 (60.4) 30 (54.6) 1.11 (0.43-2.85) 1.12 (0.43-2.92) 0.815 
AA 8(15.1) 14 (25.5) 2.07 (0.63-6.75) 2.17 (0.65-7.19) 0.205 ! 0.238 I 0.261 
GA+AA 40(75.5) 44 (80.0) 1.30 (0.52-3.23) 1.32 (0.53-3.33) 0.551 
* Low Tumor Grade: Gleason score: >7; High Tumor Grade: Gleason score: $7; **Adjusted Odds Ratios (ORs) are adjusted for age, family history, & WM 
MDR revealed the two factor model containing CASP9J51052576-
BCL2L14J56488494 as the best predictor of aggressiveness (eVe = 10/10; p=O.Ol1) [See 
Table 34]. Due to limited sample size this interaction was confirmed visually by the 
entropy graph which showed a 9.38% IG attributable to this gene combination [See 
Figure 15] . Moderately synergistic interactions were also detected between CASP9-
CASP5 (IG = 4.80%) and BCL2L13-BCL2L14 (IG = 3.S4%), however LR analysis was not 
able validate any of these combinations as statistically significant (p ~ 0.114) [See Table 
35]. 
Table 34. Unfiltered MDR models for apoptotic gene variations and peA 
aggressiveness among MAD (adjusted for age and family history) 
Two Factor 
CASP9JslOS2S76 225 10/10 0.681 
Three Factor 
CASP9JslOS2S76 3375 CASPSJsS07879 5/10 0.596 
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Figure 1. Interaction entropy graph for apoptotic gene variants and peA 
aggressiveness among MAD subjects 
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This graphical model describes the percent entropy that is explained by each apoptotic SNP or a combination of two 
loci. The BCL2L14-CASP9 interaction provides an IG=9.38%, compared to either BCL2L14 or CASPS considered 
individually (0.73% & 1.97%, respectively) . 
Table 35. Association between apoptotic gene-gene interactions & PCA 
aggressiveness among MAD 
CASP9Jsl052576 AA 2-3 0.440 
4 0.43 (0.04-5.15) 0.S02 
CASP9_,s1052576 AA 0-2 1.00 (reference) 1.00 (reference) 
CASP5_,s507879 GG 2-3 1.44 (0.65-3.17) 1.41 (0.63-3.14) 0.403 
4 0.51 0.59 (0.10-3.46) 0.555 
BCL2L14_,s6488494 CC 0-2 1.00 (reference) 1.00 (reference) 
BCL2L13_,s4488761 GG 2-3 1.02 (0.47-2.22) 0.96 (0.43-2.11) 0.909 
4 0.15 (0.02-1.27) 0.15 (0.02-1.31) 0.086 
*Adjusted OR are adjusted for age & WAA 
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SPECIFIC AIM 3 FINDINGS - MED SUBJECTS 
We assessed the effects 27 environmental OSR factors along with our panel of 
219 gene variants in relation to PCA development. We evaluated 27 variables related to 
dietary habits, vitamin/ supplement intake and exposure to meat- and cigarette-derived 
carcinogens using data collected from 2,277 CGEMS project participants (1176 cases, 
1101 controls). Risk categories for dietary intakes and vitamin/supplement use were 
based on values established in the 2005 USDA Dietary Guidelines Report & NIH Office of 
Dietary Supplements.120-121 However, variables related to meat consumption, meat 
cooking methods, and meat-derived carcinogens, were divided into quartiles using data 
for the control subjects. Statistical analyses were conducted using the 1st quartile as 
the low risk category. 
LR analysis found men in the 4nd quartile of MelQx exposure (i.e., ~ 46.64 
ng/day) were associated with a 23% reduction in PCA risk [OR (95%CI) = 0.77 (0.61-
0.97); P = 0.025; See Table 36]. We also observed a decrease in disease risk among 
current smokers in contrast to never smokers [OR (95%CI) = 0.69 (0.51-0.94); P = 0.018]. 
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Table 36. Single effects of Environmental OSR Factors and risk among MED 
Fruit (servings/day) :t4 188 (16.2) 159(14.3) 1.00 (reference) 1.00 (reference) 
<4 975 (83.8) 952(85.7) 0.87 (0.69-1.09) 0.88 (0.70-1.10) 0.260 0.220 0.238 
Vegetables (servings/day) I :t5 256 (22.0) I 280(25.2) 1.00 (reference) I 1.00 (reference) <5 907 (78.0) 831(74.8) 1.19 (0.98-1.45) 1.20 (0.99-1.46) 0.067 0.073 0.237 
Total ~eat{g/day) I :5 129.33 330 (28.4) 278(25.0) 1.00 (reference) 1.00 (reference) 
129.33-174.54 294 (25.3) 303(27.3) 0.82 (0.65-1.03) 0.82 (0.66-1.04) 0.096 
174.54-252.89 268 (23.0) 252 (22.7) 0.90 (0.71-1.14) 0.92 (0.73-1.16) 0.474 I 0.173 I 0.131 
:t252.89 271 (23.3) 278 (25.0) 0.82 (0.65-1.04) 0.83 (0.65-1.05) 0.111 
>129.33 833 (71.6) 833(75.0) I 0.84 (0.70-1.02) 0.85 (0.71-1.03) 0.100 
White ~eat (g/day) :5 26.21 288 (24.8) 278 (25.0) 1.00 (reference) 1.00 (reference) 
f-' 26.21-44.63 357 (30.7) 319 (28.8) 1.08 (0.86-1.35) 1.11 (0.88-1.39) 0.378 
IV 
IV 44.63-71.83 249 (21.4) 236 (21.2) 1.02 (0.80-1.30) 1.04 (0.81-1.33) 0.754 I 0.470 I 0.187 
:t71.83 269 (23.1) 278 (25.0) 0.93 (0.74-1.18) 0.96 (0.76-1.22) 0.747 
>26.21 875 (75.2) 833 (75.0) 1.01 (0.84-1.23) 1.04 (0.86-1.26) 0.689 
Red ~eat (g/day) I :553.90 317 (27.3) 278 (25.0) 1.00 (reference) 1.00 (reference) 
53.90-82.72 320 (27.5) 313 (28.2) 0.90 (0.72-1.12) 0.91 (0.73-1.15) 0.433 
82.72-124.19 249 (21.4) 242 (21.8) 0.90 (0.71-1.15) 0.91 (0.71-1.15) 0.418 I 0.287 I 0.181 
:t 124.19 277 (23.8) 278(25.0) 0.87 (0.69-1.10) 0.88 (0.70-1.12) 0.301 
>53.90 846 (72.7) 833 (75.0) 0.89 (0.74-1.07) 0.90 (0.75-1.09) 0.282 
Processed ~eat (g/day) I :56.08 322 (27.7) 279 (25.1) 1.00 (reference) 1.00 (reference) 
6.08-11.42 315 (27.1) 317 (28.6) 0.86 (0.69-1.08) 0.87 (0.70-1.10) 0.252 
11.42-20.96 210 (18.0) 237 (21.3) 0.77 (0.60-0.98) 0.79 (0.61-1.01) 0.056 I 0.745 I 0.146 
:t20.96 316 (27.2) 278(25.0) 0.99 (0.79-1.24) 1.00 (0.80-1.26) 0.995 
>6.08 841 (72.3) 832 (74.9) 0.88 (0.73-1.06) 0.89 (0.74-1.08' 0.232 
*Adjusted Odds Ratios (OR) are adjusted for age and family history 
Table 36. Single effects of Environmental OSR Factors and risk among MEO, continued 
Red Meat not processed I S38.65 314 (27.0) 278 (25.0) 1.00 (reference) 1.00 (reference) 
(g/day) 38.65-62.14 324 (27.9) 326(29.3) 0.88 (0.70-1.10) 0.88 (0.71-1.10) 0.272 
62.14-95.72 251 (21.6) 229 (20.7) 0.97 (0.76-1.24) 0.98 (0.n-l.25) 0.887 I 0.402 I 0.203 
~95.72 274 (23.5) 278(25.0) 0.87 (0.69-1.10) 0.88 (0.70-1.11) 0.281 
>38.65 849 (73.0) 833 (75.0) 0.90 (0.75-1.09) 0.9110.75-1.10) 0.321 
Red Meat rare/med done I S3.86 278 (23.9) 273(24.6) 1.00 (reference) (g/day) 3.86-15.98 348 (29.9) 298(26.8) 1.15 (0.91-1.44) 1.17 (0.93-1.47) 0.185 
15.98-32.41 257 (22.1) 262 (23.6) 0.96 (0.76-1.22) 0.99 (0.78-1.26) 0.913 I 0.560 I 0.155 
~32.41 280 (24.1) 278(25.0) 0.99 (0.78-1.25) 1.00 (0.79-1.28) 0.971 
>3.86 885 (76.1) 838(75.4) 1.04 (0.86-1.26) 1.06 (0.87-1.28) 0.570 
...... I Red Meat well/very well I S4.95 319 (27.4) 278(25.0) 1.00 (reference) 1.00 (reference) N done (g/day) 299(27.0) 0.94 (0.75-1.18) w 4.95-9.84 320 (27.5) 0.93 (0.75-1.17) 0.605 
9.84-19.82 250 (21.5) 256(23.0) 0.85 (0.67-1.08) 0.86 (0.68-1.09) 0.215 I 0.144 I 0.156 
~19.82 274 (23.6) 278(25.0) 0.86 (0.67-1.08) 0.86 (0.68-1.09) 0.213 
>4.95 844 (72.6) 833(75.0) 0.88 (0.73-1.07) 0.89 (0.74-1.07) 0.226 
*Adjusted Odds Ratios (OR) are adjusted for age and family history 
Table 36. Single effects of Environmental OSR Factors and risk among MED, continued 
Kcal from diet (g/day) I 2000-3000 559 (48.1) 522 (47.0) 1.00 (reference) 1.00 (reference) 
<2000 395 (33.9) 391 (35.2) 0.94 (0.79-1.13) 0.94 (0.78-1.13) 0.480 I 0.768 I 0.276 
>3000 209 (18.0) 198 (17.8) 0.97 (0.79-1.24) 0.98 (0.78-1.24) 0.884 
Fat from diet (g/day) i :S73.11 626 (53.8) 590(53.1) 1.00 (reference) I 1.00 (reference) 
>73.11 537 (46.2) 521 (46.9) 0.97 (0.82-1.15) 0.96 (0.82-1.14) 0.663 0.730 0.348 
Saturated Fat from diet :S24.95 628 (54.0) 602 (54.2) 1.00 (reference) 1.00 (reference) 
(g/day) >24.95 535 (46.0) 509(45.8) 1.01 (0.85-1.19) 1.00 (0.85-1.18) 0.976 0.929 0.407 
Body Mass Index (BMI) I Under/normal weilht 305 (26.2) 271 (24.4) 1.00 (reference) 1.00 (reference) 
Overweitht 612 (52.6) 574(51.7) 0.95 (0.78-1.16) 0.97 (0.79-1.19) 0.758 0.111 0.192 
Obese 246 (21.2) 266(23.9) 0.82 (0.65-1.04) 0.14 (0.66-1.06) 0.143 
f-' Physically Active (~30 min I Yes 556 (47.8) 494(44.5) 1.00 (reference) 1.00 (reference) 
N 
~ /day) No 607 (52.2) 617(53.5) 0.87 (0.74-1.03) 0.88 (0.74-1.04) 0.125 0.110 0.234 
Vitamin A hlg/day) I UOO I 1054 (90.6) 1008(90.6) 1.00 (reference) 1.00 (reference) <900 110 (9.4) 105 (9.4) 1.00 (0.76-1.33) 1.03 (0.77-1.36) 0.867 0.990 0.421 
Vitamin C (mg/day) I ~9O 1103 (94.8) 1042 (93.6) 1.00 (reference) 1.00 (reference) 
<90 61 (5.2) 71(6.4) 0.81 (0.57-1.16) 0.14 (0.59-1.19) 0.317 0.246 0.383 
Vitamin E (IU/day) I ~22.4 1014 (87.1) 952 (as.5) 1.00 (reference) 1.00 (reference) 
<22.4 150 (12.9) 161 (14.5) 0.88 (0.69-1.11) 0.89 (0.7D-l.13) 0.325 0.273 0.332 
Zinc (mg/day) I ~11 838 (72.0) I 775 (69.6) 1.00 (reference) 1.00 (reference) <11 326 (28.0) 338(30.4) 0.89 (0.74-1.07) 0.88 (0.74-1.06) 0.179 0.215 0.215 
Selenium hlg/day) I ~55 1128 (97.0) 1085 (97.7) 1 1.00 (reference) 1.00 (reference) 
<55 35 (3.0) 26(2.3) 1.30 (0.77-2.17) 1.30 (0.77-2.17) 0.324 0.325 0.390 
Alcohol Consumption I U I 960 (82.6) I 923 (83.1) 1.00 (reference) I 1.00 (reference) (drinks /day) <2 203 (17.4) 188(16.9) 1.04 (0.84-1.29) 1.04 (0.83-1.29) 0.747 0.736 0.427 
*Adjusted Odds Ratios (OR) are adjusted for age and family history 
Table 36. Single effects of Environmental OSR Factors and risk among MED, continued 
MelQx (ng/day) I :s 13.10 335 (28.8) 278 (25.0) 1.00 (reference) 1.00 (reference) 
13.10-23.93 310 (26.7) 278(25.0) 0.93 (0.74-1.16) 0.94 (0.75-1.00) 0.601 
23.93-46.64 263 (22.6) 277 (25.0) 0.79 (0.63-0.99) 0.79 (0.63-1.00) 0.051 0.009 
it 46.64 255 (21.9) 278(25.0) 0.76 (0.60-0.96) 0.77 (0.61-0.97) 0.025 0.042 I 0.055 
>13.10 828 (71.2) 833 (75.0) 0.83 (0.69-0.99) 0.83 (0.69-1.01) 0.057 
PhlP (ng/day) I :S36.74 297 (25.5) 278(25.0) 1.00 (reference) 1.00 (reference) 
36.74-73.98 328 (28.2) 300 (27.0) 1.02 (0.82-1.28) 1.04 (0.83-1.31) 0.722 
73.98-156.86 283 (24.3) 255(23.0) 1.04 (0.82-1.31) 1.06 (0.84-1.35) 0.620 0.251 
it 156.86 255 (21.9) 278 (25.0) 0.86 (0.68-1.09) 0.89 (0.70-1.13) 0.323 0.778 I 0.166 
>36.75 866 (74.5) 833 (75.0) 0.97 (0.81-1.18) 1.00 (0.82-1.21) 0.983 
...... DiMelQx (ng/day) I :S0.39 308 (26.5) 279 (25.1) 1.00 (reference) 1.00 (reference) tv VI 0.39-1.22 365 (31.4) 297 (26.8) 1.11 (0.89-1.39) 1.U (0.89-1.40) 0.340 
1.22-2.58 246 (21.1) 257 (23.1) 0.87 (0.68-1.10) 0.88 (0.69-1.U) 0.297 0.014 
it 2.58 244 (21.0) 278(25.0) 0.80 (0.63-1.01) 0.81 (0.64-1.02) 0.074 0.456 I 0.067 
>0.39 855 (73.5) 832 (75.0) 0.93 (0.77-1.12) 0.94 (0-78-1.14) 0.522 
BaP (meg/day) I :s 1.705 303 (26.0) 278(25.0) 1.00 (reference) 1.00 (reference) 
1.705-9.14 330 (28.4) 294(26.5) 1.03 (0.82-1.29) 1.03 (0.82-1.29) 0.792 
9.14-44.585 288 (24.8) 261 (23.5) 1.01 (0.80-1.28) 1.02 (0.81-1.29) 0.873 0.077 
it 44.585 242 (20.8) 278(25.0) 0.80 (0.63-1.01) 0.81 (0.63-1.02) 0.076 0.573 I 0.107 
>1.705 860 (74.0) 833(75.0) 0.95 (0.78-1.14) 0.95 (0.79-1.15) 0.621 
Tobacco Use r Never 477 (41.0) 421 (37.9) 1.00 (reference) 1.00 (reference) 
Fonner 593 (51.0) 570(51.3) 0.92 (0.77-1.09) 0.92 (0.77-1.09) 0.337 0.026 
Current 93 (8.0) UO(10.8) 0.68 (0.51-0.92) 0.69 (0.51-0.94) 0.018 0.128 I 0.178 
Eve? 686 (59.0) 690(62.1) 0.88 (0.74-1.04) 0.88 (0.74-1.04) 0.135 
*Adjusted Odds Ratios (OR) are adjusted for age and fam ily history 
Although MDR modeling did not confirm any single effects observed by LR, a 
significant association was found between consumption of White_meat-
Processed_meat- Well_doneJed_meat (CVC = 7/10; p = 0.038) [See Table 37]. 
Table 37. Unfiltered MDR models for environmental OSR factors and prostate cancer 
risk among MED (adjusted for age and family history) 
Best Model Number of Cross Validation Average Permutation 
Combinations Consistency Testing Testing p 
(CVe) Accuracy (ATA) value 
One Factor 27 6/10 0.497 0.544 DiMe/Qx I I I 
Two Factor 
I I I Processed_Meat 729 2/10 0.497 0.563 
Red Meat Well Done 
Three Factor I White_meat_intake I Processed_Meat 19683 7/10 0.534 0.038 Red Meat Well Done 
hlG illustrated that the strongest risk effects were attributed to variables related 
to meat intake in our panel. Taken individually IG values were considerably less (Le., IG 
:5 0.19%), compared to those obtained from the combined effects of Processed_meat-
Processed_meat-White_meat (0.29%) [See Figure 16]. LR modeling was used to validate 
these interactions, however only Processed_meat-White_meat was statistically 
significant [See Table 38] . This combination was associated with a decrease in risk 
comparing the highest quartiles of meat intake to the lowest quartiles [OR (95%CI) = 
0.77 (0.60-0.98); P = 0.032]. 
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Figure 1. Interaction entropy model for unfiltered environmental OSR panel and 
prostate cancer risk among MED 
The combined effect of Processed meat-Rare red meat consumption yield an information gain of 0.38% in comparison 
to considering either Processed_meat or RareJed_meat alone (IG = 0.19% and 0.10%, respectively). 
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Table 38. Association between environment - environment interactions & peA risk 
among MED 
Red meat rare 1 0.506 
2 0.97 (0.78-1.20) 0.780 0.181 
~3 1.11 (0.88-1.41) 1.12 (0.89-1.43) 0.325 
Processed Meat ~20.96 0 1.00 (reference) 1.00 (reference) 
Red meat well-done ~ 19.82 1 0.89 (0.67-1.18) 0.88 (0.66-1.17) 0.368 
2 0.95 (0.77-1.18) 0.97 (0.79-1.20) 0.791 0.256 
~3 0.78 (0.61-0.99) 0.79 (0.62-1.01) 0.057 
Processed Meat ~ 20.96 0 1.00 (reference) 1.00 (reference) 
White meat ~ 71.83 1 0.98 (0.76-1.27) 0.96 (0.74-1.24) 0.744 
2 0.96 (0.78-1.19) 0.97 (0.79-1.20) 0.806 0.942 
~3 0.76 0.77 (0.60-0.98) 0.032 
*Adjusted OR are adjusted for age & family history 
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To conduct MDR modeling for the entire genetic and environmental OSR panel in 
relation to disease risk, we again subjected the datafile to the SURF & TuRF filter. With 
MDR ranking and selecting factors most likely to be associated with PCA risk the number 
of possible one-, two-, and three-way combinations was reduced from over 14 million to 
about 1.3 million. Although this was still computationally challenging, MDR was able to 
carry out this analysis in roughly one week. Unfortunately, this analysis did not did not 
detect any models significantly associated with disease risk (p ~ 0.289) [See Table 39] . 
Table 39. Top 25th Percentile MDR models for OSR panel and peA risk among MED 
(adjusted for age and family history) 
Best Model Number of Cross Validation Average Permutation 
Combinations Consistency Testing Testing p 
(CVe) Accuracy (ATA) value 
One Factor 61 I Me/Qx 5/10 0.494 I 0.603 
Two Factor 
PRKCEJs935673 3721 6/10 0.503 0.420 
Me/Qx 
Three Factor 
BN/P3LJslO503786 
~ 226981 4/10 0.510 0.289 White_meat_intake Me/Qx 
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hlG revealed synergistic interactions between White meat intake-POLlJs8305 
and White meat intake-BNIP3LJs10503786 [See Figure 17]. However, neither 
combination was significant in LR analysis (p ~ 0.129) [See Table 40]. 
Figure 2. Entropy graph for OSR panel and peA risk among MED 
POU_rs830S 
0.17% 
-4.11% 
0.23% 
The combined effect of White meat intake-POLl_rs8305 yield an information gain of 0.28% in comparison to 
consumption of either White meat intake or POLl_rs8305 individually (IG = 0.09% and 0.17%, respectively) . 
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Table 40. Association between OSR gene-environment interactions & peA risk among 
MED 
POLLrs830S 0.129 
0.98 (0.79-1.21) 0.816 0.073 
~3 1.18 (0.90-1.54) 1.18 (0.90-1.54) 0.227 
White_meat (gjday) ~71.83 0 1.00 (reference) 1.00 (reference) 
BNIP3L-,s10S03786 TT 1 0.86 (0.69-1.07) 0.86 (0.69-1.07) 0.174 
2 1.09 (0.88-1.35) 1.10 (0.88-1.36) 0.402 0.477 
~3 0.82 0.161 
*Adjusted OR are adjusted for age & family history 
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When we evaluated our candidate OSR panel as predictors of disease 
aggressiveness LR identified several environmental factors that independently modified 
PCA progression. Subjects that had more than 2 alcoholic drinks per day were 
associated with a decrease in disease aggressiveness compared to those having less 
than 2 drinks daily [OR (95%CI) = 0.73 (0.54-0.99); p = 0.044; See Table 41]. We also 
observed a decrease in PCA aggressiveness among men in 3rd quartile of daily PhlP 
exposure (i.e., 73.98-156.86 ng/day) compared the men exposed to less than 36.74 ng 
each day [OR (95%CI) = 0.71 (0.51-0.99); P = 0.045]. 
Men in the 2nd quartile of processed meat consumption (i.e., 6.08-11.42 g/day) 
were associated with a loS-fold increase in disease aggressiveness in contrast to men 
who consume less than 6.08 g per day. In addition, men in the 2nd quartile for daily 
consumption of well-done or very well-done red meat (i.e., 4.95-9.84 g/day) were linked 
to increased disease aggressiveness compared to men in the 1st quartile (consuming 
less than 4.95 g per day) [OR (95%CI) = 1.38 (1.00-1.89); P = 0.049]. 
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Table 41. Single effects of Environmental OSR Factors and peA aggressiveness among MED 
Fruit (servings/day) ~4 584 (85.0) 403 (82.6) 1.00 (reference) 1.00 (reference) 
<4 103 (15.0) 85 (17.4) 1.20 (0.87-1.64) 1.16 (0.85-1.59) 0.352 0.264 0.288 
Vegetables (servings/day) ~5 547 (79.6) 370(75.8) 1.00 (reference) 1.00 (reference) 
<5 140 (20.4) 118 (24.2) 1.25 (0.94-1.65) 1.22 (0.92-1.61) 0.169 0.121 0.206 
Total~eat(g/day) I $129.33 189 (27.5) 147 (30.1) 1.00 (reference) 1.00 (reference) 
129.33-174.54 187 (27.2) 108(22.1) 1.35 (0.98-1.86) 1.30 (0.94-1.80) 0.107 
174.54-252.89 150 (21.9) 120(24.6) 0.97 (0.70-1.34) 0.97 (0.70-1.33) 0.831 I 0.951 I 0.153 
~252.89 161 (23.4) 113 (23.2) 1.11 (0.80-1.53) 1.06 (0.77-1.48) 0.712 
>129.33 498 (72.5) 341 (69.9) 1.14 (0.88-1.47) 1.10 (0.85-1.43) 0.453 
White ~eat (g/day) I $26.21 179 (26.1) 112(23.0) 1.00 (reference) 1.00 (reference) I-' 26.21-44.63 213 (31.0) 148(30.3) 0.90 (0.66-1.24) 0.89 (0.65-1.Z2) 0.454 w 44.63-71.83 146 (21.2) 106 (21.7) 0.86 (0.61-1.22) 0.83 (0.59-1.18) 0.295 I 0.116 I 0.175 w 
~71.83 149 (21.7) 122(25.0) 0.76 (0.55-1.07) 0.74 (0.53-1.04) 0.078 
>26.21 508 (73.9) 376(77.0) 0.85 (0.65-1.11) 0.82 (0.63-1.08) 0.162 
Red ~eat (g/day) I $53.90 185 (26.9) 137 (28.1) 1.00 (reference) 1.00 (reference) 
53.90-82.72 198 (28.8) 123(25.2) 1.19 (0.87-1.63) 1.18 (0.86-1.62) 0.302 
82.72-124.19 137 (20.0) 116(23.8) 0.88 (0.63-1.22) 0.87 (0.62-1.21) 0.392 I 0.996 I 0.146 
~124.19 167 (24.3) 112 (22.9) 1.10 (0.80-1.53) 1.07 (0.77-1.48) 0.700 
>53.90 502 (73.1) 351 (71.9) 1.06 (0.82-1.37) 1.04 (0.80-1.35) 0.774 
Processed ~eat (g/day) I $6.08 179 (26.1) 148(30.3) 1.00 (reference) 1.00 (reference) 
6.08-11.42 206 (29.8) 113(23.2) 1.50 (1.09-2.06) 1.49 (1.08-2.05) 0.014 
11.42-20.96 124 (18.0) 89(18.2) 1.15 (0.81-1.63) 1.13 (0.80-1.61) 0.486 I 0.958 I 0.059 
~20.96 179 (26.1) 138(28.3) 1.07 (0.79-1.46) 1.06 (0.78-1.45) 0.707 
>6.08 508 (73.9) 340(69.7) 1.24 (0.96-1.60) 1.22 '0.94-1.58) 0.127 
·Adjusted Odds Ratios (OR) are adjusted for age & family history 
Table 41. Single effects of Environmental OSR Factors and peA aggressiveness among MEO, continued 
Red Meat not processed I $38.65 188 (27.4) 132(27.0, 1.00 (reference) 1.00 (reference' 
(g/day) 38.6WZ.14 195 (28.4) 130(26.6, 1.05 (0.77-1.44) 1.04 (0.76-1.42, 0.852 
62.14-95.72 139 (20.2) 114(23.4, 0.86 (0.61-1.19) 0.85 (0.61-1.18, 0.326 I 0.844 I 0.197 
~95.72 165 (24.0) 112(23.0, 1.03 (0.75-1.44) 1.00 (0.72-1.39, 0.999 
>38.65 499 (72.6) 356(73.0, 0.98 (0.76-1.28) 0.96 (0.74-1.25, 0.781 
Red Meat rare/med done I $ 3.86 161 (23.4) W(ZS.2, 1.00 (reference) 1.00 (reference, 
(g/day) 3.86-15.98 225 (32.8) 125 (25.7, 1.38 (1.00-1.90) 1.36 (0.99-1.88, 0.060 
15.98-32.41 129 (18.8) 130(26.6, 0.76-0.54-1.06) 0.75 (0.54-1.06, 0.101 I 0.866 I 0.049 
~32Al 172 (25.0) 110(22.5, 1.20 (0.85-1.67) 1.17 (0.83-1.63, 0.375 
>3.86 526 (76.6) 365 (74.8, 1.10 (0.84-1.44) 1.09 (0.83-1.42, 0.555 
... I Red Meat well/very well I $4.95 177 (25.8) 143 (29.3, 1.00 (reference) 1.00 (reference' w done (g/day) 203 (29.5) 119(24.4, 1.38 (1.01-1.89) 1.38 (1.GO-l.89, ~ 4.95-9.84 0.049 
9.84-19.82 138 (20.1) 118(24.2' 0.95 (0.68-1.31) 0.95 (0.68-1.32, 0.756 I 0.510 I 0.088 
~19.8Z 169 (24.6) 108(22.1' 1.26 (0.91-1.75) 1.26 (0.91-1.75' 0.170 
>4.95 510 (74.2) 345 (70.7, 1.19 (0.92-1.55) 1.19 (0.92-1.55' 0.183 
*Adjusted Odds Ratios (OR) are adjusted for age & fa mily history 
Table 41. Single effects of Environmental OSR Factors and peA aggressiveness among MED, continued 
Kcal from diet (g/day) I ~3OOO 237 (34.5) 161 (33.0) 1.00 (reference) 1.00 (reference) 
<2000 336 (48.9) 230(47.1) 1.01 (0.78-1.31) 1.02 (0.78-1.32) 0.894 I 0.258 I 0.176 
>3000 114 (16.6) 97(19.9) 0.80 (0.59-1.11) 0.80 10.58-1.10' 0.169 
Fat from diet (g/day) I ~73.11 381 (55.5) 252(51.6) 
>73.11 306 (44.5) 236(48.4) I 0.86 (0.68-1.08) I 0.85 (0.68-1.08) 0.179 0.196 0.186 
Saturated Fat from diet I ~24.95 I 384 (55.9) 250(51.2) 1 1.00 (reference) I 1.00 (reference) (g/day) >24.95 303 (44.1) 238 (48.a) 0.83 (0.66-1.05) 0.83 (0.66-1.04) 0.110 0.114 0.140 
Body Mass Index (BMI) I Under/normal weicht 180 (26.2) U7(26.0) 1.00 (reference) 1.00 (reference) 
Overweilht 350 (51.0) 2n(55.a) 0.91 (0.69-1.20) 0.90 (0.68-1.19) 0.452 0.273 0.156 
Obese 157 (22.8) 89(18.2) 1.25 (0.88-1.76) 1.21 (0.85-1.71) 0.294 
..... I Physically Active (~30 min Yes 333 (48.5) 229 (46.9) 1.00 (reference) 1.00 (reference) 
w 
V1 /day) No 354 (51.5) 259(53.1) 0.94 (0.75-1.19) 0.93 (0.74-1.1a) 0.557 0.601 0.225 
Vitamin A (~g/day) UOO 620 (90.1) 444(91.0) 1.00 (reference) 1.00 (reference) 
<900 68 (9.9) 44(9.0) 1.11 (0.74-1.65) 1.08 (0.72-1.60) 0.723 0.61a 0.403 
Vitamin C (mg/day) ~9O 40(5.8) 22 (4.5) 1.00 (reference) 1.00 (reference) 
<90 648 (94.2) 466(95.5) 1.31 (0.77-2.23) 1.31 (0.n-2.24) 0.316 0.325 0.364 
Vitamin E (IU/day) ~22.4 93 (13.5) 59 (U.l) 1.00 (reference) 1.00 (reference) 
<22.4 595 (13.6) 429 (a7.9) 1.14 (0.80-1.61) 1.15 (O.al-l.63) 0.438 0.472 0.319 
Zinc (mg/day) t Hl 491 (71.5) 351(71.9) 1.00 (reference) 1.00 (reference) 
<11 196 (28.5) 137(28.1) 1.02 (0.79-1.32) 1.03 (0.79-1.33) I 0.840 I o.an 0.365 
Selenium (~g/day) I ~55 24 (3.5) 11 (2.3) 1.00 (reference) 1.00 (reference) 
<55 663 (96.5) 4n(97.7) 1.57 (0.76-3.24) 1.60 (0.n-3.29) ~ 0.206 I 0.222 0.359 
Alcohol Consumption I ~2 579 (84.3) I 390(79.9) 1 1.00 (reference) C (drinks /day) <2 108 (15.7) 98(20.1) 0.74 (0.55-1.00) I 0.7310.54-0.99' I 0.044 I 0.053 0.197 
*Adjusted Odds Ratios (OR) are adjusted for age & family history 
Table 41. Single effects of Environmental OSR Factors and peA aggressiveness among MED, continued 
MelQx (ng/day) I $13.10 190 (27.7) 148(30.3) 1.00 (reference) 1.00 (reference) 
13.10-23.93 178 (25.9) 133 (27.3) 1.04 (0.76-1.42) 1.03 (0.75-1.40) 0.875 
23.93-46.64 159 (23.1) 107(21.9) 1.16 (0.84-1.60) 1.14 (0.82-1.59) 0.423 I 0.153 I 0.193 
it 46.64 160 (23.3) 100(20.5) 1.25 (0.90-1.73) 1.23 (0.89-1.72) 0.215 
>13.10 497 (72.3) 340(69.7) 1.14 (0.88-1.47) 1.12 (0.87-1.45) 0.373 
PhlP (ng/day) ~ $36.74 178 (25.9) 119 (24.4) 1.00 (reference) 1.00 (reference) 
36.74-73.98 212 (30.9) 119(24.4) 1.19 (0.86-1.65) 1.16 (0.84-1.61) 0.366 
73.98-156.86 149 (21.7) 137 (28.0) 0.73 (0.52-1.01) 0.71 (0.51-0.99) 0.045 I 0.086 I 0.059 
it 156.86 148 (21.5) 113 (23.2) 0.88 (0.63-1.23) 0.84 (0.6G-l.19) 0.329 
>36.75 509 (74.1) 369(75.6) 0.92 (0.71-1.21) 0.90 (0.67-1.18) 0.435 
~ DiMelQx (ng/day) I $0.39 175 (25.5) 134(27.5) 1.00 (reference) 1.00 (reference) w en 0.39-1.22 215 (31.3) 153(31.3) 1.08 (0.79-1.46) 1.07 (0.79-1.46) 0.661 
1.22-2.58 150 (21.8) 99(20.3) 1.16 (0.83-1.63) 1.15 (0.82-1.62) 0.418 I 0.483 I 0.237 
it 2.58 147 (21.4) 102(20.9) 1.10 (0.79-1.55) 1.09 (0.77-1.52) 0.635 
>0.39 512 (74.5) 354(72.5) 1.11 (0.85-1.44) 1.10 (0.84-1.43) 0.488 
BaP (meg/day) I $1.705 172 (25.0) 132(27.1) 1.00 (reference) 1.00 (reference) 
1.705-9.14 203 (29.5) 130(26.6) 1.20 (0.87-1.64) 1.19 (0.87-1.63) 0.289 
9.14-44.585 170 (24.8) 120(24.6) 1.09 (0.79-1.51) 1.06 (0.76-1.47) 0.739 I 0.992 I 0.260 
it 44.585 142 (20.7) 106(21.7) 1.03 (0.73-1.44) 1.01 (0.72-1.42) 0.941 
>1.705 515 (75.0) 356(72.9) 1.11 (0.85-1.45) 1.09 (0.84-1.42) 0.517 
Tobacco Use I Never 296 (43.1) 186(38.1) 1.00 (reference) 1.00 (reference) 
Former 335 (48.8) 265 (54.3) 0.79 (0.62-1.01) 0.80 (0.63-1.03) 0.079 
Current 56 (8.1) 37(7.6) 0.95 (0.60-1.50) 0.92 (0.59-1.46) 0.732 I 0.228 I 0.160 
Evert 391 (56.9) 302 (61.9) 0.81 (0.64-1.03) 0.82-0.65-1.04) 0.098 
·Adjusted Odds Ratios (OR) are adjusted for age & family history 
MDR identified the three factor model with consumption of Processed_meat-
Rare_red_meat- BaP as a modestly significant predictor of PCA aggressiveness (CVC = 
10/10; p = 0.053) [See Table 42]. Visualization by hlG revealed additional synergistic 
effects due to the meat-related variables [See Figure 18]. The strongest combined 
effects were seen for Red_meacnoCprocessed-BaP (IG = 0.77%); 
White_meat (IG = 0.54%); and White_meat-BaP (IG = 0.51%). LR confirmed the 
Red_meat_not_processed-Processed_meat interaction was linked with increased 
disease aggressiveness [OR (95%CI) = 1.45 (1.08-2.04); P = 0.016) [See Table 43]. 
Table 42. Unfiltered MDR models for environmental OSR factors and disease 
aggressiveness among men of European descent (adjusted for age and family history) 
Best Model Number of Cross Validation Average Permutation 
Combinations Consistency Testing Testing p 
(CVe) Accuracy (ATA) value 
One Factor I 27 I Red Meat Rare 9/10 0.5344 ~ 0.093 
Two Factor I Processed_Meat 729 3/10 0.4961 0.536 
Red Meat Rare 
Three Factor 
I I i 
Processed_Meat 19683 10/10 0.5459 0.053 Red_Meat_Rare 
BAP 
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Figure 1. Interaction entropy model for unfiltered environmental OSR factors and 
disease aggressiveness in men of European descent 
The strongest synergistic interaction was attributed to the interaction between BaP_meat-Non-processed red meat 
(IG = 0.77%). Note that additionallG attributed to this combination compared to the single effects of or BaP (IG = 
0.10%) or Non-processed red meat (IG = 0.12%). 
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Table 43. Association between environment-environment OSR interactions & peA 
aggressiveness among MED 
~44.585 1 0.74 (0.51-1.06) 0.76 (0.53-1.09) 0.133 
2 1.31 (0.98-1.76) 1.30 (0.97-1.75) 0.078 0.456 
~3 0.90 0.S9 (0.63-1.25) 0.506 
Red_meaCnot ~ 95.72 0 1.00 (reference) 1.00 (reference) processed (g/day) 
Processed_Meat ~20.96 1 1.03 (0.71-1.50) 1.05 (0.72-1.53) 0.802 (g/day) 
2 1.48 (1.07-2.03) 1.45 (1.0S-2.04) 0.016 0.002 
~3 0.94 (0.67-1.32) 0.94 (0.67-1.32) 0.740 
Red_meat_not ~ 95.72 0 1.00 (reference) 1.00 (reference) processed (g/day) 
White_meat ~71.83 1 0.83 (0.5S-1.18) 0.S4 (0.59-1.20) 0.342 (g/day) 
2 1.26 (0.93-1.72) 1.25 (0.92-1.70) 0.161 0.657 
~3 0.75 (0.54-1.04) 0.75 (0.54-1.05) 0.093 
White_meat ~71.83 0 1.00 (reference) 1.00 (reference) (g/day) 
BaP (mcg/day) ~44.585 1 1.11 (0.77-1.60) 1.14 (0.79-1.64) 0.497 
2 1.12 (0.84-1.51) 1.12 (0.S3-1.50) 0.469 0.459 
~3 0.95 (0.69-1.31) 0.94 (0.6S-1.30) 0.704 
*Adjusted OR are adjusted for age & family history 
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Similar to our MDR modeling of OSR risk effects, we filtered the OSR panel using 
SURF & TuRF in order to evaluate genetic and environmental OSR factor in relation to 
disease aggressiveness. MDR analysis of the top 25th percentile of OSR factors revealed 
the three factor model AKT3Js12031994-NAT2_rs7832071-PRKC~rs571715 as the 
best predictor of disease aggressiveness among all genetic and environmental OSR 
factors {CVC = 7/10; P = 0.006} [See Table 44]. hlG detected synergistic effects from 
PRKC~rs571715-AKT3Js12031994 and PRKC~rs585881-AKT3_rs12031994 
interactions [See Figure 19]. LR confirmed the PRKC~rs585881-AKT3Js12031994 
combination was associated with increased PCA aggressiveness [OR {95%CI} = 1.86 
{1.44-2.64}; P = <0.001]. LR models for the PRKC~rs571715-AKT3Js12031994 
interaction were not associated with disease aggressiveness {p = ;:: 0.102}, but the 
interaction p value was significant {interaction p value = 0.001} [See Table 45]. 
Table 44. Top 25th percentile MDR models OSR panel and peA aggressiveness among 
MED (adjusted for age and family history) 
Best Model Number of Cross Validation Average Testing Permutation 
Combinations Consistency (CVe) Accuracy (ATA) Testing p value 
One Factor 61 I 7/10 I 0.529 I 0.118 NAT2 rs7832071 
Two Factor 
AKT3Js12031994 3721 5/10 0.539 0.069 
PRKCQ..rs571715 
Three Factor 
AKT3Js12031994 226981 10/10 0.587 0.001 NAT2Js7832071 
PRKCQ..rs571715 
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Figure 2. Interaction entropy model for top 25th percentile genetic environmental OSR 
factors in relation to peA aggressiveness among men of European descent 
This graphical model describes the percent entropy that is explained by each OSR factor or a combination of two 
factors. The strongest synergistic effect of exists in the interaction between PRKCQ.Js571715-AKT3Js12031994 (IG = 
0.64%). However, this interaction is mainly driven by AKT3 (IG = 0.74%) due to lack of additionallG obtained by 
considering PRKCQJs571715 (IG = 0.14%). 
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Table 45. Association between OSR interactions & peA aggressiveness among MED 
PRKCQ...rs585881 1 < 0.001 
2 1.36 (0.92-2.00) 0.127 0.001 
~3 0.99 (0.47-2.08) 0.98 (0.46-2.07) 0.957 
AKT3-,s12031994 cc 0 1.00 (reference) 1.00 (reference) 
PRKCQ...rs571715 CC 1 1.84 (1.43-2_38) 1.86 (1.40-2.40) 0_102 
2 1.37 (0.93-2.03) 1.39 (0.94-2.06) 0.915 0.001 
~3 1.04 (0.51-2.13) 1.04 (0.51-2.13) 0.484 
*Adjusted OR are adjusted for age & family history 
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SPECIFIC AIM 3 FINDINGS - MAD SUBJECTS 
We used LR along with MDR to assess the role of 25 OSR SNPs combined with a 
history of tobacco use in relation to PCA risk among 137 MAD case subjects (68 
aggressive, 69 non-aggressive). LR revealed that current or former smokers missing at 
least one copy of the GSTTl gene were associated with a 2.3-fold increase in disease risk 
[OR (95%CI) = 2.27 (1.20-4.30); P = 0.012; See Table 46]. In addition, 11 out of the 15 
apoptotic markers we examined were associated with a 2.1- to 3.3-fold increase in risk 
among subjects exposed to cigarette smoke (p :s; 0.020) [See Table 48]. LR models for 
GSTP1Js1695, CYP1A1Js4646903, and the three BER polymorphisms had extremely 
small p- values «0.0001) [Tables 46 & 47], suggesting that their accuracy needs to be 
validated in additional MAD populations. 
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Table 46. Association between variant Antioxidative genes - Tobacco Use Interaction and disease risk among men of MAD 
37(31.1) 
AG+GG 82(68.9) 86 (68.8) I 11.38 (6.10-21.23) I 11.85 (6.36-22.07) I <0.0001 0.278 0.114 
GSTMl I *1/*1 37(31.1) 43 (32.6) l 1.00 (reference) I 4.42 (1.80-10.88) I 0.001 *1/*0 + *1/*0 82(68.9) 89 (67.4) 2.39 (1.23-4.62) 1.89 (1.00-3.58) 0.051 0.265 0.162 
GS11l I *1/*1 I 30 (24.4) I 38 (29.2) I 1.00 (reference) I 2.69 (1.05-6.90) I 0.039 *1/*0 + *1/*0 93 (75.6) 92 (70.8) 2.OS (1.08-3.88) 2.27 (1.20-4.30) 0.012 0.571 0.068 
rs2069514 I CYPlAZ I GG 67(50.8) 91 (62.3) I 1.00 (reference) I 12.93 (6.69-24.99) I <0.0001 
GA+AA 65 (49.2) 55 (37.7) 13.73 (6.65-28.34) 9.55 (4.48-20.39) <0.0001 0.014 0.113 
rs4646903 I CYPlAl I AA 60(44.8) I 52 (35.9) 1 1.00 (reference) I 10.19 (4.76-21.84) I <0.0001 AC+CC 74(55.2) 93 (64.1) 11.45 (5.82-22.51) 11.94 (6.19-23.02) <0.0001 0.810 0.062 
..... *Adjusted Odds Ratios are adjusted for age &WAA 
~ 
~ 
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Table 47. Association between variant Base Excision Repair genes - Tobacco Use Interaction and disease risk among MAD 
rsl130409 I APEXl I TT 59(45.4) I 67 (46.9) 1.00 (reference) I 17.06 (8.09-35.98) I <0.0001 TG+GG 71 (54.6) 76 (53.1) 9.40 (4.78-18.50) 7.43 (3.75-14.72) <0.0001 0.261 o.on 
rs1052133 I OGGl I CC 102 (n.3) I 96 (63.6) 1.00 (reference) I 9.30 (5.12-16.90) I <0.0001 CG+GG 30 (22.7) 55 (36.4) 10.72 (3.92-29.34) 10.00 (4.35-22.99) <0.0001 0.846 0.133 
rs25487 I XRecl I GG 93(72.1) I 97 (64.2) 1.00 (reference) I 11.18 (5.86-21.33) I <0.0001 GA+AA 36 (27.9) 54135.81 6.22 '2.45-15.83) 7.1613.44-14.901 <0.0001 0.654 0.175 
*Adjusted Odds Ratios are adjusted for age &WAA 
Table 48. Association between variant Apoptotic genes - Tobacco Use Interaction and disease risk among MAD 
rs4645878 I SAX I cc I 62 (SO.8) I 67 (49.6) 1.00 (reference) I 1.54 (0.77-3.07) I 0.224 CT+IT 60(49.2) 68 (50.4) 2.90 (1.39-6.02) 4.23 (2.02-8.87) 0.0001 0.966 0.075 
rs3789068 I SCUL1! I IT I 56(46.3) 1 50 (37.9) 1.00 (reference) 3.85 (1.67-8.88) 0.002 TC+CC 65 (53.7) 82 (62.1) 2.55 (1.28-5.08) 2.06 (1.08-3.92) 0.029 0.111 0.003 
rs4488761 I BCLZL13 I AA 47 (37.9) 45 (33.6) 1.00 (reference) 2.26 (0.99-5.15) I 0.052 AG+GG 77(62.1) 89 (66.4) 2.20 (1.14-4.23) 2.40 (1.28-4.52) 0.007 0.857 0.118 
rs6488494 I BCUL14 I IT 29(23.6) 36 (26.7) 1.00 (reference) 1.84 (0.81-4.19) I 0.148 TC+CC 94(76.4) 99 (73.3) 2.47 (1.31-4.67) 3.47 (1.78-6.78) 0.0003 0.416 0.150 
rs1883263 I BIK I AA 99 (BO.5) 113 (84.3) 1.00 (reference) 2.41 (1.37-4.27) 0.002 
AC+CC 24(19.5) 21 (15.7) 2.58 (0.92-7.26) 0.92 (0.30-2.80) 0.881 0.147 0.150 
I-' rs738276 BlK GG 49(48.0) 45 (38.8) 1.00 (reference) 2.58 (1.14-5.83) I 0.023 .j::>. en GA+AA 53(52.0) 71 (61.2) 2.83 (1.31-6.12) 2.08 (1.03-4.22) 0.042 0.428 0.165 
rs6509364 CARDB CC 69 (57.0) 80 (61.5) 1.00 (reference) 2.06 (1.10-3.88) 0.025 
CT+IT 52(43.0) 50 (38.5) 1.76 (0.12-3.80) 1.96 (0.89-4.34) 0.097 0.626 0.113 
rs6509366 I CAROB I GG 69 (56.6) 85 (63.9) 1.00 (reference) I 2.36 (1.23-4.53) 0.010 GA+AA 53 (43.4) 48 (36.1) 2.49 (1.16-5.35) 2.09 (0.97-4.52) 0.060 0.738 0.131 
rs1049216 I CASP3 I IT 76(66.1) I 93 (74.4) 1.00 (reference) 1.87 (1.00-3.49) I 0.050 TC+CC 39 (33.9) 32 (25.6) 1.27 (0.57-2.83) 3.38 (1.24-9.19) 0.017 0.150 0.176 
rs507879 I CASPS I AA 15 (12.3) I 27 (20.2) I 1.00 (reference) I 3.62 (1.22-10.74) I 0.023 AG+GG 107 (87.7) 107 (79.8) 2.BO (1.50-5.22) 2.81 (1.50-5.25) 0.001 0.126 0.063 
rs537093 I CASP5 I GG 68(54.8) 59 (44.0) ! 1.00 (reference) 2.26 (1.10-4.64) 0.026 GA+AA 56(45.2) 75 (56.0) 1.88 (0.9G-3.93) 2.05 (1.04-4.02) 0.038 0.584 0.094 
rs6747918 I CASPB I AA 25 (30.1) 28 (30.1) 1.00 (reference) 6.03 (1.79-20.38) I 0.004 AG+GG 58(69.9) 65 (69.9) 2.07 (0.93-4.59) 1.96 (0.91-4.23) 0.088 0.500 0.178 
rs1052576 I CASPS I GG 42 (34.1) 68 (51.9) 1.00 (reference) 2.15 (1.09-4.26) ~ 0.028 GA+AA 81 (65.9) 63 (48.1) 2.81 (1.44-5.48) 2.57 (1.22-5.39) 0.013 0.599 0.114 
* Adjusted Odds Ratios (DRs) are adjusted for age, family history, & WAA 
..... 
~ 
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Table 48. Association between variant Apoptotic genes - Tobacco Use Interaction and disease risk among MAD, continued 
rs12817549 I ~ I TT 67 (54.5) 75 (56.0) 1.00 (reference) 2.50 (1.30-4.80) 0.006 
TC+CC 56 (45.5) 59 (44.0) 2.74 (1.23-6.12) 1.90 (0.89-4.05) 0.099 0.744 0.051 
rs3858606 I CRADD I GG 27 (22.3) 40 (30.3) 1.00 (reference) 1.90 (0.76-4.74) 0.170 
GA+AA 94 (77.7) 92 (69.7) 2.86 '1.51-5.42) 3.24 (1.71-6.15) 0.0003 0.845 0.188 
*Adjusted Odds Ratios (ORs) are adjusted for age, family history, & WAA 
MDR revealed the two factor model containing BCL2L11_rs3789068-Tobacco Use 
as the best predictor of risk (eVe = 10/10; P = 0.025) [See Table 49}. MDR findings may 
be limited by the small sample size (n = 216) since this method is recommended for 
populations which have at least 200 cases and 200 controls. However, BCL2L11-
Tobacco_Use was also significantly linked with a 2.1-fold increase in peA risk by LR 
analysis [See Table 48}. Furthermore, hlG showed a synergistic effect attributed to the 
BCL2L11-Tobacco_Use interaction as well (IG = 2.99%) [See Figure 20}. 
Table 49. Unfiltered MDR models for OSR polymorph isms and Tobacco Use in relation 
to peA risk among MAD 
Best Model Number of Cross Validation Average Testing Permutation 
Combinations Consistency (CVe) Accuracy (ATA) Testing p value 
One Factor I 26 I I I BAX ,s464S878 6/10 0.5169 0.352 
Two Factor I Tobacco_Use 676 10/10 0.6071 0.020 BCL2Lll '53789068 
Three Factor 
Tobacco_Use 17576 9/10 0.6581 0.001 CASPSJsS07879 
BCL2Ll4 '56488494 
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Figure 1. Interaction graph for OSR polymorph isms and Tobacco Use in relation to 
peA risk among MAD 
KULt .. ,. ......... 
This graphical model describes the percent entropy that is explained by each OSR factor or a combination of two 
factors. The combined effect of Tobacco_Use-BCL2L11Js3789068 provides an (IG = 2.99%)' in comparison to 
considering either Tobacco_Use or BCL2L11_fs3789068 loci individually (IG = 0.27% and 1.56%, respectively) . 
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When we examined the combined effects of OSR sequence variants and tobacco 
use in relation to disease aggressiveness among MAD, we found significant single effects 
linked to both GST gene deletions [See Table 50]. Former/current smokers lacking one 
or more copies of GSTMl were associated with a 3.1-fold increase in PCA aggressiveness 
[OR (95%CI) = 3.10 (1.12-8.57); P = 0.030]. Also, missing at least one copy of GSTTl 
among former/current smokers resulted in increased association with disease 
aggressiveness [OR (95%CI) = 3.39 (1.27-9.06); P = 0.015]. In addition, we observed a 
3.1- to 6.0-fold increase in disease aggressiveness associated with six apoptotic SNPs 
(BCL2L11Js3789068, BIK_ fs738276, CARD8_fs6509366, CASP3_fsl049213, 
CRADD_fs12817549, and CRADD_fs3858606) when combined with a history of tobacco 
use [See Table 50]. 
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Table 50. Association between variant Antioxidation genes - Tobacco Use Interaction and Tumor Grade among men of MAD 
rs1695 I GSTP2 I AA 37(31.1) I 39 (31.2) I 1.00 (reference) I 2.43 (0.80-7.39) I 0.119 AG+GG 82(68.9) 86 (68.8) 1.33 (0.49-3.66) 1.82 (0.68-4.85) 0.232 0.362 0.048 
651M2 I *1/*1 37 (31.1) 43 (32.6) 1.00 (reference) 2.13 (0.70-6.46) I 0.11Z *1/*0 + *1/*0 IZ (68.9) 89 (67.4) 1.51 (0.54-4.27) 3.10 (1.12-8.57) 0.030 0.844 0.048 
GSm I *1/*1 30(24.4) 38 (29.2) 1.00 (reference) 3.68 (1.00-13.54) I O.OSO *1/*0 + *1/*0 93(75.6) 92 (70.8) 2.17 (0.77-6.12) 3.39 (1.27-9.06) 0.015 0.151 0.042 
rs2069514 I CYPlAZ I GG I 67 (SO.8) I 91 (62.3) I 1.00 (reference) 2.19 (0.84-5.75) I 0.111 GA+AA 65 (49.2) 55 (37.7) 0.97 (0.34-2.77) 1.67 (0.56-4.98) 0.354 0.925 0.027 
rs4646903 I CYPlA2 I AA 60(44.8) 52 (35.9) 1.00 (reference) I 3.61 (1.18-11.08) I 0.025 AC+CC 74(55.2) 93 (64.1) 0.98 (0.34-2.78) 1.23 (0.48-3.17) 0.669 0.231 0.052 
I-' *Low Gleason score: >7; High Gleason score: 5.7; **Adjusted Odds Ratios are adjusted for age, family history, & WAA 
\J1 
I-' 
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Table 51. Association between variant Base Excision Repair genes - Tobacco Use Interaction and Tumor Grade among MAD 
rs1130409 I APEXl I 
TG::'G I 59(45.4) I 67 (46.9) 1.00 (reference) I 0.94 (0.34-2.58) I 0.906 71(54.6) 76 (53.2) 0.66 (0.23-1.89) 1.92 (0.65-5.63) 0.238 0.171 0.018 
rs1052133 I OGGl I CC I 102 (77.3) 96 (63.6) 1.00 (reference) I 1.66 (0.69-4.02) I 0.258 CG+GG 30 (22.7) 55 (36.4) 0.73 (0.19-2.79) 2.02 (0.71-5.77) 0.117 0.516 0.046 
rs25487 I XRCC I GG I 93(72.1) 97 (64.2) 1.00 (reference) I 1.26 (0.55-2.88) I 0.587 GA+AA 36 (27.9) 54 (35.8) 0.16 (0.02-1.44) 3.11 (0.88-11.01) 0.078 0.029 0.052 
*Low Gleason score: >7; High Gleason score: 5.7; **Adjusted Odds Ratios are adjusted for age, family history, & WAA 
Table 52. Association between variant Apoptotic genes - Tobacco Use Interaction and Tumor Grade among men of MAD 
rs4645878 SAX CC 62(50.8) 67 (49.6) 1.00 (reference) 3.83 (1.07-13.74) 0.040 
CT+TT 60(49.2) 68 (50.4) 0.50 (0.15-1.60) 1.22 (0.48-3.14) 0.676 0.806 0.048 
rs3789068 I BCLlL11 I TT 56(46.3) 50 (37.9) 1.00 (reference) 1.34 (0.42-4.32) 0.621 
TC+CC 65 (53.7) 82 (62.1) 0.99 (0.33-2.95) 3.68 (1.29-10.46) 0.015 0.282 0.048 
rs4488761 I BCL2L13 I AA 47 (37.9) 45 (33.6) 1.00 (reference) 3.91 (1.11-13.69) 0.033 
AG+GG 77 (62.1) 89 (66.4) 1.40 (0.50-3.94) 2.15 (0.81-5.74) 0.127 0.171 0.033 
rs6488494 I BCUL14 I TT 29(23.6) 36 (26.7) 1.00 (reference) 2.60 (0.65-10.36) 0.177 
TC+CC 94(76.4) 99 (73.3) 0.71 (0.25-2.04) 1.74 (0.67-4.50) 0.257 0.800 0.048 
rs1883263 BlK AA 99(80.5) 113 (64.3) 1.00 (reference) 2.08 (0.91-4.78) 0.084 
AC+CC 24(19.5) 21 (15.7) 0.48 (0.09-2.66) 1.75 (0.35-8.69) 0.496 0.570 0.048 
I-' rs738276 I BIK I GG I 49(48.0) I 45 (38.8) 1.00 (reference) I 1.88 (0.61-5.80) 0.274 VI OJ GA+AA 53(52.0) 71 (61.2) 1.02 (0.33-3.14) 3.32 (1.10-10.04) 0.034 0.593 0.034 
rs6509364 I CAROB j cc I 69(57.0) I 80 (61.5) 1.00 (reference) 3.33 (1.25-8.87) 0.016 CT+TT 52(43.0) 50 (38,5) 0.78 (0.20-3.03) 1.35 (0.44-4.12) 0.597 0.565 0.026 
rs6509366 I CARDS I GG I 69(56.6) 85 (63.9) 1.00 (reference) 2.13 (0.82-5.54) 0.122 GA+AA 53(43.4) 48 (36.1) 1.80 (0.59-5.50) 5.49 (1.47-20.42) 0.011 0.688 0.032 
rs1049216 I CASP3 I TT I 76(66.1) 93 (74.4) 1.00 (reference) 1.38 (0.57-3.34) I 0.475 TC+CC 39(33.9) 32 (25.6) 0.41 (0.10-1.73) 6.01 (1.16-30.99) 0.032 0.030 0.027 
rs507879 CASP5 AA 15(12.3) 27 (20.2) 1.00 (reference) 2.14 (0,46-9.91) 0.331 
AG+GG 107 (87.7) 107 (79.8) 1.39 (0.49-3.95) 2.73 (0.99-7.52) 0.052 0.946 0.039 
rs537093 CASP5 GG 68(54.8) 59 (44.0) 1.00 (reference) 2.82 (0.94-8.46) 0.064 
GA+AA 56(45.2) 75 (56.0) 0.88 (0.27-2.87) 1.81 (0.69-4.73) 0.225 0.771 0.048 
rs6747918 CASPB AA 25(30.1) 28 (30.1) 1.00 (reference) 8.73 (1.75-43.56) 0.008 
AG+GG 58(69.9) 65 (69.9) 1.52 (0.38-6.14) 3.34 (0.92-12.12) 0.067 0.120 0.050 
rs1052576 CASP9 GG 42(34.2) 68 (51.9) 1.00 (reference) 2.85 (0.96-8.47) 0.060 
GA+AA 81(65.9) 63 (48.1) 0.89 (0.33-2.44) 1.90 (0.63-5.71) 0.253 0.942 0.040 
*Low Gleason score: >7; High Gleason score : 5.7; **Adjusted Odds Ratios (ORs) are adjusted for age, family history, & WAA 
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Table 52. Association between variant Apoptotic genes - Tobacco Use Interaction and Tumor Grade among men of MAD, 
continued 
rs12817549 I CRADD I TT 67 (54.5) 75 (56.0) 1.00 (reference) 2.37 (0.92-6.13) I 0.074 TC+CC 56(45.5) 59 (44.0) 2.38 (0.71-7.93) 4.06 (1.28-12.84) 0.017 0.622 0.017 
rs3858606 I CRADD I . GG 27 (22.3) 40 (30.3) 1.00 (reference) 2.35 (0.58-9.59) I 0.232 GA+AA 94(77.7) 92 (69.7) 1.SS (0.56-4.49) 3.10 (1.10-8.71) 0.032 0.953 0.013 
*Low Gleason score : >7; High Gleason score: $7; **Adjusted Odds Ratios (ORs) are adjusted for age, family history, & WAA 
MDR modeling identified Tobacco Use alone as the best predictor of disease 
aggressiveness (CVC = 10/10, P = 0.034) [See Table 53] . This finding was confirmed by 
hlG which revealed Tobacco Use as the strongest independent effect (IG = 7.16%) [See 
Figure 21]. Synergistic interactions between CASP9_rs1052576-BCL2L14_rs6488494 and 
BAX_rs4645878-GSTT1_deletion were also observed in the entropy graph. However, 
neither combination was statistically significant in LR two-way analysis (p ~ 0.961) [Table 
53]. 
Table 53. Unfiltered MDR models for OSR polymorphisms and Tobacco Use in relation 
to peA aggressiveness among MAD 
Best Model Number of Cross Validation Average Testing Permutation 
Combinations Consistency (CVe) Accuracy (ATA) Testing p value 
One Factor 26 I 1 1 Tobacco Use 10/10 0.637 0.034 
Two Factor 
CASP9Jsl052576 I 676 7/10 0.629 0.056 BCL2Ll4Js6488494 
Three Factor 
BCL2L13_,s4488761 17576 5/10 0.639 0.058 GSTP1Js1695 
CYP1Al '54646903 
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Figure 21. Interaction graph for OSR polymorph isms and Tobacco Use in relation to 
PCA aggressiveness among MAD 
GSTT1_deletion ____ -
1
.
03
% _____ _ 
BCL2L 13Js44lI8761 
2.23'10 
This graphical model describes the percent entropy that is explained by each OSR factor or a combination of two 
factors. The combined effect of BCL2L14Js6488464-CASP9Jsl052576 provides an (IG = 9.38%), in comparison to 
considering either BCL2L14_rs6488464 or CASP9_,s1052576 loci individually (IG = 0.73% and 1.97%, respectively). 
Table 54. Association between apoptotic gene-gene interactions & PCA 
aggressiveness among MAD 
Genes Minor # Minor OR (95% (I) Adj OR (95% (1) * P value * interaction 
Alleles Alleles p value 
BCL2L14Js6488494 CC 0-2 1.00 (reference) 1.00 (reference) 
CASP9Jsl052576 AA 2-3 0.77 (0.34-1.73) 0.73 (0.32-1.65) 0.440 0.961 
4 0.44 (0.04-4.99) 0.43 (0.04-5.15) 0.502 
BA)Crs46465878 TT 0-2 1.00 (reference) 1.00 (reference) 
GSTT1_deletion I ·0/*0 >2 1.65 (0.77-3.56) 1.60 (0.74-3.46) 0.236 0.985 
·Adjusted OR are adjusted for age & WAA 
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SUMMARY AND CONCLUSIONS 
Specific Aim 1 Summary. We evaluated a panel of 242 oxidative stress response (OSR)-
related polymorphisms to determine their single- and joint-modifying effects on PCA 
risk. LR analysis revealed seven genetic variants capable of individually modifying risk 
among MED. We found one antioxidative (CYP2C8_rs7909236) and one BER 
(OGG1_rs125701) SNP independently associated with a 1.2-fold increase in PCA risk. In 
addition, the EPHX1_rs1051741 polymorphism was linked with 2.5-fold increase in 
disease risk. We also observed an 18-25% decrease in PCA risk associated with one 
antioxidative-related (NATl_rs4921581), one BER (POL'-rs8305), and four apoptotic 
(BIK_rs4988366, BNIP3L_rs10503786, IKBKE_rs1539243, TNFRSF1A_rs4149576) 
polymorph isms. 
MDR indentified CYP2C8_rs7909236-NATl_rs4921581 as the best two factor 
model in predicting disease risk. LR two-way analysis indicated this combination was 
linked with 1.3-fold increase in PCA risk [OR (95%CI) = 1.28 (1.04-1.57); P = 0.019]. hlG 
did reveal any synergistic effects due to NA Tl-CYP2C8, but several additional 
interactions were seen that remained significant in LR analysis. In particular, men with 3 
or more minor TNFRSF1A_rs4149576-PRKCE_rs935673 alleles were associated with a 
42% decrease in PCA risk [OR (95%CI) = 0.58 (0.42-0.81); p = 0.001]. Also, possessing at 
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least 2 variant CYP2C8_fs7909236-GSTP1_fs1695 or NA Tl_fs4921581-GSTM2_fs638820 
alleles resulted in a l.4-fold increase in peA susceptibility. 
Among the MAD subjects, we detected two apoptotic polymorph isms associated 
with increased peA risk (BAX_fs4645878 & BCL2L11_fs3789068). However, there were 
no significant single effects were observed for antioxidative or BER targets. MDR did not 
confirm the BAX SNP, but MDR and hlG revealed five interactions containing apoptotic 
targets and both GST gene deletions. Only one of these interactions remained 
significant in LR (BCL2L14_fs6488494_CASP5_fs507879). 
Specific Aim 1 Conclusions. Among both populations we observed single risk effects in 
antioxidative, BER, and apoptotic gene variants. For MED, these SNPs were either a 
decrease or increase in risk, however, in MAD subjects significant effects were limited 
to apoptotic markers associated with increased risk. These SNP associations in relation 
to peA susceptibility may be attributable to altered gene/protein function caused by the 
variation [See Table 53]. For instance, CYP2C8_fS7909236 was associated with 
increased risk. This particular SNP is located in the promoter region of CYP2C8 and 
predicted to interfere with transcription factor binding sites (TFBS), resulting in 
increased transcription. 129 As a cyp4S0 enzyme, 2e8 can that can detoxify or bioactivate 
a wide range of xenobiotics via oxidation or reduction.52 However, one of cyp2c8's 
substrates is the suspected carcinogen B[a]P which is able to form DNA adducts during is 
metabolism.14o Therefore, increased CYP2C8 transcription leading to higher gene 
expression or protein activity could ultimately result in elevated BaP bioactivation. 
158 
f-' 
U'1 
~ 
Table SS. Possible function consequences of genetic variants associated with peA outcomes based on previous publication or SNP 
prediction database tools 
GSTMl 
GSTM2 
GSTPl 
GSTTl 
IKBKE 
NAn 
·Predicted or observed effects of genetic variants are based on previous publications and SNP prediction database too 
~ 
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Table 55. Possible function consequences of genetic variants associated with peA outcomes based on previous publication or SNP 
prediction database tools, continued 
·Predicted or observed effects of genetic variants are based on previous publications and SNP prediction database 
Similarly, natl enzyme activity can either detoxify or bioactivate many 
xenobiotics and these effects are largely substrate dependent. Unfortunately, no 
published data or functional predictions are available regarding the intronic rs4921581 
SNP. Therefore, we can only speculate the protective association we observed is due to 
decreased bioactivation or increased detoxification. Interestingly, when 
NA TlJs4921581 was combined CYP2C8Js7909236 or GSTM2Js638820, the 
interaction was associated an increase in PCA risk. Unlike CYP2C8, the GSTM2 variant 
was not individually linked to risk, however both are promoter region SNPs so altered 
TF binding may be the reason their effects. Taken together, these findings warrant 
further investigation of the functional consequences caused by CYP2C8, NA Tl, and 
GSTM2 polymorphisms. 
Decreased protein function may explain the risk effects observed in two BER 
SNPs: OGG1Js125701 and POUJs8305. Oggl is a DNA glycosylase involved in the 
repair of the 8-oxoguanine. Therefore, the rs125701 may compromise oggl's capacity 
to remove these mutagenic adducts and subsequently increase PCA susceptibility. Poli 
is polymerase that proceeds during DNA synthesis when normal polymerases may fail. 
Since this protein is error prone, particularly opposite a thymidine template, a SNP 
linked to decrease poli activity may decrease risk by reducing the protein's ability to 
insert in correct bases. 
The decreased PCA risk observed in the four apoptotic SNPs may be attributed to 
a reduction in their ability to promote cell survival. For example, BIK is a pro-apoptotic 
gene, but is believed to be a target for anti-apoptotic proteins. Consequently, the 
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rs4988366 variant is located in the promoter region of and may result in disruption of 
transcription or apoptotic suppressors interacting with BIK, and would therefore be 
associated with decreased PCA risk. BNIP3L is pro-survival, IKBKE inhibits the pro-
survival NFkB gene, and TNFRSF1A is a major cell death receptor in apoptosis. 
Therefore, the SNPs we found linked to risk may be due a reduced the ability of these 
markers to block apoptosis. 
BAX_fs4645878 was linked to increased PCA risk in MAD subjects and is also 
located in the promoter region of this gene. Since bax is induces apoptosis, 
transcription factor interference could reduce protein expression, and ultimately 
decrease apoptosis. Similarly, the increase risk associated with BCL2L11Js3789068, 
BCL2L14_rs6488494, and CASP5Js507879 among the subjects may result from a 
comprised ability for the targets to induce or signal apoptosis. 
Gene-gene interactions identified by MDR and hlG modeling validated as 
significant by LR only contained antioxidative or apoptotic markers. These findings 
suggest a possible jointly modifying effect among variant antioxidative and apoptotic 
genes may contribute to risk. However, BER polymorphisms appear to playa less 
important role in PCA risk, particularly among men of African descent. 
Specific Aim 2 Summary. In a case-only analysis, we examined the role of 173 apoptotic 
variants on disease aggressiveness in a population of 1,176 MED (688 aggressive and 
488 non-aggressive cases). We found the AKT3_rs12031994 alone and in the two-factor 
162 
MDR model with PRKC~,s571715 was significantly associated PCA aggressiveness. hlG 
and two-way LR analysis revealed the BCL2L14Js10845479-BAX_,s905238 and 
BCL2L14Js10845479-BCL2L11Js724710 interactions were significantly linked to 
increase aggressiveness in LR two-analysis. 
Evaluation of 15 apoptotic sequence variants among 137 MAD (68 aggressive 
and 69 non-aggressive cases) did not show any single effects. We observed several 
interactions using MDR and hlG modeling between CASP9Js1052576-
BCL2L14Js6488494, CASP9Js1052576-CASP5Js507879, and BCL2L13_,s4488761-
BCL2L14Js6488494. However, two-way LR analysis was not able validate any of these 
combinations as statistically significant (p ~ 0.114). 
Specific Aim 2 Conclusions. We detected several gene-gene interactions linked 
to PCA aggressiveness among both populations involving BCL2-related genes. Since 
BCL2L11, BCL2L13, BCL2L14, BAX, as well as CASP5/9 all function in cell death signaling 
and induction. Combined polymorphisms that reduce their ability to signal apoptosis 
would like promote cellular transformation or tumor formation (Le., more aggressive 
phenotypes). In fact, a previous study found the amino acid change of glutamine to 
arginine in CASP9Js1052576 has also been shown to have functional significance. 129, 141 
CASP9 activation is an important step that occurs early in apoptosis and our data 
suggest this polymorphism along with other apoptotic SNPs increase PCA risk possibly 
due to compromised cell death mechanisms. 141 
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Although we found AKT3 individually modified risk, we would anticipate that 
most single effects would not strongly contribute to risk since apoptotic regulation 
involves many complex interacting mechanisms. Akt3 and prkcq are important 
upstream signaling proteins in apoptotic regulation and the intronic SNPs we examined 
in these may interfere with splicing or miRNA binding; thereby possibly lead to 
deformed or non functional proteins due to skipped or inhibited exon sites. 99 
Specific Aim 3 Summary. We assessed the effects 27 environmental OSR factors 
along with our panel of 219 gene variants in relation to PCA development. We 
evaluated 27 variables related to dietary habits, vitamin/ supplement intake and 
exposure to meat- and cigarette-derived carcinogens using data collected from 2,277 
CGEMS project participants {1176 cases, 1101 controls}. LR analysis revealed that 
MelQx exposure and current smokers were independently associated with a decrease in 
disease risk. MDR and hlG also identified interactions involving meat consumption 
linked with PCA risk. LR modeling validated Processed_meat-White_meat was 
associated with a decrease in risk. 
We also found subjects that had more than 2 alcoholic drinks per day and PhlP 
exposure were associated with a decrease in disease aggressiveness. However, 
consumption of processed meat and well-done or very well-done red meat were 
independently linked to increased disease aggressiveness. Interaction analyses revealed 
the combinations effects of Red_meacnocprocessed-Processed_meat and 
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PRKC~rs585881-AKT3_'s12031994 were associated with increased disease 
aggressiveness. 
Among MAD subjects, LR revealed that current or former smokers missing at 
least one copy of the GSTTl gene were associated with a 2.3-fold increase in PCA risk. 
Also, 11 apoptotic polymorphisms were associated with a 2.1- to 3.3-fold increase in risk 
among subjects exposed to cigarette smoke (p ~ 0.020). However, we found several LR 
models had extremely small p values «0.0001), suggesting that the targets may need to 
be validated in larger MAD populations. 
When we examined the combined effects of aSR sequence variants and tobacco 
use in relation to disease aggressiveness among MAD, we found significant single effects 
linked to both GST gene deletions and six apoptotic SNPs. 
Specific Aim 3 Conclusions. We were surprised to find MelQx and PhlP exposure, 
smoking, alcohol use independently associated with a decreased PCA development 
among MED. MelQx and PhlP are both possible carcinogens capable of producing 
damaging DNA adduct during their metabolism. These compounds are derived from 
cooking meats at high temperature or for long durations, but we found consumption of 
well-done or very well-done red meat was linked to increased disease aggressiveness. 
This inconsistency may be caused by the PLCa project deriving these exposures from 
meat consumption data, so the measurements may not accurately reflect actual levels 
of these compounds. Therefore, further analysis of measured adducts or plasma 
metabolites would be needed to validate this finding. 
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Also the association between men who had more than 2 alcoholic drinks per day 
and decreased peA risk may require future analyses examining the type of alcohol and 
further stratification of the number of drinks per day. This finding may have been 
limited by only considering men consuming either more or less than 2 drinks based on 
the USDA recommendation that these beverages should be limited to no more than 
two. 
That fact that smoking was associated with a decreased risk in MED but 
increased risk and aggressiveness when combined with OSR variants among MAD 
subjects suggests that its possible protective effect in the former population likely 
involves a mechanism that was not examined in this study. For instance, smoking may 
activate additional detoxification targets that we either did not investigate or weren't 
due to genetic variation. Nevertheless, when we analyzed higher order interactions in 
the MED subjects, smoking was not involved with any significant models. 
In fact, the combined effects we observed were related to meat consumption. 
We found Processed_meat-White_meat associated with a decrease in risk, but 
consumption of Red_meat_nocprocessed-Processed_meat was linked to increased 
disease aggressiveness. This finding warrants further investigation into the biological 
mechanisms involved in the metabolism of these meats to examine how processed 
meat was associated with a decrease in risk with white meat but increased 
aggressiveness with non-processed red meat. 
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DISCUSSION 
Despite high incidence and mortality rates of PCA, especially among African-
American men in particular, its etiology is poorly characterized. Identifying and 
validating new genomic profiles in biological pathways to serve as effective predictors of 
PCA susceptibility and aggressiveness are critical to overcoming this Iimitation.3, 9 
Oxidative stress response (OSR) is one such biological pathway that appears to 
play an important role in prostate carcinogenesis.3, 7 Oxidative stress is a condition in 
which the amount of reactive oxygen species (ROS) produced exceeds the amount 
removed. 13-16 Cells are constantly exposed to reactive oxygen species (ROS) generated 
from multiple endogenous and exogenous sources.13-16 Although they are required for 
cellular functioning, ROS are highly reactive electrophiles that can interact with 
biomolecules, interfere with cell signaling, and promote cellular malignant 
transformation. 11,14-17 ROS can directly damage nucleic acids and proteins, as well as 
alter protein function or activation.9, 14-15, 17-18 These effects can be manifested as 
altered gene and protein expression, cell proliferation or apoptosis. 15 Left unrepaired, 
accumulating ROS damage can lead to cellular transformation and ultimately progress 
into to cancer. 12, 15, 18-19 
Genetic variation resulting in decreased function of OSR related mechanisms, 
such as antioxidation (e.g., carcinogen metabolism/ detoxification), DNA repair, and 
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apoptotic regulation may contribute to PCA progression?-3, 87 Previous studies have 
investigated the relationship between single variant OSR alleles and PCA, but many are 
either limited in scope, null, or conflicting. 2-3, 5, 87 Such inconsistencies may be attributed 
to inadequate statistical rigor or failure to consider gene-gene and gene-environment 
interactions. Consequently, this study evaluated the single- and joint- modifying effects 
of OSR factors on PCA using a combination of traditional and advanced statistical 
methods. This comprehensive analytical strategy utilized LR combined with MDR and 
hlG to examine the role of a unique OSR panel in relation to the PCA risk and disease 
aggressiveness. 
Our unique candidate panel included 242 genetic and 27 environmental OSR 
factors related to diet and lifestyle habits. The OSR panel was generated using factors 
involved in antioxidation (e.g., carcinogen detoxification and metabolism), repair of 
oxidative DNA damage, and apoptotic regulation. We identified targets based on 
published PCA epidemiology studies as well as functional/pathway databases and tools. 
The latter provided important molecular interactions and genes that may not be readily 
found by literature search or traditional candidate SNP search methods. In addition, 
prediction tools aid in selecting markers likely to have a functional consequence 
resulting in compromised OSR capacity that may modify PCA disease outcomes. From 
an initial list of 118 OSR genes, more than 1500 had genotype available in through the 
CGEMS project. We finalized this list by first confirming sequence variants were related 
to our pathway of interest using NCBI Entrez SNP/Gene databases. Then we focused on 
polymorphisms that were (1) detected within all exons, 2.5kb upstream of the gene, 
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2.Skb downstream of intron 1, 2.Skb downstream of the gene; (2) had a minor allele 
frequency >1%; and (3) the genotype frequency among controls passed the Hardy-
Weinberg Equilibrium test (HWE p > 0.005). 
We evaluated our OSR panel using genetic profiles from 2277 men of European 
descent (MED) [488 non-aggressive and 688 aggressive cases, 1101 controls] and 923 
men of African descent (MAD) [224 peA cases and 699 controls]. Tumor grade 
(measured by Gleason Score) was available for 137 (68 aggressive, 69 non-aggressive) to 
examine disease aggressiveness in the population. Statistical analyses were conducted 
adjusting for age and family history of peA, as well as population admixture (WAA) for 
MAD subjects. Our single risk findings associated several OSR sequence variants to peA 
risk among MED. In contrast, only antioxidative- and apoptotic-related SNPs were 
linked to increased disease risk in MAD. Higher order interaction analyses for across 
both populations detected gene-gene combinations associated with increased risk. 
Several of the targets we found that modify risk are intronic or have unknown 
functional consequence. However, based on data available from previous publications 
and prediction tools, as well as considering gene function, we presume that these 
variants result in compromised OSR. More specifically, our findings suggest that 
reduced detoxification and apoptotic induction are linked to increased peA 
susceptibility. 
When we investigated the role of apoptotic polymorph isms in relation to disease 
progression, BCL2-related and CASPs markers were jointly associated with increased 
peA aggressiveness. This effect was found across both populations. These genes are 
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critical to apoptotic regulation and can activate downstream targets that commit cells to 
undergo this process.97, 107 Failure to undergo apoptosis may enable survival of 
transformed cells that are prone to undergo further genetic alteration and show 
genomic instability, leading to more invasive phenotypes. 100 
Unfortunately we were not able to characterize the role of environmental 
factors in PCA among our study populations. The MAD analysis findings suggest 
smoking and apoptotic targets jointly increased risk. However, the apoptotic variants 
independently increased disease risk and aggressiveness so they may be driving this 
association. Also, these findings are limited by the small MAD sample size so these 
effects require validation in larger study populations. We were able to evaluate 27 
environmental factors within the larger MED population. Our results indicate that meat 
consumption and cooking methods may contribute to PCA development. However, 
these factors most likely involve additional targets or mechanisms that were not 
examined in this study. To address this issue, future studies would need to focus on 
improved exposure analyses as well as biological mechanisms involved in meat 
metabolism. 
Our study findings may be limited by filtering some of the OSR analyses for MED 
subjects. MDR filtering allows users to analyze large numbers of SNPs (e.g., GWAS) by 
ranking and selecting factors most likely to be associated with the disease outcome. 130. 
131 The filter essentially reduces "background noise" by removing SNPs that have the 
lowest predictive value. 130-131 The resulting filtered dataset improves the chance of 
detecting relevant interactions in MDR analysis. 130-131 However, it is possible that 
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filtering the largest datasets in this study removed some relevant targets. To overcome 
this limitation, future analyses will secure additional computational support to order to 
analyze unfiltered OSR and apoptotic targets in relation to peA. 
In addition, MAD findings are limited due to small sample size. However, future 
analyses using consortia and GWAS data will allow us to confirm results from this study. 
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Award, 2008 Annual Meeting 
2008- Environmental Health Sciences Training Program, Department of 
Pharmacology and Toxicology 
2009-2010 CODRE/Graduate School Diversity Grant for Graduate Students Research 
Award 
2010 2009-2010 K.C. Huang Outstanding Graduate Student Award, 
Department of Pharmacology and Toxicology 
E. ABSTRACTS AND PRESENTATIONS 
El. ORAL PRESENTATIONS: LOCAL/REGIONAL MEETINGS 
Lavender, N.A., Kruer, T.L., Kerr II, D.A., Smolenkova, LA., Wittliff, J.L. Fractionation of 
Botanicals Exhibiting Estrogen Mimicry. Undergraduate Research Symposium, UofL, 
Louisville, KY, April 18, 2005. 
Lavender, N.A. Impact of Xeroderma Pigmentosum Group 0 (XPD) Polymorphisms on 
Prostate Cancer Risk. Pharmacology and Toxicology 1st year graduate departmental 
seminar, University of Louisville, Louisville, KY, March 9, 2007. 
191 
---------------------------------
Lavender, N.A. Influence of Polymorphic Genes Involved in Oxidative Stress and 
Apoptosis on Prostate Cancer Risk, Scientific Writing Course lecture. Department of 
Pharmacology and Toxicology, University of Louisville, Louisville, KY, September 25, 
2007. 
Lavender, N.A. Insulin Therapy. Endocrinology and Metabolism Course lecture. 
Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY, 
October 31,2007. 
Lavender, N.A. Joint Modifying Effects Variant Oxidative Stress in Relation to Prostate 
Cancer. Master's Thesis Defense. Department of Pharmacology and Toxicology, 
University of Louisville, Louisville, KY, November 6, 2008. 
Lavender, N.A. Joint Modifying Effects of Variant Oxidative Stress and Apoptosis 
Markers and Smoking in Relation to Prostate Cancer Risk in African-American Men. 
University of Louisville CODRE Monthly meeting, University of Louisville, KY, June 11, 
2010. 
E2. POSTER PRESENTATIONS: NATIONAL/INTERNATIONAL MEETINGS 
Kerr II, D.A., Smolenkova, I.A., Andres, SA, Russell, A.J., Nicholson, E.S., Smolenkov, 
A.S., Lavender, N.A., Kruer, T.L., Spatola, A.S., Zabel, S., Gangemi, J.D., Wittliff, J.L. 
Elucidating Medicinal Properties of Botanicals: Activities Altering Ligand & DNA 
Recognition by Estrogen Receptors. Annual International Clinical Ligand Assay Society 
Meeting, San Diego, CA, May 11, 2005. 
Lavender, N.A., Komolafe, 0.0., VanCleave, T.T., Srivastava, D.S., Thacker, B., States, 
J.e., Brock, G.N., Kidd, L.R. Interplay Between Xeroderma Pigmentosum 
Complementation Group D and Multi-drug Resistant 1 Genes (XPD and MDR1) and 
Prostate Cancer Risk. Annual American Society for Pharmacology and Toxicology and 
Experimental Therapeutics, Washington DC, April 27-30, 2007. 
Lavender, N.A., Komolafe, 0.0., Brock, G.N., Moore, J.H., Vancleave, T.T., Srivastava, 
D.S., Benford, M.L., States, J.e., Kittles, R.A., Kidd, L.R. Influence of high order 
interactions between variant DNA repair genes on prostate cancer risk in African-
American Men. 99th Annual American Association for Cancer Research Conference, San 
Diego, CA, April 12-16, 2008. 
Zhu, Y., Benford, M., Lavender, N.A., Vancleave, T.T., Kittles, R., Wittliff, J., Kidd, L.R. 
TaqMan Allelic Discrimination Validation of Angiogenesis-associated Biomarkers. 99th 
Annual American Association for Cancer Research Conference, San Diego, CA, April 12-
16,2008. 
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Lavender, N.A., Zhu, V., Benford, M.L., Vancleave, T.T., Kidd, L.R. Role of Glutathione 5-
Transferases (GSTs) Polymorphisms in Predicting Prostate Cancer Risk Among African-
American Men. 100th Annual American Association for Cancer Research Conference, 
Denver, CO, April 18-22, 2009. 
Benford, M.L., VanCleave, T.T., Lavender, N.A., Kittles, R.A., Kidd, L.R. 8q24 Sequence 
Variation in Relation to Prostate Cancer Risk among African-American Men. 100th 
Annual American Association for Cancer Research Conference, Denver, CO, April 18-22, 
2009. 
Lavender, N.A., Kimbro, K.S., Tang, W., Vancleave, T.T., Bouzyk, M., Kidd, L.R. Oxidative 
Stress Response Sequence Variants as Predictors of Prostate Cancer Risk and Aggressive 
Disease among men of European and African Descent. 101th Annual American 
Association for Cancer Research Conference, Washington, DC, April 17-21, 2010. 
E3. POSTER PRESENTATIONS: LOCAL/REGIONAL MEETINGS 
Lavender, N.A., Komolafe, 0.0., Vancleave, T.T., Srivastava, D.S., Thacker, B., States, 
J.c., Brock, G.N. Interplay Between Xeroderma Pigmentosum Complementation Group 
D and Multi-drug Resistant 1 Genes (XPD and MDR1) and Prostate Cancer Risk. James 
Graham Brown Cancer Center Retreat, Louisville, KV, November 29, 2006. 
Komolafe, 0.0., Vancleave, T.T., Srivastava, D.S., Thacker, B., Lavender, N.A., Doll, M., 
Hein, D.W., Brock, G.N., Kidd, L.R. Multifaceted Analytical Approach for Predicting 
Prostate Cancer Susceptibility Among African-American Men. School of Public Health 
and Information Sciences, University of Louisville, Louisville, KV, April 24, 2007. 
Lavender, N.A., Komolafe, 0.0., Brock, G., Moore, J.H., Vancleave, T.T., Srivastava, D.S., 
Benford, M.L., States, J.c., Kittles, R., Kidd, L.R. Variant Base and Nucleotide Excision 
Repair Alleles and Prostate Cancer Risk among African-American Men. 
Research!Louisville, Louisville, KV, October 16, 2007. 
Zhu, V., Lavender, N.A., Benford, M.L., Vancleave, T.T., Kidd, L.R. TaqMan Allelic 
Discrimination Validation of Angiogenesis-associated Biomarkers. Research!Louisville, 
Louisville, KV, October 17,2007. 
Lavender, N.A., Komolafe, 0.0., Brock, G.N., Moore, J.H., Vancleave, T.T., Srivastava, 
D.S., Benford, M.L., States, J.c., Kittles, R.A., Kidd, L.R. Influence of High Order 
Interactions between Variant DNA Repair Genes on Prostate Cancer Risk in African-
American Men. James Graham Brown Cancer Center Retreat, Louisville, KV, November 
28,2007. 
Zhu, V., Lavender, N.A., Benford, M.L., Vancleave, T.T., Kidd, L.R. TaqMan Assay for 
Genotyping of Single Nucleotide Polymorphisms (SNPs) in Genes Regulating Tumor 
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Angiogenesis. James Graham Brown Cancer Center Retreat, Louisville, KY, November 
28,2007. 
Lavender, N.A., Zhu, Y., Benford, M.L., Vancleave, T.T., Kidd, L.R. Role of Glutathione S-
Transferases (GSTs) Polymorph isms in Predicting Prostate Cancer Risk Among African-
American Men. Research !Louisville, University of Louisville, Louisville, KY, October 21, 
2008. 
Zhu, Y., Benford, M.L., Vancleave, T.T., Lavender, N.A., Zeng, J., Kidd, L.R. Interplay of 
Genetic Polymorphisms and Prostate Cancer Risk. Research!Louisville, University of 
Louisville, Louisville, KY, October 22, 2008. 
Vancleave, T.T., Brock, G. N., Benford, M. L., Lavender, N.A., Zhu, Y., Kruer, T. L., Wittliff, 
J.L., Kidd, L. R. Clinical Relevance of Angiogenesis SNP Profiles in Breast Cancer 
Recurrence. Research!Louisville, University of Louisville, Louisville, KY, October 22, 
2008. 
Lavender, N.A., Zhu, Y., Benford, M.L., Vancleave, T.T., Kidd, L.R. Role of Glutathione S-
Transferases (GSTs) Polymorphisms in Predicting Prostate Cancer Risk Among African-
American Men. James Graham Brown Cancer Annual Retreat, University of Louisville, 
Louisville, KY, October 29, 2008. 
Vancleave, T.T., Brock, G.N., Benford, M.L., Lavender, N.A., Zhu, Y., Kruer, T.L., Wittliff, 
J.L., Kidd, L.R. Clinical Relevance of Angiogenesis SNP Profiles in Breast Cancer 
Recurrence. James Graham Brown Cancer Annual Retreat, University of Louisville, 
Louisville, KY, October 29, 2008. 
Zhu, Y., Benford, M.L., Vancleave, T.T., Lavender, N.A., Zeng, J., Kidd, L.R. Interplay of 
Genetic Polymorphisms and Prostate Cancer Risk. James Graham Brown Cancer 7th 
Annual Retreat, University of Louisville, Louisville, KY, October 29, 2008. 
Lavender, N.A., Zhu, Y., Benford, M.L., Vancleave, T.T., Kidd, L.R. Role of Glutathione S-
Transferases (GSTs) Polymorphisms in Predicting Prostate Cancer Risk Among African-
American Men. 1st University of Louisville Graduate Research Symposium, University of 
Louisville, Louisville, KY, March 6, 2009. 
Lavender, N.A., Zhu, Y., Benford, M.L., Vancleave, T.T., Kidd, L.R. Role of Glutathione S-
Transferases (GSTs) Polymorphisms in Predicting Prostate Cancer Risk Among African-
American Men. Environmental Health Science Fellows Showcase, University of 
Cincinnati, Cincinnati, OH, September 18, 2009. 
Lavender, N.A., Komolafe, 0.0., Brock, G.N., Moore, J.H., Vancleave, T.T., Benford, M.L., 
States, J.e., Kittles, R.A., Kidd, L.R. Influence of High Order Interactions between Variant 
DNA Repair Genes on Prostate Cancer Risk in African-American Men. 12th Annual 
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Midwest DNA Repair Symposium, University of Louisville, Louisville, KY, May 14-15, 
2010. 
F. RESEARCH SUPPORT 
F.l ACTIVE GRANTS 
Clinical & Translational Science Pilot grant (Kidd) 10/01/10-present 
Clinical & Translational Science Pilot Program 
Innate Immune Response Predictors of Prostate Cancer Outcomes. 
This project utilizes a case-cohort to evaluate whether patients who inherit 
compromised innate immunity markers will suffer shortened disease-free relapse and 
even death. Increased prostate cancer risk, disease progression, poor prognosis may be 
partially attributed to inheritance of variant innate immunity-related loci linked with 
enhanced pro-inflammatory, presumably due to alterations macromolecules that may 
lead to changes in responsiveness to pathogens by toll-like receptors and their 
cytokine/chemokine production. These biochemical changes may result in chronic 
inflammation and other microenvironment changes that support tumor growth and 
disease progression. 
Role: Research Assistant 
F2. COMPLETED GRANT AWARDS 
NIEHS T32 Training Program Grant 10/01/08 - 09/30/10 
National Institute of Environmental Health Sciences, NIEHS 
Joint Modifying Effects of Variant Oxidative Stress and Apoptosis Markers and Second 
Hand Cigarette Smoke in Relation to Prostate Cancer Risk in African-American Men. 
The goal of this project is to examine the impact of complex interactions among 
oxidative stress, apoptosis, and second hand smoke on prostate cancer risk and disease 
progression among men of African-descent. These complex interactions will be 
analyzed using traditional and advanced bioinformatic approaches, including multifactor 
dimensionality reduction. This multi-faceted approach is designed to capture gene-
environment interactions that would remain undetected using conventional strategies 
such as logistic regression models. 
Role: Principal Investigator 
Intramural Award (Kidd) 
Bales Medical Research Fund 
04/15/06 - 03/15/07 
Impact of DNA Repair Genes on Prostate Cancer Risk Among Men of African Descent. 
Determine the role of variations in base excision (OGG1, XRCC1, APEX1) alone or in 
combination with nucleotide excision repair genes (XPA, XPD) in the risk of developing 
prostate cancer among African-American men. 
Role: Research Assistant 
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Intramural Award 02/01/07 - 01/31/08 
JGBCC Pilot Program Initiative 2007 (Kidd) 
Genomic Approach to Predicting Breast Cancer Recurrence. 
The purpose of this study is to identify important SNP or mRNA signatures to optimize 
breast cancer. 
Role: Research Assistant 
2006 Competition Awards Program (Kidd) 02/1/07 - 01/31/08 
Prostate Cancer Foundation 
Combined Genetic Assessment of Angiogenesis Pathway Variants Predictive of Prostate 
Cancer Risk. 
Systematically evaluate the interaction among 12 highly variant angiogenesis genes and 
their combined modifying effects on prostate cancer risk and disease progression within 
a unique and large case-control study. This assessment involves genetic profiles 
collected from 918 men of African-descent (220 cases and 698 controls) using highly 
advanced statistical tools. The project tests the hypothesis that variations within 
regulatory or coding regions within selected angiogenesis markers genes will individually 
or jointly modulate prostate cancer risk and disease progression (i.e., high tumor grade), 
presumably due to alterations in mRNA/protein expression critical to tumor vasculature 
formation capacity. 
Role: Research Assistant 
Cancer Prevention R03 (Kidd) 06/1/07 - 5/31/09 
National Cancer Institute, NIH 
A Pharmacogenetic Approach to Prostate Cancer Susceptibility. 
The purpose of the study is to systematically evaluate the capacity of an innovative 
panel of genetic variants within carcinogen-biotransformation, -transport, and -DNA 
repair pathways to predict prostate cancer susceptibility among men of African descent. 
In order to accomplish this high-impact research objective, the proposed project will use 
a multi-faceted statistical strategy that combines orthodox statistical methods with 
computation algorithms and hierarchical interaction graphs. 
Role: Research Assistant 
CODRE/Graduate School Diversity Grant for Graduate Students 06/01/09 - 05/31/10 
UofL Commission on Diversity and Racial Equality 
Joint Modifying Effects of Variant Oxidative Stress and Apoptosis Markers and Smoking 
in Relation to Prostate Cancer Risk in African-American Men. 
This study aims to identify and evaluate whether a complex array of oxidative stress-
related genetic and environmental markers can detect PCA risk, disease aggressiveness 
and treatment response using a combination of traditional and innovative advanced 
mathematical methodologies. 
Role: Principal Investigator 
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G. ADMINISTRATIVE AND COMMUNITY SERVICES 
G1. SERVICE TO THE DEPARTMENT 
Interviewer, Department of Pharmacology & Toxicology, Spring 2008 - present 
University of Louisville, School of Medicine, Louisville, KY 
Responsibilities: 
• Interview and recommend prospective graduate students 
• Address questions/concerns regarding graduate school 
• Disseminate recruitment materials 
• Follow-up with interested candidates 
G2. SERVICE TO THE UNIVERSITY 
Member, Academic Grievance Committee, September 2009-2010 
University of Louisville, School of Medicine, Louisville, KY 
Responsibilities: 
• Handle grievances from medical students, graduate students and post-
doctoral trainees 
G3. SERVICE TO THE PROFESSION 
Manuscript Peer Reviews 
Cancer Epidemiology, review submitted March 19, 2010 
• Polymorphisms of Glutathione S-Transferase Ml and T1 and Prostate Cancer 
Risk in a Tunisian population, manuscript reference number: CANEP-D-l0-
00055 
Disease Markers, review submitted September 28, 2010 
• Association of GSTMl and GSTIl polymorphism and tobacco usage with 
oxidative stress in benign prostate hyperplasia and prostate cancer, 
manuscript reference number: DMA0910 
G4. SERVICE TO THE COMMUNITY 
Volunteer Activities 
Team member/participant, American Cancer Society Relay For Life, May 15, 2010 
Mentor, YMCA Black Achievers Program, 2008-present 
Mentor/advisor, Nativity Academy at Saint Boniface Science Fair, Spring 2008 
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H. PUBLICATIONS, BOOK CHAPTERS, MONOGRAPHS AND TEXTBOOKS 
HI. PEER-REVIEWED MANUSCRIPTS 
Lavender N.A., Benford M.L., VanCleave T.T., Brock G.N., Kittles R.A., Moore J.H., Hein 
D.W., and Kidd L.R. Examination of polymorphic glutathione S-transferase (GST) genes, 
tobacco smoke and prostate cancer risk: A case-control study. BMC Cancer. 2009 Nov 
16; 9:397. 
Lavender N.A., Komolafe 0.0., Benford M.L., Brock G.N., Moore J.H., VanCleave T.T., 
States J.c., Kittles R.A., and Kidd L.R. No association between variant DNA repair genes 
and prostate cancer risk among men of African descent. Prostate. 2010 Feb 1; 
70(2):113-9. 
Kidd L.R., Brock G.N., VanCleave T.T., Benford M.L., Lavender N.A., Kruer T., Wittliff J.L. 
Angiogenesis-associated Sequence Variants Relative to Breast Cancer Recurrence and 
Survival. Cancer Causes and Control. 2010 Oct; 21(10):1545-57. 
Benford M.L., VanCleave T.T., Lavender N.A., Kittles R.A., Kidd L.R. 8q24 Sequence 
Variants in Relation to Prostate Cancer Risk among Men of African Descent. BMC 
Cancer. 2010 Jun 28; 10:334. 
I. SCIENTIFIC MEETINGS, WORKSHOPS, SEMINARS 
James Graham Brown Cancer Center Memorial Lecture Series, weekly seminars 
September 2006 to present 
James Graham Brown Cancer Center, University of Louisville 
Louisville, KY 
Pharmacology and Toxicology Departmental Seminars, weekly seminars September 
2006 to present 
University of Louisville, School of Medicine 
Louisville, KY 
Grant Workshop: NIH Training and Career Development Programs, October 18, 2007 
Research Louisville! 
University of Louisville, School of Medicine 
Louisville, KY 
Third American Association for Cancer Research Conference: The Science of Cancer 
Health Disparities, September 30-0ctober 3, 2010 
Loews Miami Beach Hotel 
Miami, FL 
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